











This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
• This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
• A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
• This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
• The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
• When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given. 
 
 
PhD – The University of Edinburgh – 2012 
 







I, Gillian McHugh, declare that the following thesis has been composed by me and 
has not been submitted for any other degree or professional qualification. 
 
This thesis was part of a larger project.  Grant support for the IMPACT study was 
provided by NIH NS 42691.  This thesis is my own work, however as it is part of a 
larger project, some results provided by others have been incorporated.  For example, 
I personally only extracted data from three of the eleven studies in the IMPACT 






I would like to thank Professor Gordon Murray for his excellent supervision, advice 
and guidance.  I am very grateful for having this opp rtunity. 
 
This project was part of a collaboration and could not have been done without my 
IMPACT colleagues in Richmond, Rotterdam and Antwerp.  It certainly could not 
have been done without the Edinburgh ‘team’ and I thank them for their support and 
friendship. 
 
Thank you to my mother for her enthusiasm.  To John, thank you for all of your 
encouragement and support, as well as doing all the things I would have been doing 
had I not been doing this.  Finally, to Natalie, thank you for making me smile as I’ve 




Many promising Phase II trials have been carried out in head injury however to date 
there has been no successful translation of the positive results from these explanatory 
trials into improved patient outcomes in Phase III trials.  Many reasons have been 
hypothesised for this failure.  Outcomes in head injury trials are usually measured 
using the five point Glasgow Outcome Scale.  Traditionally the ordinality of this 
scale is disregarded and it is dichotomised into two groups, favourable and 
unfavourable outcome.  This thesis explores whether suboptimal statistical analysis 
techniques, including the dichotomisation of outcomes could have contributed to the 
reasons why Phase III trials have been unsuccessful. 
 
Based on eleven completed head injury studies, simulation modelling is used to 
compare outcome as assessed by the conventional dichotomy with both modelling 
that takes into account the ordered nature of the outcome (proportional odds 
modelling) and modelling which individualises a patien ’s risk of a good or poor 
outcome ( the ‘sliding dichotomy’).  The results of this modelling show that both 
analyses which use the full outcome scale and those which individualise risk show 
great efficiency gains (as measured by reduction in required sample sizes) over the 
conventional analysis of the binary outcome.  These r ults are consistent both when 
the simulated treatment effects followed a proportional odds model and when they 
did not.  Consistent results were also observed when targeting or restricting 
improvement to groups of subjects based on clinical ch racteristics or prognosis.  
Although proportional odds modelling shows consistently greater sample size 
reductions the choice of whether to use proportional dds modelling or the sliding 
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1.1 Introduction 
Given the difficulties often experienced in recruiting patients into randomised 
controlled trials (RCTs) we need more sensitive methods of analysis, so that fewer 
subjects are required.  For example, a review of 114 trials (McDonald et al. 2006) 
reported that less than a third of these trials achieved their original recruitment target.  
We also need more efficient trial designs to allow us to maximise the chance of 
detecting any treatment benefits that may exist. 
 
Qureshi et al (Qureshi et al. 2004) wrote an excellent article on design methods for  
evaluating treatments for stroke covering randomisation, intention to treat analysis 
etc.  However, even although he does discuss the ascert inment of outcomes, 
analysing outcomes scales as they were originally recorded rather than, as a typically 
done, collapsing into fewer categories is not discus ed. 
 
It has been postulated that large trials based on synthesised evidence from previous 
studies are needed to find moderate but worthwhile effects (Yusuf, Collins, & Peto 
1984).  Choi and Bullock (Choi & Bullock 2001) subsequently agreed with the 
philosophy: “There is currently a statistical ground swell of opinion calling for much 
larger trials in head injury, directed at much smaller magnitudes of effect, as has 
been the case with successful stroke trials.”  However, as McDonald et al (McDonald 
et al. 2006) have shown, few trials, especially those in head injury, achieve their 
original recruitment target.  There has been one large ‘mega-trial’ in head injury in 
the last decade, Corticosteroid Randomisation After Significant Head injury 
(CRASH) (Edwards et al. 2005), which followed the “k ep it simple” philosophy 
with the aim to recruit as many patients as possible with minimal data recording.  
This trial did demonstrate a statistically significant treatment effect, but unfortunately 
the effect of the experimental intervention was to increase mortality.  Perhaps 
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suggesting that the large simple trial is not the answer to the problems facing trials in 
head injury. 
 
1.2 Head injury - epidemiology 
Traumatic Brain Injury (TBI) is the leading cause of death and disability among 
young adults in developed countries and the incidence i  the elderly population is 
increasing (Kannus, Palvanen, & Niemi 2001;Luukinen et al. 1999;Vink & Bullock 
2010).  Approximately 1.5 million people die each year world wide from traumatic 
brain injury with most of the deaths occurring in the developing world (Menon 
2009).  In the United States approximately 2 million head injuries occur each year.  
The direct and indirect costs of these injuries are estimated to be $56 billion per 
annum in the United States.  The World Health Organisation (WHO) has projected 
that by 2020, road traffic accidents, a major cause of traumatic brain injury, will rank 
third as a cause of the global burden of disease and disablement, behind only 
ischemic heart disease and unipolar major depression (F nfer & Cohen 2001). 
 
1.3 Head injury - classification 
Head injury is heterogeneous with different pathological processes and causes (Guha 
2004).  Injury severity can be classified in several fundamentally different ways: 
using the degree of impairment of consciousness - typically measured by the 
Glasgow Coma Scale (GCS); measuring evidence of structural brain damage - 
observed on a scan; and measuring at the cellular level the underlying cytotoxic 
cascade which follows brain injury.  Saatman et al (S atman et al. 2008) set out a 
pathoanatomic classification, this describes the anatomical features, location or the 
abnormality to be treated.  The Marshall computerised tomography (CT) 
classification is one such classification (Marshall et al. 1991).  It categorises patients 
based on their CT scan with categories going from Diffuse Injury I -No visible 
intracranial pathology seen on CT scan to having a mass lesion.  More detail is given 
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in Table 9-3 in the Appendix.  However this approach does not take into account the 
cytotoxic cascade which has been shown to occur in human head injury, validating 
the previous results observed in animal models (Hovda et al. 1995).  A cellular 
approach rather than a CT approach may be the way forward for developing new 
drug treatments. 
 
1.4 Head injury - outcome measures 
The two most commonly used measures to assess outcome after head injury are the 
Glasgow Coma Scale (GCS), used to asses a patient’s degree of impairment of 
consciousness soon after the initial insult, and the Glasgow Outcome Scale (GOS), 
used to assess longer term functional outcome. 
 
The Glasgow Coma Scale (Teasdale & Jennett 1974) comprises three components: 
an eye response score ranging from ‘one-no eye opening’ to ‘four-spontaneous eye 
opening’; a verbal response score ranging from ‘one-no response’ to ‘five – 
orientated’ and a motor response score ranging from‘one-no response’ to ‘six-
obeys’.  These components are then summed to give a total Glasgow Coma Scale 
score of 3 to 15.  Fuller details of the GCS are given in the Appendix in Table 9-2. 
 
The Glasgow Outcome Scale, (Jennett & Bond 1975), is a f ve point ordinal scale 
with categories of good recovery, moderate disability, severe disability, vegetative 
state and death, conventionally assessed six months after injury.  Fuller details of the 
scoring of this scale are given in the Appendix in Table 9-1. 
 
The components of the Glasgow Coma Scale and the Glasgow Outcome Scale are all 
ordinal scales.  Ordinal data occur when data are cl ssified into a small number of 
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ordered categories and the ordering has no numerical value.  For example, the 
Glasgow Outcome Scale with its categories of good recovery, moderate disability, 
severe disability, vegetative state and death is clearly ordered although no numerical 
value can be assigned to the ordering. 
 
Traditionally, the GOS has been dichotomised into a favourable outcome group, 
combining the good recovery and moderate disability ca egories, and an 
unfavourable outcome group, combining the severe disabil ty, vegetative state and 
death categories.  Dichotomising the GOS does reflect c inical judgement as to what 
constitutes a ‘desirable’ outcome.  It also has the advantage of allowing relatively 
unsophisticated techniques to be used to analyse the data which give an easily 
understood outcome.  However, dichotomising the scale in this way does not exploit 
its underlying ordinal nature.  The dichotomisation may also be insensitive in 
patients with more favourable outcomes.  The effects of varying the threshold 
between “good” and “poor” outcome for different progn sis groups will be examined 
in this thesis.  This is the concept of the “sliding dichotomy” as first proposed by 
Barer, (Barer 1999); more detail on this is given in subsequent chapters.  Analysis 
across the distribution of scores maximises the use of the scale (Kasner 2006).  
Dichotomising into favourable and unfavourable does not reflect the clinical benefit 
that moving up or down the scale has (Menon 2009).  Also, analysing a binary 
outcome forces trialists to discard large quantities of outcome information which can 
lead to underestimation of treatment benefit or harm o  both (Saver 2007). 
 
A limitation of current analysis of the GOS and indee  the Disability Rating Scale 
(Rappaport et al. 1982), also used to measure outcome after head injury; and the 
Barthel Index (Mahoney & Barthel 1965) and the modifie  Rankin Scale (mRS) (van 
Swieten et al. 1988), used to measure outcome after stroke, is that the criteria for 
assessment do not specify how pre-existing physical or psychological problems 
should be taken into account (Pettigrew, Wilson, & Teasdale 1998).  The sliding 
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dichotomy, although it does not take into account pre-injury morbidities, 
individualises the prognosis for each patient rather an seeing if they achieve an 
arbitrary “good” outcome.  These outcome scales are also often inappropriately 
dichotomised.  It is remarked, (Lai & Duncan 2001), that the definition of favourable 
outcomes should include the transition in the modifie  Rankin Scale rather than the 
difference either side of a cutpoint.  Using the full range of a scale to determine an 
outcome that is clinically meaningful is much more appropriate than an arbitrary 
dichotomisation.  Treatment effect will also more like y be captured by using a shift 
analysis rather than a dichotomisation (Schabitz & Fisher 2006).  As with all 
analyses, selection of the primary endpoint is crucial in detecting differences 
between interventions (Kasner 2006). 
 
This thesis will primarily focus on moderate to severe head injury and explore 
whether using a more sophisticated analysis ‘adds value’ and provides an intuitive 
and useful outcome or whether by using a more sophiticated analysis, unnecessary 
complexity is added without efficiency gains and a simple dichotomous analysis 
provides the most useful summary. 
 
1.5 Head injury – failure of previous studies to sh ow an effect 
Many trials in TBI have been carried out over the last three decades and the reasons 
given for them failing to show efficacy are varied.  A series of articles have been 
written citing the failure of neuroprotective drugs to work in confirmatory (Phase III) 
trials in head injury (Dickinson et al. 2000;Maas et al. 1999).  At an initial clinical 
level, the data available from Phase I and Phase II trials may not be reliable; the 
results obtained in explanatory trials may not be extrapolated to pragmatic trials or 
the drug may simply not work (Maas, Roozenbeek, & Manley 2010).  Also at the 
clinical level, there is the juxtaposition between the desire for early treatment and the 
need to obtain consent and fulfil inclusion criteria prior to commencing treatment.  
At a mechanistic level, the TBI patient population s very heterogeneous with very 
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differing mechanisms of injury and differing prognostic risk (Bullock, Lyeth, & 
Muizelaar 1999;Maas 2000;Narayan et al. 2002).  Doppenberg et al (Doppenberg, 
Choi, & Bullock 1997) hypothesised that poor brain penetration of drug was the 
reason for the failure of a large number of Phase III trials.  There is also the 
requirement to test new drugs on healthy volunteers, a equirement not needed for 
other diseases with high morbidity and mortality, such as cancer chemotherapy or 
Acquired Immune Deficiency Syndrome (AIDS) therapy (Doppenberg, Choi, & 
Bullock 1997).  A review of over one thousand neuroprotectants found little 
relationship in experimental effectiveness between drugs that were effective 
clinically and those tested only in animal models (O'Collins et al. 2006).  It is still not 
known if the mechanisms that cause secondary injury in humans are the same as 
those in animals and, even if they are, whether these findings can be translated from 
bench to bedside (Bullock, Lyeth, & Muizelaar 1999;Ioannidis 2006). 
 
It has been hypothesised that the failure of head injury studies to translate from 
exploratory Phase II trials to confirmatory Phase III may be to do with the population 
being studied but could equally and even more so be t  do with the design and 
analysis of the trials carried out so far (Teasdale et al. 1999).  One of the key 
requirements for any trial is that the outcome must be sufficiently sensitive to detect 
a clinically meaningful effect of the intervention (Bullock, Lyeth, & Muizelaar 
1999).  With all trials, but fundamentally with head injury trials, the design has to 
match the question being asked (Murray & Teasdale 2000).  At the analysis stage, 
there are problems with the use of surrogate endpoits and the dichotomisation of the 
outcome measure, usually the GOS which leads to a loss of sensitivity.  There are a 
plethora of factors which affect outcome after head injury, therefore head injury 
lends itself to statistical modelling (Helmy, Timofeev, & Hutchinson 2010).  The 
different prognostic risk factors and the analysis of the outcome measures are 
explored within this thesis. 
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A partial explanation of the failure of Phase III trials may also be observer variation.  
The Glasgow Outcome Scale and the extended Glasgow Outcome Scale (GOSE) 
(Teasdale et al. 1998) have both been found to havesignificant observer variation 
(Choi et al. 2002;Lu et al. 2008;Lu et al. 2010;Wilson et al. 2007).  The GOSE, an 
extension of the GOS, is an eight point scale with the categories of good recovery, 
moderate disability and severe disability being split into upper and lower bands.  
Wilson et al (Wilson et al. 2007), in examining misclassification of the GOSE, found 
that the greatest levels of disagreement were found between the categories of upper 
severe disability and lower moderate disability traditionally where the 
dichotomisation is made between good and poor outcomes.  Whitehead (Whitehead 
1993) showed that for a four category outcome, misclas ification of 20% could lead 
to the same loss of efficiency as having a binary outc me. 
 
Other factors to consider in terms of the efficiency of a confirmatory trial in 
traumatic brain injury are the entry criteria and the use of covariate adjustment.  
Machado et al (Machado, Murray, & Teasdale 1999) showed that by only targeting 
the intermediate prognosis patients sample size savings of up to 30% could be 
achieved.  However this was when using a binary rathe  than an ordinal outcome 
analysis.  Roozenbeek et al (Roozenbeek et al. 2009b) showed that by adopting more 
strict enrolment criteria, as expected, a more homogeneous population is recruited 
which can lead to a more efficient trial but recruitment is slowed to such an extent 
that the manoeuvre becomes self defeating.  Others have shown the benefits of 
adding covariates into the model (Hauck, Anderson, & Marcus 1998;Hernandez, 
Steyerberg, & Habbema 2004;Roozenbeek et al. 2009a). 
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1.6 Literature review 
1.6.1 Ordinal methods of analysis in the literature 
Four methods of ordinal analysis have been focused on in the literature to varying 
degrees: the proportional odds model (McCullagh 1980); the continuation ratio 
model (Fienberg 1980); the stereotype (alternatively named canonical regression) 
model (Anderson 1984) and the latent normal model (Poon 2004).  Both the 
proportional odds and continuation ratio approaches can be regarded as grouped 
continuous.  That is they use discrete versions of an underlying continuous outcome 
variable (Anderson & Philips 1981;Feldmann & Steudel 2000).  The proportional 
odds and the latent normal model both assume that there is an underlying latent 
variable.  However, the proportional odds model assumes that the distribution of the 
variables are logistic whereas the latent normal model assumes that the underlying 
distribution is normal (Poon 2004).  The stereotype model assumes that several 
multidimensional factors contribute to the scale.  More details on these models and 
the extensions to clustered or repeated ordinal dat are reported (Liu & Agresti 
2005).  The proportional odds model has most commonly been used in applied rather 
than theoretical settings.  
 
1.6.2 Search strategy – head injury and stoke trials and ordinal methods in the 
literature 
Literature searches were undertaken to identify: 1) all Phase III trials in head injury 
and 2) all Phase III stroke studies that had used an ordinal method of analysis. 
 
Stroke studies were included in the search as head injury and stroke have many 
similar features.  The most universally used description of a stroke is “ a clinical 
syndrome characterised by rapidly developing clinical signs of focal, at times global 
(applied to patients in deep coma and those with subarachnoid haemorrhage), loss of 
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cerebral function, with symptoms lasting more than 24h or leading to death, with no 
apparent cause other than that of vascular origin” (Hatano 1976). 
 
Further literature searching was done to identify sudies which had adjusted for 
baseline severity.  Studies that had cited either Barer’s (Barer 1999) original paper 
that mentioned the concept of the sliding dichotomy or Murray et al’s (Murray et al. 
2005) paper which expanded on the topic in more detail were identified.  The term 
“sliding dichotomy” was also searched for.  Alternative methods of adjusting for 
baseline severity such as patient-specific and responder analysis were also searched 
for.  The term “baseline severity adjusted end point analysis” was also searched for.  
Also papers that had cited Saver’s (Saver 2007) paper on this topic were searched 
for. 
 
Papers discussing responder analysis were searched for and more detailed searches 
were done on responder analysis and stroke, head injury or brain injury. 
 
1.6.3 Phase III trials in head injury 
In order to establish what outcome measures are curntly used in Phase III trials in 
head injury and how these outcome measures are analysed a systematic review was 
carried out.  Particular attention was placed on whether the outcome was 
dichotomised or not.  PubMed, Medline, the Cochrane Library and Web of 
Knowledge were searched for head or brain or cranial injur* and Phase III or Phase 3 
or trial* or random*.  An asterisk indicating that the search term was truncated on the 
right.  The search was last updated in September 2011. 
 
The results of the search strategy are summarised in the flow chart below, Figure 1-1  
 
Chapter 1 Background and Introduction 10  
Figure 1-1 Flow chart showing references considered for Phase III trials in head injury 
 
Articles identified from database 
searching N=1072 





Papers the met criteria for 
review N=41 
Papers included in review 
N=29 
Articles rejected because 
review or methodological 
articles N=81 
Papers rejected because 
non randomised or Phase 
II studies or studies with 
no clinical outcome or 
duplicate papers N=53 
Articles reviewed that 
discussed trials N=175 
Papers rejected because 
N<50 in each group N=12 
Articles identified from 
other sources N=5 
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The first stage was to examine the abstracts of the pap rs found in the literature 
search.  Although the word random* was used as one of the search terms when some 
of the studies were examined in more detail they were found to be observational 
studies.  The full paper was then obtained for any relevant study and examined 
carefully to see if a ‘clinical’ outcome was measured e.g. GOS or mortality.  For this 
review any studies with laboratory measures as the outcome measure e.g. increase in 
intracranial Pressure (ICP) were not included.  As a final stage in the review process, 
only studies which included at least 50 subjects in each arm were included. 
 
As the flow chart shows, 29 references were found which related to Phase III trials in 
head injury.  These were all studies with a clinical outcome measure and with greater 
than or equal to 50 subjects in each arm.  Details of these trials are given in Table 
1-1.  Most of the trials used the Glasgow Outcome Scale to assess outcome.  Three 
trials used the extended GOS (Cooper et al. 2004;Maas et al. 2006;Temkin et al. 
2007) and one used a modification of the GOS with six points, distinguishing 
between severe disability requiring constant care and severe disability without the 
need for constant care (Gaab et al. 1994).  Twenty of the trials recorded GOS at six 
months.  GOS was reported at three months only by Xiao and Young (Xiao et al. 
2008;Young et al. 1996); twelve months only by Gaab (Gaab et al. 1994) and at 
multiple time points up to one year for the remaining six studies. 
 
The GOS was dichotomised before being analysed in 18 of the trials.  Fifteen of 
these trials used the conventional dichotomy and combined the good recovery and 
moderate disability categories into a favourable outc me group and the severe 
disability, vegetative state and death categories into an unfavourable group.  One trial 
(Saul et al. 1981) considered good recovery, moderate disability or severe disability 
as a favourable outcome and vegetative state or death as an unfavourable outcome.  
Maas et al (Maas et al. 2006) used a prognosis based dichotomy (sliding dichotomy) 
 
Chapter 1 Background and Introduction 12  
and it is unclear where Gaab and colleagues (Gaab et l. 1994) dichotomised their 
modification of the GOS. 
 
Table 1-1 Phase III trials in head injury1 
Trial Year Population Outcome N 
Saul 1981 GCS<=7. US, single centre GOS at 6 months 100 
Braakman  1983 Comatose patients. Europe, 2 
centres 
GOS at 6 months 161 
Dearden 1986 Severe head injury. UK, single 
centre 
GOS at 6 months 130 
Bailey 
(HIT I) 
1991 Not obeying commands. 
Europe, 6 centres 
GOS at 6 months 351 
Muizelaar  1991 GCS<=8. 
US, single centre 
GOS at 3, 6 and 
12 months 
113 
Rockswold 1992 GCS<=9. US, single centre GOS at 6, 12 and 
18 months 
168 
Wolf 1993 GCS<=8. US, 2 centres GOS at 3, 6 and 
12 months 
149 





1994 Not obeying commands. 
Europe, 13 centres 
GOS at 6 months 852 
Grumme 1995 Severe head injury. Europe, 9 
centres 







Germany, 21 centres 
GOS at 6 months 123 
                                                
1 Abbreviations in table: GCS - Glasgow Coma Scale; GOS – Glasgow Outcome Scale; GOSE – 
Glasgow Outcome Scale Extended; tSAH – traumatic subarachnoid haemorrhage; ESGN – The 
European Study Group on Nimodipine in Severe Head Injury 
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Trial Year Population Outcome N 
Young 
(PEGSOD) 
1996 GCS<=8.  
US, 29 centres 




1998 85% GCS<=8, 15% GCS 9-12. 
Worldwide, 50 centres 
GOS at 6 months 1131 
Marmarou 
(BRADYCOR) 
1999 GCS <=8. 
US, 31 centres 





1999 GCS 4-8. 
Worldwide, 99 centres 
GOS at 6 months 693 





2001 GCS 3-8. 
US, 11 centres 
Mortality. GOS 
at 6 months 
392 
Cruz 2001 Acute subdural haematoma. 
Brazil, single centre 
GOS at 6 months 178 
Cruz 2002 Temporal lobe haemorrhage. 
Single centre, unknown 
location 
GOS at 6 months 141 
Lu 2003 GCS<=8. China, single centre  GOS at 6 months 230 
Zhi  2003 GCS<=8. China, single centre GOS at 6 months 396 
Cooper 2004 GCS<=8. Australia, multiple 
centres  





2005 GCS<=14  
Worldwide, 52 centres 
GOS at 6 months 10008 
Jiang  2005 GCS<=8 & hypertension. 
China, five centres 
GOS at 6 months 486 
Yurkewicz 2005 GCS 4-8. US, 40 centres GOS at 6 months 404 
                                                
2 Paper shows results for 463 subjects however all 1574 subjects included in analysis in thesis. 
3 CRASH trial did not distinguish between outcome measures of vegetative state and severe disability. 
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Trial Year Population Outcome N 
Jiang  2006 GCS<=8. China, three centres GOS at 6 months 215 
Maas 
(PHARMOS) 
2006 Motor 2-5 & CT 
abnormalities.  
Worldwide, 86 centres 
GOSE at 6 
months 
861 
Temkin 2007 GCS <=12. US, single centre GOSE at 6 
months 
499 
Xiao 2008 GCS<=8. China, single centre  GOS at 3 months 159 
 
 
In the 18 trials which dichotomised the GOS, six (Bailey et al. 1991;Jiang et al. 
2006;Morris et al. 1999;Rockswold et al. 1992;Saul et al. 1981;Xiao et al. 2008) 
specified that a Chi-squared analysis was used.  However, Jiang only compared 
within rather than between study groups.  Marmarou et al (Marmarou et al. 1999) did 
not specify what analysis had been used, however, from examining the figures given 
in the paper, it seems likely that Chi-squared analyses were performed.  Three of the 
trials (Dearden et al. 1986;Marshall et al. 1998;The European Study Group on 
Nimodipine in Severe Head Injury 1994) compared the proportions with 
unfavourable outcome, good recovery and favourable outcome respectively.  Three 
of the trials (Harders et al. 1996;Wolf et al. 1993;Yurkewicz et al. 2005) used logistic 
regression analysis, with Harders also using Fisher’  exact test, a modification of the 
Chi-squared test, to analyse outcome.  Two of the trials (Clifton et al. 2001;Edwards 
et al. 2005) presented relative risks.  Braakman et al (Braakman et al. 1983) used a 
Mann Whitney test, Gaab et al (Gaab et al. 1994) used a Cochrane Mantel Haenszel 
test and Maas et al (Maas et al. 2006) the sliding chotomy analysis. 
 
Seven of the trials trichotomised the GOS.  Four of these (Cruz, Minoja, & Okuchi 
2001;Cruz, Minoja, & Okuchi 2002;Robertson et al. 1999;Young et al. 1996) 
grouped good and moderate outcomes together and vegetative and death outcomes 
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together; whereas the other three trials (Jiang et al. 2005;Lu et al. 2003;Muizelaar et 
al. 1991) grouped good and moderate outcomes together and severe and vegetative 
outcomes together.  Most of these trials (5/7) performed Chi-squared analysis.  
Young et al (Young et al. 1996) used a Cochran Mantel Haenszel mean score test 
assigning scores of 0, 0.5 and 1 to poor, intermediat  and good outcomes 
respectively to each trichotomy, and compared the mean score between groups.  
Muizelaar et al (Muizelaar et al. 1991) stratified by motor score and carried out a 
multiple logistic regression analysis; no mention was made in the paper if this was a 
proportional odds analysis. 
 
The remaining four trials did not group the outcome variable.  Two trials used the 
Mann Whitney test to assess differences in GOS between comparison groups 
(Cooper et al. 2004;Grumme et al. 1995).  Zhi et al (Zhi, Zhang, & Lin 2003) tried to 
assess differences using a two-sample t-test!  It was unclear from the paper how the 
GOSE measured by Temkin et al (Temkin et al. 2007) was analysed. 
 
Bolland et al (Bolland, Sooriyarachchi, & Whitehead 1998) reported a sample size 
review of a study comparing eliprodil (a N-Methyl-D-aspartate (NMDA) receptor 
antagonist) with placebo in head injury.  Outcome was measured using the GOS and 
a proportional odds model was fitted.  The clinical results of this study have not been 
published to date. 
 
Therefore, in conclusion, only five of the trials ued an analysis which incorporated 
all of the outcome scale (Cooper et al. 2004;Grumme et al. 1995;Maas et al. 
2006;Temkin et al. 2007;Zhi, Zhang, & Lin 2003).  Of these five, one (Zhi, Zhang, & 
Lin 2003) used an inappropriate t-test to analyse outcome and Temkin et al’s 
(Temkin et al. 2007) analysis was unclear, leaving o ly three Phase III trials which 
used the full outcome scale. 
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1.6.4 Ordinal analysis - stroke 
Stroke and head injury can lead to similar functional impairments.  The most 
commonly used scale to assess outcome following stroke, the modified Rankin Scale 
is an ordinal scale.  It has seven categories ranging from ‘0 - no symptoms’ to ‘6 – 
death’.  It was of interest to explore whether thisscale had been analysed as an 
ordinal outcome, as typically, as with head injury outcomes, it is dichotomised. 
The Barthel Index is also commonly used to measure o tcome after stroke.  It 
comprises a ten item scale covering items such as mobility and toileting.  For each 
item, subjects are scored 0 if dependent or unable to p rform a task and up to 15 if 
able to perform a task independently.  Each item is therefore measured on an ordinal 
scale although the total score (ranging from 0 to 100) is not ordinal. 
 
In order to find stroke trials that had used an ordinal analysis the following search 
strategy was used.  PubMed, Medline, the Cochrane Library and Web of Knowledge 
were searched for (stroke or cerebrovascular) and (Phase III or Phase 3 or random or 
trial) and (ordinal or proportional odds or cumulative logit or continuation ratio).  
The search was last updated in September 2011. 
 
Twenty studies were identified from the literature.  These were either trials or 
subgroup analysis based on trials.  Cohort studies were not included in this search.  
Almost all (18/20) trials used the modified Rankin Scale to assess outcome.  
Zingmark et al (Zingmark et al. 2003) measured outcme as the degree of sedation.  
Mendelow et al (Mendelow et al. 2005) in the Surgical Trial in Intracerebral 
Haemorrhage (STICH) measured outcome using the GOSE at six months.  Nine of 
the studies used ordinal regression analysis to examine outcome (Bath et al. 
2009;Bath et al. 2010;Diener et al. 2008a;Lees et al. 2006b;Mishra et al. 
2010;Mishra et al. 2011;Sandset et al. 2011;Shuaib et al. 2007;Zingmark et al. 2003). 
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Two subgroup analyses of the Prevention Regimen For Effectively avoiding Second 
Strokes (PRoFESS) trial (Diener et al. 2008b) were published, both of which used 
ordinal regression.  In the first, Bath et al (Bath e  al. 2009) examined the effects of 
telemisartan on recurrence, functional outcome and blood pressure using ordinal 
logistic regression and the Mann Whitney U test to examine outcome.  Both 
analyses, the ordinal logistic regression and the Mann Whitney U test, showed 
similar results and the results of the ordinal logistic regression showed the same 
magnitude as those obtained from a conventional binry analysis.  No statistically 
significant effect of telemisartan was found on functional dependency.  In the second 
published subgroup analysis of the PRoFESS trial, Bth et al (Bath et al. 2010) 
examined 30 day functional outcome in a post-hoc analysis.  This analysis included 
over 1300 patients and compared those randomised to aspirin and extended release 
dipyridamole with those on clopidogrel.  Using ordinal logistic regression, no 
difference was found in modified Rankin Scale betwen groups at 30 days.  
Outcomes were also compared by examining a shift in the distribution of a composite 
endpoint measure, where again no statistically significa t differences were found. 
 
Two major studies were carried out of drug NXY-059 in acute stroke.  The first trial, 
Stroke Acute Ischemic NXY Treatment (SAINT) I (Lees et al. 2006b), showed a 
positive outcome in reducing disability at 90 days.  A subgroup analysis was also 
done of SAINT I trial which examined the number of days over the first 90 days of 
stroke onset that a patient spends at home (Mishra et al. 2011).  This was found to be 
extended in patients who received thrombolytic therapy.  The second much larger 
trial, SAINT II (Shuaib et al. 2007), showed no evidence that the treatment reduced 
mortality or disability.  A pooled analysis was then done of both the SAINT I and 
SAINT II studies, (Diener et al. 2008a).  This confirmed the results of the SAINT II 
study and showed no benefit of the treatment.  In all of the analyses of the SAINT 
trials, the Cochran-Mantel-Haenszel test adjusted for stratification variables was used 
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for the primary outcome analysis.  Proportional odds regression was used to give an 
estimate of the treatment effect. 
 
Mishra et al (Mishra et al. 2010) used an archive of individual patient data, the 
Virtual International Stroke Trials Archive (VISTA) (Ali et al. 2007) to compare 
outcomes in over five thousand patients between those receiving thrombolysis and 
those not, adjusted for baseline National Institutes of Health Stroke Scale (NIHSS) 
(Brott et al. 1989) and age.  As a formal test of the interaction between baseline 
NIHSS and the use of thrombolysis showed a statistically significant result, the 
authors decided to categorise the baseline NIHSS into seven categories.  The authors 
used a Cochran Mantel Haenszel test to assess the asoci tion of treatment 
(thrombolysis) with outcome and then performed a propo tional odds regression, 
even although they believed that the assumption of proportional odds was violated as 
the interaction test was statistically significant.  For all NIHSS baseline categories, 
functional outcome improved for those in the thromblysis group compared to the 
control group.  For all categories of the baseline NIHSS score, except the lowest and 
highest (which had fewer subjects that the other categories), this was a statistically 
significant result. 
 
Zingmark et al (Zingmark et al. 2003) used proportional odds modelling to model the 
probability of observing a particular degree of sedation.  Sedation was measured 
using a six point scale ranging from ‘1-fully awake’ to ‘6 - does not react to pain’. 
 
The Scandinavian Candesartan Acute Stroke Trial (SCAST) (Sandset et al. 2011) 
recruited over 2000 stroke patients in a trial comparing candesartan and placebo.  
There were two co-primary effect variables: a composite endpoint variable and 
modified Rankin Scale at 6 months.  Ordinal logistic regression was used as the 
primary method of analysis for the mRS with the sliding dichotomy being performed 
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as a sensitivity analysis.  Using ordinal regression a statistically significant shift in 
favour of placebo was observed at the 5% significance level.  However the result was 
not statistically significant following adjustment for the co-primary outcome 
variables.  The sliding dichotomy method showed a similar magnitude and direction 
of result to the ordinal regression although it was not statistically significant. 
 
Two stroke trials (den Hertog et al. 2009;Mendelow et al. 2005) have used the 
sliding dichotomy methodology as their primary analysis.  The Paracetamol 
(Acetaminophen) In Stroke (PAIS) stroke trial examined whether early treatment 
with paracetamol to reduce body temperature would lea to improved outcomes (den 
Hertog et al. 2009).   More patients receiving high dose paracetamol had 
improvement beyond what would be expected compared with those receiving 
placebo although the difference was not statistically significant.  STICH was a
randomised trial of a policy of early surgery with medical treatment versus a policy 
of initial conservative treatment in patients with spontaneous supratentorial 
intracerebral haematomas (Mendelow et al. 2005).  Just over 1000 subjects were 
recruited.  The primary outcome was death or disability, assessed using the GOSE at 
six months.  Risk stratification was based on baseline prognosis using a score derived 
from observational studies of non-STICH intracerebral haemorrhage data.  The 
prognostic score was a composite of GCS, age and haematoma volume.  The 
prognostic score was used to divide patients into two groups, above and below the 
median score.  For those with a better score a favour ble outcome was deemed to be 
good recovery or better as classified by the GOSE.  For those with a worse score a 
favourable outcome was upper severe disability or better.  A neutral result was 
observed showing neither a benefit nor a detriment to early surgery or initial 
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Eight studies (Adams, Jr. et al. 2004;Bluhmki et al. 2009;Levy et al. 2009;Saver & 
Yafeh 2007;Solling et al. 2009;Song et al. 2008;Thomassen et al. 2005;Yoo et al. 
2008) used an analysis which uses a marker of stroke severity at baseline to 
distinguish between groups of patients.  This analysis uses a binary cut point to 
distinguish between a favourable and unfavourable outcome.  A favourable outcome 
is however defined differently for each of these baseline groups.  This type of 
analysis is denoted as responder or baseline severity adjusted analysis (Saver 2007). 
 
Adams et al (Adams, Jr. et al. 2004) used responder analysis to analyse the data from 
three studies: the two European Cooperative Acute Stroke Studies (ECASS) and 
Trial of Org 10172 in Acute Stroke Treatment (TOAST) (Hacke et al. 1995;Hacke et 
al. 1998;The Publications Committee for the Trial of ORG 10172 in Acute Stroke 
Treatment (TOAST) Investigators 1998).  Instead of using a prognostic score to 
determine baseline risk, as the sliding dichotomy uses, Adams used the baseline pre 
treatment NIHSS as a measure of baseline stroke severity.  For those with NIHSS 
scores 1-7 a good outcome was a Rankin Scale=0; for those with NIHSS scores 8-14 
a good outcome was Rankin Scale=0 or 1 and for those with NIHSS scores >14 a 
good outcome was a Rankin Scale of 0 to 2.  For the ECASS studies the outcome 
was the modified Rankin Scale and for TOAST aggregate scores of the Barthel Index 
and GOS were substituted for the modified Rankin Scale.  For all of these trials the 
overall result remained the same as the conventional dichotomised analysis.  
However, as would be expected, the number of less sverely affected patients who 
had a favourable outcome was inflated under the conventional analysis whilst the 
number of seriously ill patients who had a favourable outcome was reduced. 
 
Five studies (Bluhmki et al. 2009;Saver & Yafeh 2007;Solling et al. 2009;Song et al. 
2008;Yoo et al. 2008) performed baseline severity adjusted analysis using the same 
baseline grouping of NIHSS scale and outcome as Adams et al (Adams, Jr. et al. 
2004). 
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Bluhmki et al (Bluhmki et al. 2009) performed a secondary analysis of the ECASS 
III trial.  Using responder, and more conventional analysis, all additional endpoints 
studied showed improvement in favour of the group given alteplase.  The National 
Institute of Neurological Disorders and Stroke (NINDS) (The National Institute of 
Neurological Disorders and Stroke rt-PA Stroke Study Group 1995) trials were 
reanalysed (Saver & Yafeh 2007).  Using baseline sev rity adjusted analysis 
confirmed the initial trial results.  Solling et al (Solling et al. 2009) examined 
outcome after acute ischemic stroke.  Magnetic Resonance Imaging (MRI) and CT 
were compared to allow identification of patients who would benefit from 
recombinant tissue plasminogen activator (rtPA) treatment.  Using MRI to identify 
patients who would benefit from rtPA was found to be safe in the population studied.  
Song (Song et al. 2008) assessed outcome after stroke in Korean stroke patients.  The 
primary analysis was a comparison of those with and without elevated cardiac serum 
troponin T levels.  Yoo et al (Yoo et al. 2008) in a study of under-nutrition found that 
one week NIHSS score strongly predicted poorer outcome and one week under-
nutrition was a weaker predictor of poorer outcome. 
 
Thomassen et al (Thomassen et al. 2005) compared responder analysis with a 
uniform assessment of outcome.  For the uniform assessment of outcome, using the 
mRS, excellent outcome was 0-1, favourable 0-2, unfavourable 3-5 and death 6 for 
all subjects.  For the responder analysis excellent outcome varied by original NIHSS 
score in the same manner as Adams et al (Adams, Jr. et al. 2004).  Comparing the 
responder analysis to the uniform analysis, more subjects with severe strokes had 
favourable outcomes using the responder analysis whil t fewer subjects with mild 
strokes had favourable outcomes.  Although the overall number of subjects who had 
a favourable outcome was very similar using both methods of analysis, the actual 
subjects were different. 
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Levy et al (Levy et al. 2009) also used a responder analysis in the “Ancrod in Acute 
Ischemic Stroke” trial.  Responders were defined based on both pre-stroke mRS and 
pre-treatment NIHSS scores.  For those with a pre-stroke mRS of 0-1 and an NIHSS 
score of 5-15 a favourable outcome was a mRS of 0-1. For those with a NIHSS 
score >=16 and a pre-stroke mRS of 0-1 a favourable outcome was mRS of 0-2.  For 
subjects with a pre-stroke mRS of >=2 a favourable outcome was defined as 
returning to the pre-stroke mRS or better.  This trial was halted as a planned interim 
analysis showed that the study should be stopped early for lack of efficacy. 
 
Diener et al (Diener et al. 2008b), in the primary nalysis of the PRoFESS trial 
examined outcome at 3 months using the modified Rankin Scale (using all points on 
the scale without dichotomy).  This was a trial of over 20000 subjects who had 
previously had a stroke.  Subjects were randomised in a 2x2 factorial design to 
aspirin (ASA) + extended release dipyridamole (ER-DP) and either telmisartan or 
placebo; or clopidogrel and telemisartan or placebo.  Only subjects with an initial 
modified Rankin Scale score of less than or equal to four were included.  Using one 
way ANOVA no difference was found in modified Ranki Scale score between the 
two groups for analyses comparing ASA+ER-DP versus clopidogrel or telmisartan 
versus placebo.  These analyses would assume that the mRS scores were normally 
distributed – an assumption which seems unlikely looking at the figures in the paper.  
Although this was not an ordinal analysis it did include all the points on the mRS 
scale in the analysis, hence its inclusion here. 
 
1.6.5 Discussion 
This systematic review has shown that the Glasgow Outcome Scale is the most 
commonly used outcome measure for Phase III head injury trials.  However, only 
three trials exploited the ordinal nature of the scale appropriately when assessing 
outcome.  None of the 29 head injury trials identified carried out a proportional odds 
analysis of the data.  Examining stroke trials with an ordinal outcome found ordinal 
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logistic regression being used appropriately in eight studies and the sliding 
dichotomy in three, one of which also used ordinal logistic regression.  This thesis 
will use the data from eleven published studies in TBI to explore the strengths and 
limitations of using an ordinal analysis in place of the conventional binary analysis. 
 
Note – the published papers from the IMPACT (International Mission on Prognosis 
and Analysis of Clinical Trials in TBI) project, details given in section 1.7, which 
show results of ordinal modelling in head injury, have not been included in the 
results of the searches above as these results form part of this thesis and are expanded 
on in detail throughout the thesis. 
 
1.7 IMPACT project 
This thesis describes part of the IMPACT project, a National Institutes of Health 
(NIH) funded project, looking at the application of conventional and innovative 
methods for the design and analysis of studies in traumatic brain injury.  The primary 
aim of the project is to optimise chances for demonstrating benefit of a new 
therapeutic agent in the field of TBI.  The rationale for this project is that to date no 
Phase III randomised clinical trials in TBI have convincingly shown benefit. 
 
Within the NIH project four specific areas were to be examined: 1) the heterogeneity 
of the TBI patient population; 2) the Glasgow Outcome Scale (GOS) assessment; 3) 
the development and validation of prognostic models and 4) design issues such as 
recruitment, sequential designs and early endpoints.  Each of these four specific aims 
has been further split into two areas of interest.  The project was run over three 
centres: Edinburgh, Richmond and Rotterdam with eac centre having lead 
responsibility for different parts of the project, although all centres shared 
responsibility for the development and validation of prognostic models in head 
injury.  In Edinburgh there were two major areas of responsibility: specific aims 1a) 
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prognostic and mechanistic targeting - within the investigation of the heterogeneity 
of the TBI population and 2b) the “sliding dichotomy” - within the examination of 
the GOS. 
 
Specific aim 1a) - prognostic and mechanistic targetin  - studied the potential for 
increasing statistical power by targeting therapy to specific risk groups, (Machado, 
Murray, & Teasdale 1999).  As the population of traum tic brain injury is very 
heterogeneous it is reasonable to target therapies t patients that can potentially show 
benefit.  Those patients with either a very good prognosis or those with a very poor 
prognosis contribute little to the statistical power of a conventional study.  
Intermediate risk groups can be defined according to prognosis (prognostic targeting) 
or type of head injury (mechanistic targeting). 
 
Specific aim 2b) – the application of the sliding dichotomy – addressed problems in 
assessing outcome after head injury.  The GOS was explor d as an ordinal scale with 
the point of dichotomisation varying between different prognostic risk groups. 
 
1.8 Thesis outline 
The first aim of this thesis is to examine ordinal methods of analysing Phase III data, 
such as the sliding dichotomy and proportional odds modelling and compare these to 
more conventional methods of analysing outcomes.  The second aim is to determine 
which method of analysis is best under which circumstances.  That is the merits of a 
simple easily understood outcome, for example a clinical audience may prefer the 
simplicity of an outcome which is e.g. favourable or n t versus the merits of a model 
which is statistically more efficient (such as the proportional odds model).  The 
primary approach of this thesis is to use data from eal trials in order to determine 
how trials with ordinal outcomes may best be analysed. 
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In order to do this, this thesis will describe methods currently used in the literature 
for trials in head injury and stroke studies – Chapter 1.  The IMPACT data used in 
the modelling with the preliminary stages prior to analysis (data extraction, 
imputation of missing data etc.) are then described n Chapter 2.  A description of the 
methodology used for the binary analysis, ordinal alysis and meta analysis is given 
in Chapter 3.  Binary analysis and ordinal analyses – both unadjusted and adjusted 
for covariates are described in Chapter 4.  Chapter 5 compares different sliding 
dichotomy modelling strategies.  Then in Chapter 6 the optimised sliding dichotomy 
is compared with other modelling strategies.  A discussion of the results shown in the 
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2 Chapter 2 Subjects and Methods 
2.1 Data collection and datasets 
2.1.1 Introduction 
As part of the IMPACT project we were able to obtain the original subject-level data 
from 11 completed head injury studies, eight Phase III trials and three observational 
studies.  For the eight trials, no re-analysis by original treatment group was permitted 
as a condition of obtaining the data.  Staff at each centre (Edinburgh, Richmond and 
Rotterdam) took responsibility for extracting variables from different studies.  
Summary characteristics of the studies are given below in Table 2-1. 
 
After reviewing the literature and providing an outline of the project in Chapter 1, 
this chapter, Chapter 2, will describe the IMPACT datasets.  The data collection, 
extraction and synthesis will all be described.  This chapter will also discuss the 
handling of missing data, the pre-screening of continuous variables exploring their 
distribution, relationship with outcome and the codings and categorisations used in 
subsequent analysis.  Binary analysis of outcomes, with illustration, to allow data 
checking, is then shown. 
 
Table 2-1 Studies in the IMPACT database 




(Foulkes et al. 1991) GCS<=8 following non surgical 
resuscitation or GCS deteriorating 
to <8 
677 
UK Four Centre 
Study 
UK4 
(Murray et al. 1999b) Admitted to centre within 3 days of 
severe head injury resulting in coma 
988 
Nimodipine Trial  
HIT I 
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Study Publication Population N 
Nimodipine Trial 
HIT II 
(The European Study 
Group on Nimodipine in 
Severe Head Injury 
1994) 
Not obeying commands within 24h 
of injury 
852 
Tirilazad US study 
TIUS 
Not published 70% severe head injury (GCS 4-8) 






(Marshall et al. 1998) 85% severe head injury (GCS 4-8)
15% moderate head injury (GCS 9-
12) 
1131 






(Murray et al. 1999a) GCS <=12 1005 
Selfotel International 
SLIN 
(Morris et al. 1999) GCS<=8 post resuscitation 409 
Bradycor 
SKB 
(Marmarou et al. 1999) GCS<=8 139 




The main initial aim was to extract data which would be available at the point of 
entry into a trial (i.e. randomisation) with outcome.  At a later stage potential 
early/surrogate endpoints were extracted.  In order to combine data from these 11 
studies, a common format for the extraction of variables was specified.  A detailed 
template was developed giving variable names and formats in order that a permanent 
record could be kept of the derivation of variables, the link between the extracted 
variables from each dataset and the merged dataset, and how the extracted variables 
would be derived if they did not have a one-to-one correspondence.  In preparation 
                                                
4 polyethylene glycol-conjugated bovine superoxide dismutase 
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for extracting these variables literature searching was performed to find the key 
publications for each of the studies in order that e results obtained using the raw 
data could be compared with published results.  Problems with the data extraction or 
invalid or inconsistent data values were documented.  This extraction of the data was 
not a one off process performed in isolation but rather an iterative process which 
evolved over time.  We wished to not only assess traditional predictors of outcome, 
such as pupil reactivity, but also to explore novel pr dictors of outcome such as 
glucose.  We also wished to convert the data we had into a useable, well-documented 
format.  The database within which the extracted data were held was denoted the Top 
Priority Data Set (TPDS). 
 
It was agreed that the data should be extracted ‘as is’ with no cleaning to give a 
record for posterity of what was recorded in each dataset, albeit in a common format.  
These data were denoted source one data.  Subsequently th  data were cleaned and 
denoted source two data.  These source two data were us d in all of the analyses. 
 
2.1.2 Description of datasets used in analysis 
2.1.2.1 TCDB - Traumatic Coma Data Bank 
The TCDB (Foulkes et al. 1991) was the oldest dataset included in the database.  
This was an unselected series of 677 severely head injured patients admitted to four 
US centres (California, Texas, Virginia University and Virginia Medical College) 
between 1984 and 1987.  It recorded details on initial severity, demographics and 
mechanisms of injury.  Outcome was assessed at 6 months post injury.  These were 
also the data on which the Marshall CT (Marshall et al. 1991) classification was 
based.  These data were extracted by staff in Richmond. 
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2.1.2.2 UK4 – UK Four Centres study 
As with the TCDB study this too was an unselected serie .  It consisted of 988 
patients admitted to four neurosurgical centres within he UK (Edinburgh, Liverpool, 
Glasgow and Southampton) (Murray et al. 1999b).  The study ran from 1986 to 1988 
and subjects were recruited within three days of their ead injury.  Demographics, 
CT classification and neurosurgical unit management were measured.  Outcome was 
assessed six months post injury using the Glasgow Outcome Scale.  These data were 
extracted by staff in Edinburgh. 
2.1.2.3 HIT I 
This was a prospective randomised trial to study the effects of the calcium antagonist 
nimodipine (Bailey et al. 1991).  Subjects with a head injury and not obeying 
commands were recruited within 24 hours of injury.  The study recruited 351 
subjects between 1987 and 1989.  Outcome was assessed at 6 months using the GOS.  
These data were extracted by staff in Edinburgh. 
2.1.2.4 HIT II 
This was, as with HIT I, a prospective randomised stu y to compare nimodipine with 
placebo although in a larger number of subjects, 852 (The European Study Group on 
Nimodipine in Severe Head Injury 1994).  The study ran from January 1989 to June 
1991 and collected data on demographics and CT chara teristics as well as outcome 
as measured by the GOS at six months.  These data were extracted by staff in 
Edinburgh. 
2.1.2.5 TIUS – Tirilazad United States study 
This unpublished randomised trial studied the effects of tirilazad mesylate in 1155 
patients with a head injury in the US and Israel.  Patients were recruited from 1991 to 
1994.  Information on demographics, CT classification and neurosurgical 
management was recorded.  Outcome was assessed at 6 mon hs using the GOS.  
These data were extracted by staff in Rotterdam. 
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2.1.2.6 TINT – Tirilazad International study 
This trial ran in parallel to the US study and studied the effects of tirilazad mesylate 
in countries excluding the US and Israel (Marshall et al. 1998).  It recruited 1131 
patients with a head injury with the same variables and outcomes being collected as 
the US study.  These data were extracted by staff in Rotterdam. 
2.1.2.7 PEGSOD – polyethylene glycol-conjugated bovine 
superoxide dismutase 
This was a series of randomised, multicentre parallel group trials studying the effects 
of pegorgotein, a scavenger of oxygen-derived free radicals (Young et al. 1996).  
Between 1993 and 1995 the trials recruited 1574 subjects.  The data from all of these 
trials were obtained by IMPACT even although only the analysis of one of the series 
of trials, on 463 subjects, was published.  Subjects were recruited from 29 American 
centres.  Outcome was assessed using the GOS at three months.  These data were 
extracted by staff in Richmond. 
2.1.2.8 EBIC – European Brain Injury Consortium 
This was a survey of 1005 moderately and severely injured adult head injured 
patients admitted to 67 centres in 12 European countries (Murray et al. 1999a).  The 
survey was conducted in 1995.  Demography, clinical fe tures, management and 
investigations were recorded.  Outcome was assessed at six months using the GOS.  
These data were extracted by staff in Edinburgh. 
2.1.2.9 SLIN – Selfotel International study 
This was the international arm of a trial of the N-methyl-D-aspartate receptor 
antagonist Selfotel.  It recruited 409 subjects betwe n 1994 and 1996.  Subjects were 
severely injured having a post-resuscitation Glasgow C ma Scale of four to eight.  
Information on demographics, clinical features, andtreatment management was 
recorded.  We were unable to obtain data for the Amrican arm of the trial.  This trial 
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was stopped early because of possible safety concerns.  However, six month outcome 
was assessed by the GOS.  Staff in Rotterdam extracted these data. 
2.1.2.10 SKB – the Bradycor study 
This was a randomised, placebo controlled trial studying the effects of the bradykinin 
antagonist Bradycor in 31 North American centres (Marmarou et al. 1999).  One 
hundred and thirty one severely brain injured patients with GCS three to eight and at 
least one reacting pupil were recruited in 1996.  The primary objective was to assess 
the efficacy of a continuous infusion of Bradycor in preventing elevation of 
intracranial pressure (ICP).  Demographic details, clinical details and ICP were all 
recorded.  Outcome was assessed at three and six months by the GOS.  These data 
were extracted by staff in Richmond. 
2.1.2.11 SAPHIR 
This was an unpublished double blind placebo controlled trial of the drug CPP-ene, a 
competitive NMDA receptor.  Subjects not obeying commands and with at least one 
reactive pupil were recruited from 51 European Centres within 12 hours of injury.  In 
total, 924 head injured subjects were recruited betwe n 1995 and 1997.  
Demographics, clinical features and treatment management were recorded.  Outcome 
was assessed at three and six months by the GOS.  Staff in Edinburgh extracted these 
data. 
 
2.2 Data extraction 
The data extraction was not a trivial task as the historical data were in numerous 
formats with many files relating to the one study and often little, incomplete or even 
incorrect and inconsistent documentation.  An overview of the extraction of the three 
datasets for which I was explicitly responsible, EBIC, HIT I and SAPHIR is given 
below. 
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2.2.1 EBIC 
The EBIC data consisted of one file with information n 1005 subjects from 67 
centres.  An annotated Case Record Form (CRF) was available for the data making 
the process of extracting information relatively straightforward.  The extracted 
variables were renamed and reformatted and then checked against the main EBIC 
publication (Murray et al. 1999a).  All extracted variables were found to agree with 
the published paper. 
 
2.2.2 HIT 1 
The HIT I data consisted of 25 data files and one comments file with records on 352 
subjects from six centres.  One subject was found to have been randomised twice, 
having had two separate head injuries within the recruitment period of the study.  
Only information from the first head injury within the recruitment period was used, 
giving data on 351 subjects.  The data were originally stored as character files in 
column format with no text headings or identifiers on the files.  Each dataset had a 
corresponding descriptive file which specified the column names, formats and 
position in the dataset.  The extraction of the data into a readable format was very 
challenging.  The completed paper case record forms were available and had to be 
compared with the dataset in order to decipher the placement, format and names of 
columns for all 25 data files as only one of the data files was formatted as the 
descriptive file had specified.  An un-annotated CRF was available for the HIT I 
data.  As with the EBIC data, the extracted HIT I data were compared with the study 
publication, (Bailey et al. 1991), and found to agree. 
 
2.2.3 SAPHIR 
The SAPHIR data consisted of thirty-nine files with records on 924 subjects.  The 
data were originally stored in zipped SAS files with embedded formats.  The data 
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were unzipped and formatted in SAS.  The structure of the data files was very 
complex making the selection of the correct variables and records problematic.  An 
incomplete partially annotated CRF was available for the SAPHIR data.  The 
SAPHIR data have not been published however an unpublished study report and 
draft paper were available.  There were many major and minor discrepancies 
between the raw data and the study report and indeed b tween the study report and 
the draft paper.  For example: there was no one unique patient identifier for subjects; 
dates of death varied for some patients in the three and six month outcome files; 
many subjects had a start date of intracranial pressur  monitoring before their date of 
injury and, for approximately 5% of subjects, their date of baseline examination 
varied in every file in which it was recorded. 
Monitoring data, such as blood pressure and intracranial pressure, were particularly 
difficult to clean and convert to a useable format.  These data were recorded over 
multiple files, notionally being recorded every hour for up to seven days of 
monitoring.  As these data had never been cleaned there were many discrepancies 
and errors within the file, such as multiple different records at the same time point 
for the same subject.  It took many days of work to extract the data into a suitable 
format with each subject only having one record for each time point.  These 
discrepancies were resolved in discussion with members of the three IMPACT 
centres. 
 
2.3 Data synthesis 
The five Edinburgh datasets, EBIC, UK4 Centres, HITI, HIT II and SAPHIR were 
sent to Richmond where they were entered into a comm n database along with the 
other extracted studies.  Templates produced in Ediburgh, specifying how variables 
were coded in our datasets, were circulated so that the other centres could copy this 
model when sending their own data. 
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Once nine of the eleven datasets had been received by Richmond they circulated a 
SAS file which contained all of the extracted data with a consistent coding system 
where possible.  For example, in the Edinburgh datasets death was coded as 0, 1 and 
Richmond recoded this to 1, 2.  Upon checking the extracted data it was apparent that 
firstly not all variables sent to Richmond had been included, and secondly, for those 
that were included, some errors had been made in recoding.  These problems were 
notified to Richmond and after many iterations the Edinburgh datasets were entered 
into the common database and had been recoded correctly and consistently.  As part 
of the data extraction and checking process preliminary results were circulated 
between the centres.  These identified various problems, such as the extracted data 
for TINT showing 85% of subjects with bilateral non-reacting pupils at first hospital, 
changing to only 11% on admission to study hospital and then changing again to 
93% at post resuscitation – obviously an impossible sequence of events.  TIUS also 
had similar problems.  This led to more iterations f the datasets.  This process, 
although vital, was very time consuming.  However it did allow the progression of 
the analysis with confidence in the results. 
 
2.4 Missing data 
The datasets used in IMPACT had two kinds of missing data.  The first kind was 
where a specific study did not record a particular variable, for example in HIT 1 
place and cause of injury were not recorded.  Using L ttle and Rubin’s definition this 
would be denoted as Missing Completely At Random (MCAR) where the probability 
of data being missing does not depend on the observed or unobserved data (Little & 
Rubin 1987).  The second kind of missing data occurred when a variable was 
recorded within a study although some individuals did not have a value recorded.  
For example, traumatic subarachnoid haemorrhage was recorded in all studies except 
UK4 however its completeness ranged from 100% in SLIN to 73% in HIT I.  For the 
univariate analyses shown in Chapter 4 a complete cas analysis was performed in 
that analysis was restricted to subjects with data available on the covariate of interest 
and the GOS. 
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Imputation techniques were used to minimise the problems associated with the 
analysis of incomplete data due to missing values in the multivariate analysis, shown 
in Chapter 4.  Using complete case analysis would have been inappropriate as the 
missingness of a single covariate would have led to the subject’s entire record being 
discarded and not included in the analysis.  Complete case analysis has also been 
shown to lead to bias (Little & Rubin 1987).  Multip e Imputation (Rubin 1987) uses 
the distribution of the observed data, including the outcome variable, to estimate the 
missing data (van Buuren, Boshuizen, & Knook 1999;White, Royston, & Wood 
2011).  In the IMPACT database, staff in Rotterdam used Multiple Imputation to 
create 10 datasets based on all of the data.  The first dataset created using the 
multiple imputation procedure was then used in the multivariate analyses (McHugh 
et al. 2007a). 
 
2.5 Pre-screening of continuous variables 
Previous studies in head injury have typically categorised continuous variables.  This 
approach leads to loss of sensitivity and, as with categorising continuous outcome 
variables, can lead to a substantial loss of information.  Prior to conducting any 
formal analysis the distribution of the continuous variables and their relationship 
with outcome was explored.  This exploration was performed on all of the studies 
merged together. 
 
Boxplots and histograms were examined for each continuous variable.  These and the 
results from univariate analysis showed that in a very few instances, less than 1% of 
all data, ‘extreme’ values for continuous variables had been recorded.  It would have 
been wrong for a few extreme values to influence the results of prognostic 
modelling.  It was therefore decided to truncate values that were outside the range 
(defined in Table 2-2 below) to the lower and upper oints of the range.  This process 
keeps all of the original data and simply shifts extr me values to the ends of the 
range.  There are no guidelines as to what values the range should take.  This was 
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therefore determined by examining the plots and the results from the univariate 
analysis. 
 
Only two studies had included children younger than 14 years of age, TCDB and 
UK4.  It was therefore decided to restrict analyses to those aged 14 or older.  These 
were the only data excluded from the analysis.  Forall of the other continuous 
variables, more extreme values were shifted to the ranges shown in Table 2-2.  For 
example all haemoglobin values less than 6 g/dL were s t to 6 g/dL and all values 
greater than 17 g/dL were set to 17 g/dL after truncation. 
 
Splines 
After truncating each variable, splines were used to visualise the shape of the 
relationship with outcome for each variable and thus g ide the statistical modelling. 
 
Spline functions are piecewise polynomials used in curve fitting which can be fitted 
using regression programs.  They have been used primarily in the physical sciences 
to approximate a wide variety of functions (Harrell, Jr. 2001).  The most commonly 
fitted splines are linear and cubic.  In order to fit the spline function knots (i.e. the 
points at which the spline bends) have to be chosen.  Cubic spline functions can be 
used to fit highly curved shapes, however, they can be poorly behaved in the tails 
(Stone & Koo 1985).  It is therefore recommended that restricted cubic splines are 
fitted which constrain the tails of the function to be linear and also result in fewer 
parameters being specified (Harrell, Jr. 2001). 
 
For the continuous variables modelled in the IMPACT data restricted cubic splines 
were fitted with five prespecified knots at the 5, 27.5, 50, 72.5, and 95 percentiles of 
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the data for each continuous prognostic factor (McHugh et al. 2007a).  It has been 
shown that the number of knots is more important than t e exact location (Harrell, Jr. 
2001).  Five knots (giving four degrees of freedom) were chosen as it has been 
shown in practice that five knots are sufficient to m del most non linear functions 
(Stone 1986). 
 
Fitting splines although technically intricate can often lead to much simpler forms of 
the model between variables and outcome as was shown with the IMPACT data.  A 
linear spline function was observed to fit approximately the relationship observed 
between seven of the covariates and GOS.  The relationship between each of Systolic 
Blood Pressure, Mean Arterial Blood Pressure and Sodium with GOS showed a U 
shaped effect (McHugh et al. 2007a;Royston 2000). 
 
Coding/categorisation 
For those variables which had a linear relationship with outcome, the variables were 
scaled by the interquartile range 25th percentile to 75th percentile, p75-p25.  For 
example age was divided by 24.  Scaling creates estimates of odds ratios which are 
comparable between different prognostic factors both ca egorical and continuous 
(Harrell, Jr. & Shih 2001).  For those variables with a U shaped relationship with 
outcome a range was defined for the central category p75-p25 as previously.  So, for 
example, Mean Arterial Blood Pressure would be defined as low if below 85mmHg, 
middle if between 85 and 110mmHg inclusive and high if greater than 110 mmHg. 
 
Table 2-2 below produced by staff in Rotterdam shows the ranges chosen to truncate 
at, whether or not the variable had a linear relationship with GOS, and what coding 
or categorisation was used in the analysis. 
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Table 2-2 Handling of continuous variables 
Variable Range Linear Coding 
/Categorisation 
Age (years) 14+ Yes /24 
Systolic Blood pressure 
(mmHg) 
60-230 No 120-150 
Mean Arterial Blood Pressure 
(mmHg) 
40-160 No 85-110 
pH 7.0-7.7 Yes /0.15 
Haemoglobin (g/dL) 6-17 Yes /3.3 
Glucose (mmol/L) 3-20 Yes /3.7 
Sodium (mmol/L) 125-155 No 137-142 
Haematocrit (%) 18-50 Yes /10 
Platelets x109/L Lower Range-450 Yes /100 
Prothrombin Time (seconds) Lower Range-20 Yes /2 
 
2.6 Data checking introduction 
Prior to proceeding with any analysis, each variable in the merged database was 
summarised in tabular form and graphically to provide not only an indication for 
future analyses but also to assist with the checking of the data.  The relationship 
between each variable and outcome was also examined.  Outcome was measured 
using the Glasgow Outcome Scale at six months for all studies except PEGSOD, 
where it was only recorded at three months.  In all analysis outcome was taken at six 
months where available and three months if not avail ble at six.  In order to develop 
prognostic models the first stage was to carry out a conventional analysis of all 
covariates with the GOS as a binary outcome. 
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2.7 Summary methods for 2x2 tables 
Using a similar approach to that postulated by Chesnut et al (Chesnut et al. 1993) and 
illustrated by McHugh et al (McHugh et al. 2007a) the relationship between 
dichotomous predictors and outcome can be thought of in a similar way as the 
methods used to evaluate diagnostic tests.  The dichotomous outcome measure can 
be thought of as the reference measure against which a diagnostic test is assessed 
with, in effect, the prognostic factor of interest replacing the diagnostic test.  
Dichotomous predictors can be categorised as present or absent, for example pupils 
reactive or unreactive.  Using this notation the relationship between a prognostic 
factor and outcome can be shown in a 2 x 2 table, Table 2-3 below.  Many summary 
measures can be obtained from such a table: odds ratio ((ad)/(bc)); relative risk 
((a/g)/(b/h)); sensitivity (a/g); specificity (d/h); positive predictive value (a/e) and 
negative predictive value (d/f). 
 






Factor present a b e 
Factor absent c d f 
Total g h N 
 
For the data in the merged database the odds of an unf vourable outcome were 
modelled.  Reference categories were picked for each of the variables, usually the 
category that made sense clinically or the category with the largest number of 
subjects.  For example, for the variable place of injury, street/highway was used as 
the reference category and the odds of a poor outcome f r each of the other 
categories relative to the odds of a poor outcome of street/highway were compared.  
For some categorical variables, e.g. cause of injury, there were many possible 
categorisations over all of the studies.  A decision was made to group the levels of 
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these categorical variables in order to have reasonable numbers within each level 
whilst still keeping the distinct causes separate.  For example, car occupant and 
motor vehicle occupant were combined however these categories were not combined 
with, for example, pedestrian.  For the continuous variables modelled with a linear 
relationship with outcome, the odds were scaled by the interquartile range.  For 
continuous variables with a U shaped relationship with outcome the interquartile 
range was taken as the reference category, as detaile  previously.  Each level of each 
variable was compared back to a reference category and the odds tabulated and 
graphed. 
 
2.8 Illustration of binary outcome analysis - each covariate by study 
Three outcomes were modelled based on the GOS classifi tion:  (i) mortality - death 
versus everything else; (ii) an unfavourable outcome - grouping the GOS into death, 
vegetative state and severe disability versus moderate disability and good recovery; 
(iii) a bad outcome - grouping death, vegetative state, severe disability and moderate 
disability versus a good recovery.  For each of the eleven studies separately 
univariate odds ratios, 95% confidence intervals for the odds ratios and areas under 
the Receiver Operating Characteristic (ROC) curve, were calculated for each of the 
comparisons.  A SAS macro was written by Dr Butcher (Edinburgh centre) to 
calculate these values as to look at each level of ach variable relative to a reference 
category involved over 100 comparisons.  This number of comparisons was then 
multiplied three fold for the three different outcomes.  This was a crude preliminary 
analysis in that all of the data from the eleven studies were analysed together without 
any weighting. 
The table below, Table 2-4, examines gender and shows the number of subjects in 
each category as well as odds of mortality for each of t e eleven studies and overall.  
For each study the category ‘male’ was used as the reference category and the odds 
shown are the odds of mortality for females relative o the odds of mortality for 
males.  The ‘ALL’ category is an amalgamation of the numbers from all of the 
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studies and does not represent any weighted estimate; this was done to simplify the 
first examination of the data.  Table 2-4, shows that no significant difference was 
found between the odds of mortality of females compared with males for any of the 
studies as all of the confidence intervals overlap one.  The AUCs (area under the 
curve) are of a similar magnitude (0.50 to 0.54) for all studies. 
 








Ratio  95% CI AUC 
HIT2 female 190 49 25.79 1.23 (0.84 to 1.78) 0.519 
 male 629 139 22.10    
EBIC female 212 75 35.38 1.09 (0.79 to 1.51) 0.508 
 male 622 208 33.44    
SKB female 30 6 20.00 0.61 (0.22 to 1.65) 0.542 
 male 96 28 29.17    
TCDB female 137 64 46.72 1.17 (0.80 to 1.72) 0.514 
 male 467 200 42.83    
UK4 female 242 99 40.91 1.11 (0.82 to 1.49) 0.510 
 male 744 286 38.44    
HIT1 female 56 12 21.43 0.65 (0.33 to 1.29) 0.527 
 male 294 87 29.59    
PEG female 350 71 20.29 0.76 (0.57 to 1.02) 0.523 
 male 1160 291 25.09    
SAPH female 180 40 22.22 0.94 (0.64 to 1.39) 0.505 
 male 739 172 23.37    
SLIN female 89 19 21.35 0.89 (0.50 to 1.57) 0.510 
 male 320 75 23.44    
TIUS female 233 55 23.61 1.16 (0.82 to 1.64) 0.513 
 male 809 170 21.01    
TINT female 268 67 25.00 1.01 (0.73 to 1.38) 0.501 
 male 853 212 24.85    
 








Ratio  95% CI AUC 
ALL female 1987 557 28.03 1.01 (0.91 to 1.13) 0.501 
 male 6733 1868 27.74    
 
In order to represent visually these odds ratios and confidence intervals, forest plots 
were constructed for each of the three outcomes: mortality, unfavourable and bad.  
Again, SAS macros were written to produce these as no standard SAS procedure is 
able to construct these types of graph.  These plots showed for each of the variables 
the odds ratio and corresponding 95% confidence interval.  The odds ratios are 
shown on a log scale with the size of the square, representing the point estimate of 
the odds ratio, proportionate to the size of the study.  As with the tables, the 
diamond, representing the estimated odds for the ‘ALL’ group is based on an 
amalgamation of the numbers in each study without weighting.  The study name is 
given on the left. 
 
The forest plot for gender, measured in all 11 studies, is shown in Figure 2-1 below.  
This reflects the information in the table showing no evidence of a difference in the 
odds of a poorer outcome between males and females for any of the eleven studies. 
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Figure 2-1 Forest plot showing odds of mortality by gender 
 
More interesting patterns however emerge when examining the plot for traumatic 
subarachnoid haemorrhage (tSAH). 
Figure 2-2 below shows the corresponding forest plot for this variable.  It can be seen 
that subjects who have had a subarachnoid haemorrhage have a greater odds of dying 
than those subjects who have not.  For all studies except SKB the 95% confidence 
intervals do not overlap one.  However, the SKB study does have very few subjects.  
The UK4 centres study did not record information on subarachnoid haemorrhage 
therefore it is not shown in this figure. 
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Figure 2-2 Forest plot showing odds of mortality by traumatic subarachnoid haemorrhage 
 
2.9 Software 
All analyses were performed using SAS 9.1 (SAS v9. 2004. Cary, NC, USA) with 
the exception of the generation of the odds ratios chosen to increase the proportion of 
favourable outcomes in the simulation modelling shown in Chapter 5 which were 
calculated using the Solver add on in Excel (Microsoft Office Excel 2003). 
 
2.10 Discussion 
This chapter has detailed the eleven IMPACT datasets and the careful extraction and 
synthesis of these data.  The handling of continuous variables and summary methods 
for 2x2 tables has also been discussed.  This first stage allowed assessment of odds 
ratios prior to carrying out any more formal analysis.  It was helpful in screening for 
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any coding errors in data extraction.  It was also u eful to inspect visually the 
variables for heterogeneity.  A more formal test of heterogeneity was performed on 
the estimates from the proportional odds modelling, as detailed in Chapter 3.  
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3 Chapter 3 Methodology 
3.1 Introduction 
After the data checking and visual inspection of the variables, the next stage was to 
model more formally the ‘treatment’ effects over all eleven studies.  Modelling was 
performed both by taking the outcome (GOS) as a binry outcome, over all four 
possible splits, and as a four point ordinal outcome.  A four point ordinal outcome 
was modelled as the categories of death and vegetative state were pooled on both 
statistical and ethical grounds.  The statistical grounds being that vegetative state is a 
relatively rare outcome (only 4% of patients had a 6 month GOS classification of 
vegetative state); and the ethical grounds being that a vegetative state should never 
be regarded as being a favourable outcome, irrespective of baseline prognosis.  For 
the binary outcomes logistic regression models were fitted.  For the ordinal outcome 
cumulative logit models with proportional odds, hereafter referred to as proportional 
odds models, were fitted.  The first part of this chapter discusses both binary analysis 
and proportional odds theory.  The proportional odds model is then considered in 
more depth paying particular attention to the addition of covariates, the application of 
the model and testing goodness of fit.  The second part of the chapter discusses meta 
analysis demonstrating how it can be applied using fixed and random effects 
methods. 
 
3.2 Binary analysis theory 
For a binary outcome variable using standard notation let 
Y be the response variable, X be the explanatory variable and π  be the probability of 
success. 
Then: 
( )xπ =P(Y=1|X=x) =1-P(Y=0|X=x) 
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where α  is the intercept and β the parameter estimate from the explanatory variable. 
Equivalently the logit (log odds) is 




π=π  (Agresti 2002) 
These formulae can be extended to incorporate multiple covariates. 
3.3 Proportional odds theory 
 The proportional odds model has no distributional assumptions about the ordered 
categorical response.  However it does have a paramet ic assumption about the 
relationships between the response distributions of any two individuals.  If the 
assumption of proportional odds holds, using proportional odds analysis will exploit 
the ordinal nature of the GOS without losing any information. 
The proportional odds model is palindromic invariant in that the model will accept 
the ordering of the outcome categories (1 to k) in increasing order 1,…,k or 
decreasing order k, k-1,…,1 but reject all other orderings (McCullagh 1978).  
Changing the order of the outcome categories from increasing to decreasing or vice 
versa will change only the sign of the parameter estimates on the logit scale. 








log  (Agresti 2002) 
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3.4 Proportional odds model – addition of covariate s 
The logit distribution, unlike the Normal distribution is a sigmoidal shape, as shown 
Figure 3-1 below.  With ( )xπ  as defined above. 
 
Figure 3-1 Logistic curve 


















As illustrated by the example below, this non-linearity means that the addition of 
even a completely balanced covariate inflates the estimate of the odds ratio (Pocock 
et al. 2002;Robinson & Jewell 1991).  This is not seen with the addition of covariates 
to a normal linear model where the addition of a completely balanced covariate does 
not change the treatment effect estimate. 
 
With linear regression the addition of covariates to a model gives more precise 
treatment effect estimates(Gail, Wieand, & Piantadosi 1984).  This improvement in 
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precision can be explained due to a reduction in residual variance (Robinson & 
Jewell 1991).  In a linear model if the covariates are completely balanced then 
unadjusted and adjusted estimates are the same.  This improvement in precision 
however does not occur with logistic regression and lmost counter-intuitively the 
addition of even completely balanced covariates to a n n-linear model leads to a loss 
of precision (Ford & Norrie 2002;Robinson & Jewell 1991).  
 
This is illustrated using the hypothetical example below in a similar manner to that 
shown by Steyerberg and Eijkemans (Steyerberg & Eijkemans 2004).  Table 3-1 
below shows treatments A and B and overall survival.  Table 3-2 shows stratification 
by tSAH.  The odds ratio for survival changes from 0.44 overall, to 0.38 when 
stratified by having a tSAH.  This covariate although completely balanced between 
treatment groups is highly predictive of outcome with far greater numbers of those 
without a tSAH surviving compared to those with a tSAH. 
 
Table 3-1 Hypothetical example showing overall survi al by treatment 
Overall 
Treatment Dead Survive Total 
A 40 60 100 
B 60 40 100 
  50%  
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Table 3-2 Hypothetical example showing survival stratified by tSAH 
tSAH no tSAH yes 
Dead Survive Total Dead Survive Total 
10 40 50 30 20 50 
20 30 50 40 10 50 
 70%   30%  
 
This hypothetical result has been shown in a published trial.  Steyerberg et al 
(Steyerberg, Bossuyt, & Lee 2000) illustrated the addition of covariates with the 
GUSTO I trial (GUSTO investigators 1993).  The GUSTO I trial was a comparison 
of tissue plasminogen activator (t-PA) and streptokinase in patients with a 
myocardial infarction (MI).  The primary outcome was death by 30 days.  The 
unadjusted OR for mortality was 0.853, changing to 0.829 when adjusted for age.  
Corresponding to logistic regression coefficients and standard errors of -0.1586 
(0.09) and -0.1878 (0.050) respectively.  This gave n increase of 18% on the logistic 
scale for the treatment effect and an increase of 3% or the standard errors.  
However, this increase was less than the increase due to stratification.  Robinson and 
Jewell (Robinson & Jewell 1991) showed that adjusting for covariates is always 
more statistically efficient when using logistic reg ssion despite the increase in 
standard error. 
 
Covariate adjustment provides individualised (conditional) effect estimates in 
logistic regression in comparison to an unadjusted analysis which gives a population 
effect (Hernandez, Steyerberg, & Habbema 2004).  The unadjusted (unconditional) 
estimate is a biased estimate; therefore all of the simulation modelling in this thesis 
uses covariate adjusted multinomial regression, details of which are given in Chapter 
5. 
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3.5 Proportional odds application 
As discussed by McHugh et al (McHugh et al. 2007a) a binary covariate such as 
hypotension (no/yes) can be summarised as a 2x4 table for each study.  Table 3-3 
below shows the data for the EBIC study.  A far greater percentage of those with 
hypotension died or were in a vegetative state compared to those without 
hypotension. 
Table 3-3 Relationship between hypotension on admission and six month GOS in EBIC 
hypotension 
/ GOS 










Yes 116 (57.7) 30 (14.9) 28 (13.9) 27 (13.4) 201 
No 182 (29.0) 94 (15.0) 131 (20.9) 221 (35.2) 628 
 
Using the conventional approach to prognostic analysis with the GOS dichotomised 
into favourable and unfavourable the table would be as shown in Table 3-4. 
 










Yes 146 (72.6) 55 (27.4) 201 
No 276 (43.9) 352 (56.1) 628 
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The corresponding odds ratio for this table is (146/55)/(276/352)=3.39.  Table 3-3 
can also be dichotomised as dead/vegetative versus better outcome or as not good 
versus a good outcome, giving odds ratios of 3.34 and 3.50 respectively. 
 
The three estimated odds ratios (3.39, 3.34 and 3.50) are very similar.  The 
proportional odds model assumes that no matter where t  outcome is dichotomised 
the true underlying odds ratio is the same.  The estimate of this common odds ratio is 
3.38 95%CI (2.49 to 4.60).  That is having hypotensio  hifts the distribution of 
outcome in a negative direction.  This estimate of 3.38 is very close to the estimates 
from the three dichotomous splits. 
 
Goodness of fit of the proportional odds model can be examined in a variety of ways, 
using Generalised Estimating Equations (GEE) (Liang & Zeger 1986), comparing 
score and Wald tests (Stiger, Barnhart, & Williamson 1999) and comparing observed 
and expected values (Ashby, Pocock, & Shaper 1986).  Here the score test for 
goodness of fit of the proportion odds model gives p=0.976; showing that the 
proportional odds model fits well for these data. 
 
In other IMPACT studies however the goodness of fit tes  showed that the 
proportional odds assumption did not hold.  Table 3-5 below shows hypotension in 
the UK4 centres study. 
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Table 3-5 Relationship between hypotension on admission and six month GOS in UK4 
hypotension / 
GOS 










Yes 161 (67.6) 24 (10.1) 22 (9.2) 31 (13.0) 238 
No 233 (33.2) 138 (19.7) 133 (18.9) 198 (28.2) 702 
 
The odds ratio for comparing unfavourable versus favourable is 3.11; death and 
vegetative state versus better is 4.21; and not good recovery versus good recovery is 
2.62.  The formal goodness of fit test gives p=0.016 showing there is evidence that 
the underlying odds ratios are not identical.  However the three estimates are in the 
same direction and of similar magnitude suggesting that the odds ratio obtained from 
the proportional odds model 3.74 95%CI (2.78 to 5.04) is still a sensible summary of 
the three odds ratios from the dichotomous splits even though the formal assumption 
of proportional odds does not hold. 
 
This method can be extended to covariates with more than two levels.  A reference 
category is chosen, usually the most clinically meaningful and quite common.  The 
other categories are then individually compared back to this reference category.  For 
example, with place of injury, street/highway was tken as the reference category 
and the other categories e.g. home or recreational etc. were compared back to the 
reference category.  Occasionally, within each study, some categorical variables had 
no observations in one cell of the table of GOS by variable.  Where this occurred, 
one extra observation was added to each cell of the tabl  to avoid dividing by zero.  
This is typically done in the analysis of categorical data (Agresti 2002).  
 
Proportional odds analysis can also be used in the analysis of continuous variables.  
As shown above the log odds of, say, an unfavourable outcome can be written as a 
linear function.  As with the analysis of binary or categorical variables, the regression 
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modelling can be performed for different dichotomies of the GOS.  A common slope, 
assuming all of the individual slopes are similar, c n be modelled to allow fitting of 
the proportional odds model for continuous data. 
 
Each of the levels of all variables was tested to see if the assumption of proportional 
odds held.  The assumption of proportional odds was not violated in most cases.  
This test has however been shown to perform poorly.  When modelling data no 
model is, of-course, ‘correct’ - “Essentially, all models are wrong, but some are 
useful” (Box & Draper 1987).  As with any model fitting the choice of model can be 
quite arbitrary and there may be other models which fit t e data equally well (Copas 
& Eguchi 2010).  One of the most important things is to develop a prognostic model 
which fits the data well (Harrell, Jr., Lee, & Mark 1996).  This is something that a 
goodness of fit test can perform poorly at.  Generally goodness of fit tests are 
irrelevant: with small numbers they will not pick up deviations; and with large 
samples, as studied here, the test is potentially over-sensitive.  This is particularly 
illustrated in the goodness of fit test for proportional odds.  For sparse data or where 
an explanatory variable is continuous it has been shown to perform poorly (Peterson 
& Harrell 1990).  Also, where the data are not spare it has been shown to be too 
liberal in that it may show a significant result with only small departures from 
proportional odds (Peterson & Harrell 1990).  It has also been shown that the 
conventional Pearson’s Chi Squared test used to assess goodness of fit may not be 
valid when the model includes covariates (Pulksteni & Robinson 2004).  Fitting the 
proportional odds model can be thought of as being analogous to meta analysis.  The 
final estimate, as with that from a proportional odds model, gives an overall 
summary measure of the data.  Even when the assumption of proportional odds is 
violated the pooled estimate might still be judged to give a useful summary measure 
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3.6 Meta analysis introduction 
Meta analysis allows results to be combined from different studies and can provide a 
quantitative measure of ‘treatment’ effect allowing conclusions to be drawn about 
therapeutic effectiveness (L'Abbe, Detsky, & O'Rourke 1987;Whitehead & 
Whitehead 1991).  Thompson and Pocock stated that “meta analysis has the potential 
to remove idiosyncrasy, …, however it is unrealistic to imagine that it will produce 
simple statistical answers to complex clinical problems” (Thompson & Pocock 
1991).  There are two main ways of combining data in  meta analysis using either a 
fixed or random effects analysis.  A fixed effects analysis assumes that the studies 
observed are from the same population and that the und rlying effect is the same in 
each trial i.e. the studies are homogeneous (DeMets 1987;Thompson & Pocock 
1991).  A random effects analysis assumes that the studies observed are from a 
random sample of possible studies and that the true und rlying effect varies between 
studies i.e. it takes into account the heterogeneity be ween studies (DeMets 1987). 
 
Cochran’s Q test is used to test for heterogeneity.  The test statistic, Q, is a weighted 
sum of squares of deviations.  When treatment effects are homogeneous it follows a 
Chi-squared distribution with (k-1) degrees of freedom, where k is the total number 
of studies under consideration.  The test is however known to be insensitive for 
detecting true heterogeneity amongst studies as stati tic lly significant (Higgins et al. 
2003).  Therefore a cut off of p<0.1 is conventionally used to assess heterogeneity 
although this increases the type I error rate. 
Using conventional notation: 
Q= ( )∑ − 2ˆˆ θθ iiw  
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where iθ̂  is the ith treatment effect estimate (here the log odds ratio for the 
proportional odds model), θ̂ is the estimate of the overall effect and wi is the 





3.7 Meta analysis application 
Meta analysis was performed on each variable separately.  The proportional odds 
model was fitted for each trial, with each level of c variate analysed separately and 
compared to a reference category in a similar manner as described in Chapter 2.  
These resulting proportional odds estimates were pooled over all the studies.  The 
process used for fixed and random effects pooling is described below. 
 
3.7.1 Fixed effects pooling 
Under a fixed effects model, using the inverse variance method to combine studies 








 with the terms as defined above. 
It is assumed that 
iθ̂ ~N(θi,, wi
-1) for i=1, …, k. 
To test the global null hypothesis H0: θ1= … = θ k the statistic U can be used, defined 
below.  It has a Chi-squared distribution with one degree of freedom under the null 
hypothesis.  This assumes that there is a common ‘treatment’ effect in all studies. 
 





















with the 95% CI for the odds ratio obtained by exponentiation. 
For example, for traumatic subarachnoid haemorrhage (tSAH) the odds ratios from 
the proportional odds model for the individual studies are shown in the Table 3-6 
below. 
 
Table 3-6 tSAH estimates from proportional odds model by study 
Study OR 95% CI 
iθ̂  SE wi ii wθ̂  ii w
2θ̂  
TINT 2.72 (2.17,3.41) 1.000 0.116 74.517 74.491 74.465 
TIUS 2.48 (1.95,3.14) 0.906 0.121 68.717 62.291 56.465 
SLIN 2.39 (1.53,3.73) 0.871 0.228 19.290 16.796 14.624 
SAP 2.51 (1.97,3.20) 0.921 0.124 64.984 59.849 55.120 
PEG 2.30 (1.90,2.78) 0.832 0.096 108.108 89.998 74.922 
HIT1 3.90 (2.32,6.57) 1.361 0.266 14.126 19.224 26.163 
TCDB 3.18 (2.26,4.46) 1.156 0.173 33.383 38.605 44.645 
SKB 2.73 (1.25,5.98) 1.005 0.399 6.279 6.313 6.347 
EBIC 3.24 (2.48,4.23) 1.174 0.136 53.834 63.214 74.227 
HIT II  2.64 (2.01,3.45) 0.969 0.138 52.718 51.070 49.474 
Sum     495.956 481.851 476.452 
 
 
Chapter 3 Methodology 58 



















Odds ratio and 95%CI 2.64 (2.42 to 2.89) 
















Q= ( )∑ − 2ˆˆ θθ iiw =∑ −Uwii2θ̂ =476.452-468.147=8.30 (9df) p=0.50 
Thus there is strong evidence of an association between tSAH and outcome, 
p<0.0001 with little evidence of heterogeneity. 
 
Other variables however do show statistically signif cant heterogeneity.  For example 
Table 3-7 below shows estimates for hypoxia in the eight studies that recorded it. 
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Table 3-7 Hypoxia estimates from proportional odds model by study 
Study 
iθ̂  SE wi ii wθ̂  ii w
2θ̂  
TINT 0.702 0.164 37.164 26.103 18.333 
TIUS 0.938 0.135 55.068 51.655 48.454 
SLIN -0.209 0.382 6.837 -1.461 0.299 
SAP 0.703 0.186 28.954 20.359 14.316 
UK4 0.609 0.146 47.160 28.712 17.481 
TCDB 0.638 0.209 22.948 14.649 9.351 
SKB 0.536 0.416 5.790 3.104 1.665 
EBIC 1.165 0.147 46.043 53.623 62.451 
Sum   249.964 196.776 172.350 
 
In a similar manner to above, the pooled fixed effect estimate, 95% Confidence 



















Odds ratio and 95%CI 2.20 (1.94 to 2.49) 
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Test of heterogeneity: 
Q= ( )∑ − 2ˆˆ θθ iiw = 196.776-154.905=17.45 (7df) p=0.01 
It can be observed that there is statistically significant heterogeneity between the 
studies for hypoxia. 
 
3.7.2 Random effects pooling 
The fixed effect estimate takes no account of variation between studies.  A random 
effects model relaxes the assumption of a common intervention effect.  Using the 
DerSimonian and Laird (DerSimonian & Laird 1986) random effects model with 
Whiteheads’ notation (Whitehead & Whitehead 1991). 
( )21 ˆ,~ˆ τθθ +−ii wN  for i=1, …, k  
Letting ( ) 121* ˆ −− += τii ww  gives 
( )( )1*,~ˆ −ii wN θθ  
where 2τ̂ is a measure of the degree to which the ‘treatment’ effect varies across 










2τ   
with Q= ( )∑ − 2ˆˆ θθ iiw as with the fixed effect model. 
The test statistic for the random effects model U* is denoted as below.  As with the 
fixed effects model, this follows a Chi-squared distribution with one degree of 
freedom under the null hypothesis. 
 





















Extending Table 3-7 to show *i  and θ̂
*
iw  below in Table 3-8. 
Table 3-8 Hypoxia estimates from random effects model 
Study 





TINT 0.702 0.164 37.164 13.012 9.139 
TIUS 0.938 0.135 55.068 14.684 13.774 
SLIN -0.209 0.382 6.837 5.097 -1.066 
SAP 0.703 0.186 28.954 11.837 8.323 
UK4 0.609 0.146 47.160 14.055 8.557 
TCDB 0.638 0.209 22.948 10.693 6.826 
SKB 0.536 0.416 5.790 4.491 2.408 
EBIC 1.165 0.147 46.043 13.954 16.252 
Sum   249.964 87.823 64.213 
 





































Odds ratio and 95%CI 2.08 (1.68 to 2.56) 
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Using a random effects model gives a similar estimate, lbeit slightly smaller, and a 
wider confidence interval than the estimates from the fixed effects model.  As can be 
seen in Table 3-8 the weights from the random effects model, *iw , are closer to each 
other than the weights from the fixed effects model, iw . 
3.8 Discussion 
This chapter has shown the theory for both the binary and proportional odds models 
used in subsequent chapters.  The methodology for meta analysis, both fixed and 
random effects has also been shown.  For the studie in the IMPACT database both 
the fixed and random effects estimates were calculated.  However, as the assumption 
of homogeneity between the different studies seemed i plausible, the proportional 
odds modelling shown in subsequent chapters uses the pooled estimates from the 
random effects analysis. 
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4 Chapter 4 Analyses using IMPACT data 
4.1 Introduction 
The next stage was to model the IMPACT data using both unadjusted and adjusted 
analyses.  Known and novel predictors of outcome were examined.  Using the 
methods in Chapter 3, models (both logistic and propo tional odds) were fitted 
separately for each study.  The resulting odds ratios were pooled by using random 
effects models. 
In the first part of this chapter univariate analyses are performed on all four possible 
binary splits of the five point GOS.  These show the odds of an unfavourable 
outcome for each level of each covariate compared back to a reference category.  
These results were then examined to see if fitting a proportional odds model using 
the full outcome scale would provide a useful summary measure of the four binary 
splits.  Examining the results this seemed a reasonable assumption.  The second part 
of this chapter shows the unadjusted pooled random effects estimates of the common 
odds ratios from the proportional odds model.  Subsequently, multivariate analyses 
are then performed, adjusting the results obtained from the proportional odds model 
for covariates that were considered to be both a-priori important and also those that 
showed statistically significant associations with outcome in the univariate 
proportional odds analysis.  Four sets of covariate models with three, four, seven and 
nine covariates were developed. 
 
In the tables below showing the associations, Global is the U test Global test statistic 
assuming that the difference between categories across studies=0 and Q is the test for 
heterogeneity as described in Chapter 3.  The p-value for the Q test is only shown to 
two decimal places as p<0.1 is considered to be statistic lly significant. 
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4.2 Binary analysis on pooled data – four dichotomi es 
The odds of an unfavourable outcome were estimated for each level of each covariate 
referred back to a reference category.  This was repeat d four times for each for the 
four possible splits of the five point GOS.  Table 4-1 below shows each of the four 
splits labelled by the ‘unfavourable’ outcome.  Items in bold below the double line 
were the outcome of interest for each of the four modelling strategies.  These 
outcomes were modelled using logistic regression. 
 
Table 4-1 GOS with four binary splits 
Mortality Dead/Vegetative State Unfavourable Not Good 
Good Recovery Good Recovery Good Recovery Good Recovery 
Moderate Disability Moderate Disability Moderate Disability Moderate Disability 
Severe Disability Severe Disability Severe Disability Severe Disability 
Vegetative State  Vegetative State  Vegetative State  Vegetative State  
Death Death Death Death 
 
4.2.1 Dichotomous analysis – mortality outcome 
The first binary outcome was death versus good outcome, moderate disability, severe 
disability and vegetative status.  The results for all of the variables considered are 
shown below in Table 4-2.  The odds ratio for e.g. gender shows the odds of an 
unfavourable outcome for females compared to males.  As can be seen there is very 
little difference in the odds of dying between men and women p=0.925.  The odds 
ratio is almost one (1.01) with a narrow 95% confidence interval (0.90 to 1.13).  
These results are homogeneous across the 11 studies, p=0.50.  The odds ratios for 
age, pH, haemoglobin, glucose, haematocrit, platelets and prothrombin time are 
scaled by their interquartile range over all studies as described in Chapter 2.  Little 
differences were observed in outcome between races, years of education, primary or 
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secondary referral and contusions with most other variables showing an association 
with mortality.  Having a traumatic subarachnoid haemorrhage, increasing age, CT 
class of swelling or shift, GCS of 3-5, not having a motor response of localises or 
obeys and having lower lab values (with the exception of glucose for which a higher 
value had a stronger association) were very strongly associated with death.  Having 
an epidural haematoma was strongly associated with a better outcome after injury, 
which may be explained by the potential ease with which these haematomas can be 
surgically evacuated.  With an epidural haematoma, brain function is disturbed 
because of compression although there is generally little intrinsic brain damage.  If 
compression is relieved promptly, full recovery is more likely to occur (Steyerberg et 
al. 2008).  Little statistically significant heterogeneity between studies was observed 
with the exceptions of hypotension, cisterns, contusions and some of the GCS 
components which did show statistically significant he erogeneity between studies. 
 
Table 4-2 Pooled random effects estimates of binary odds ratios for mortality outcome 
(unadjusted) 













male       Gender 
female 1.01 (0.90 to 1.13) 0.01 0.925 9.35 0.50 
Caucasian       
Black 1.24 (0.98 to 1.55) 3.30 0.069 4.17 0.53 
Asian 1.42 (0.94 to 2.15) 2.84 0.092 2.69 0.61 
Race 
other 1.15 (0.77 to 1.71) 0.46 0.496 5.73 0.22 
0-8 years       
9-12 years 0.92 (0.56 to 1.54) 0.09 0.763 3.08 0.21 
Education 
> 12 years 0.87 (0.57 to 1.34) 0.39 0.531 2.30 0.32 
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street/highway       
home 1.82 (1.34 to 2.48) 14.85 <0.001 0.98 0.61 
work/school 1.20 (0.69 to 2.08) 0.40 0.527 5.11 0.08 
recreational 0.50 (0.28 to 0.87) 5.91 0.015 0.06 0.97 
Place Injury 
other 1.29 (0.88 to 1.89) 1.70 0.192 1.25 0.54 
domestic/fall       
road traffic accident 0.54 (0.48 to 0.61) 99.78 <0.001 3.84 0.95 
assault 0.56 (0.44 to 0.71) 21.96 <0.001 9.92 0.45 
work-related 0.84 (0.61 to 1.16) 1.12 0.291 4.49 0.81 
sports/recreation 0.40 (0.23 to 0.71) 9.91 0.002 13.52 0.10 
Cause Injury 
other 0.78 (0.63 to 0.98) 4.74 0.030 7.21 0.62 
primary       Referral 
secondary 0.99 (0.87 to 1.13) 0.01 0.913 2.00 0.85 
no       Hypoxia 
suspected/definite 2.02 (1.61 to 2.55) 36.18 <0.001 16.18 0.02 
no       Hypotension 
suspected/definite 2.62 (1.99 to 3.47) 6.19 <0.001 29.42 <0.01 
no       Hypothermia 
suspected/definite 2.11 (1.35 to 3.30) 1 .61 0.001 14.15 0.01 
diffuse class II       
no visible pathology 0.51 (0.28 to 0.92) 5.03 0.025 8.82 0.18 
swelling/shift 3.50 (2.67 to 4.60) 81.60 <0.001 12.06 0.06 
CT class 
mass 2.88 (2.45 to 3.39) 162.52 <0.001 4.73 0.58 
present       Cisterns 
compressed/absent 2.74 (1.98 to 3.78) 37.43 <0.001 19.48 <0.01 
no       
1-5 mm 1.62 (1.30 to 2.03) 18.26 <0.001 8.17 0.23 
Shift 
> 5mm 2.66 (2.04 to 3.480 51.84 <0.001 15.13 0.02 
no       tSAH 
yes 2.82 (2.52 to 3.16) 325.88 <0.001 9.19 0.42 
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no       Epidural 
Haematoma 
(EDH) 
yes 0.68 (0.57 to 0.80) 19.75 <0.001 8.77 0.36 
no       Subdural 
Haematoma 
(SDH) 
yes 2.41 (2.11 to 2.76) 169.04 <0.001 11.26 0.19 
no       Contusion 
yes 1.18 (0.89 to 1.57) 1.32 0.251 31.27 <0.01 
none       
pain/sound/ 
spontaneous 
0.42 (0.30 to 0.59) 25.90 <0.001 41.13 <0.01 
Eye 
missing/untestable 0.66 (0.50 to 0.87) .53 0.004 9.43 0.22 
none       
sounds-orientated 0.38 (0.29 to 0.49) 56.00 <0.001 22.86 0.01 
Verbal 
missing/untestable 0.88 (0.68 to 1.15) 0.87 0.350 20.16 0.01 
localises/obeys       
none 5.73 (3.72 to 8.82) 62.87 <0.001 40.08 <0.01 
extension 5.46 (3.95 to 7.55) 105.91 <0.001 34.09 <0.01 
abnormal flexion 2.75 (2.12 to 3.56) 58.58 <0.001 19.65 0.03 
normal flexion 1.60 (1.28 to 1.99) 17.67 <0.001 17.80 0.06 
Motor 
missing/untestable 1.94 (1.50 to 2.51) 25.64 <0.001 5.19 0.52 
6-8       
3-5 3.54 (2.72 to 4.61) 88.53 <0.001 31.12 <0.01 




missing/untestable 1.98 (1.67 to 2.36) 60.17 <0.001 3.08 0.88 
both sides +ve       
one side +ve 2.38 (2.02 to 2.79) 111.39 <0.001 6.69 0.57 
Pupil 
both side -ve 5.93 (4.42 to 7.96) 141.09 <0.001 37.05 <0.01 
120-150mmHg       




(SBP) >150 mmHg 1.54 (1.32 to 1.79) 30.37 <0.001 8.72 0.37 
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85-110 mmHg       






>110 mmHg 1.47 (1.24 to 1.73) 19.89 <0.001 7.54 0.48 
137-142 mmol/L       
<137 mmol/L 1.35 (1.12 to 1.62) 10.04 0.002 7.61 0.27 
Sodium 
>142 mmol/L 1.21 (0.99 to 1.48) 3.51 0.061 8.51 0.20 
Age /24 years 2.08 (1.91 to 2.26) 288.56 <0.001 12.19 0.27 
pH /0.15 0.73 (0.64 to 0.83) 22.07 <0.001 6.14 0.19 
Haemoglobin /3.3 g/dL 0.69 (0.58 to 0.82) 18.56 <0.001 10.12 0.07 
Glucose /3.7 mmol/L 1.85 (1.70 to 2.01) 196.41 <0.001 5.86 0.32 
Haematocrit /10 % 0.69 (0.55 to 0.87) 9.97 0.002 2.65 0.27 
Platelets /100 x109/L 0.65 (0.55 to 0.77) 24.82 <0.001 1.97 0.58 
Prothrombin 
time 
/2 seconds 1.64 (1.34 to 2.00) 23.75 <0.001 3.21 0.20 
 
4.2.2 Dichotomous analysis – dead/vegetative outcome 
Table 4-3 below shows the odds ratios when dead/vegetative is taken as 
‘unfavourable outcome’.  Similar results are observed as with the mortality outcome, 
with increased odds of an unfavourable outcome for older patients, those having a 
traumatic subarachnoid haemorrhage, lower GCS score and non reacting pupils.  
Lower values of the laboratory parameters, except glucose, are again strongly 
associated with a poorer outcome.  Little statistically significant heterogeneity 
between studies was observed for most variables however it was observed with 
hypotension, cisterns and some of the GCS components. 
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Table 4-3 Pooled random effects estimates of binary odds ratios for dead/vegetative outcome 
(unadjusted) 













male       Gender 
female 1.03 (0.93 to 1.15) 0.37 0.542 5.94 0.82 
Caucasian       
Black 1.20 (0.97 to 1.49) 2.72 0.099 2.79 0.73 
Asian 1.20 (0.75 to 1.91) 0.58 0.447 5.02 0.28 
Race 
other 1.08 (0.83 to 1.40) 0.36 0.549 3.96 0.41 
0-8 years       
9-12 years 0.79 (0.58 to 1.07) 2.41 0.121 1.20 0.55 
Education 
> 12 years 0.81 (0.58 to 1.12) 1.58 0.209 1.07 0.58 
street/highway       
home 1.63 (1.21 to 2.21) 0.10 0.002 0.86 0.65 
work/school 1.39 (0.93 to 2.07) 2.58 0.108 3.07 0.21 
recreational 0.59 (0.35 to 0.99) 4.05 0.044 1.39 0.50 
Place Injury 
other 1.35 (0.93 to 1.94) 2.55 0.110 0.15 0.93 
domestic/fall       
road traffic accident 0.60 (0.53 to 0.68) 72.83 <0.001 4.60 0.92 
assault 0.57 (0.45 to 0.72) 1.68 <0.001 7.11 0.71 
work-related 0.84 (0.62 to 1.15) 1.14 0.286 3.44 0.90 
sports/recreation 0.42 (0.25 to 0.71) 10.42 0.001 12.75 0.12 
Cause Injury 
other 0.81 (0.66 to 1.01) 3.64 0.056 2.58 0.98 
primary       Referral 
secondary 0.97 (0.85 to 1.10) .28 0.595 3.24 0.66 
no       Hypoxia 
suspected/definite 2.08 (1.71 to 2.54) 3.54 <0.001 12.59 0.08 
no       Hypotension 
suspected/definite 2.68 (2.02 to 3.54) 47.42 <0.001 30.61 <0.01 
no       Hypothermia
suspected/definite 2.13 (1.45 to 3.14) .60 <0.001 11.30 0.02 
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diffuse class II       
no visible pathology 0.43 (0.24 to 0.78) 7.69 0.006 9.13 0.17 
swelling/shift 3.50 (2.75 to 4.45) 104.55 <0.001 10.45 0.11 
CT class 
mass 2.86 (2.45 to 3.33) 178.21 <0.001 5.74 0.45 
present       Cisterns 
compressed/absent 2.86 (2.06 to 3.95) 39.95 <0.001 21.76 <0.01 
no       
1-5 mm 1.61 (1.28 to 2.03) 16.61 <0.001 9.39 0.15 
Shift 
> 5mm 2.50 (1.93 to 3.24) 48.78 <0.001 14.93 0.02 
no       tSAH 
yes 3.00 (2.66 to 3.40) 307.65 <0.001 11.19 0.26 
no       EDH 
yes 0.63 (0.54 to 0.73) 33.74 <0.001 6.05 0.64 
no       SDH 
yes 2.26 (2.04 to 2.51) 234.13 <0.001 6.86 0.55 
no       Contusion 
yes 1.25 (0.97 to 1.62) 2.94 0.086 29.15 <0.01 
none       
pain/sound/ 
spontaneous 
0.36 (0.26 to 0.51) 33.72 <0.001 47.16 <0.01 
Eye 
missing/untestable 0.65 (0.50 to 0.85) 9.80 0.002 9.54 0.22 
none       
sounds-orientated 0.35 (0.27 to 0.45) 62.88 <0.001 25.33 <0.01 
Verbal 
missing/untestable 0.92 (0.71 to 1.19) 0.41 0.523 20.19 0.01 
localises/obeys       
none 6.07 (3.70 to 9.95) 1.02 <0.001 55.23 <0.01 
extension 7.29 (5.00 to 0.63) 106.39 <0.001 47.76 <0.01 
abnormal flexion 3.39 (2.58 to 4.45) 77.33 <0.001 23.30 0.01 
normal flexion 1.74 (1.36 to 2.21) 20.02 <0.001 23.29 0.01 
Motor 
missing/untestable 2.16 (1.68 to 2.77) 36.25 <0.001 4.33 0.63 
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6-8       
3-5 3.89 (3.00 to 5.04) 105.55 <0.001 31.97 <0.01 
9-15 0.68 (0.43 to 1.09) 2.59 0.108 36.10 <0.01 
GCS 
missing/untestable 2.07 (1.75 to 2.44) 72.13 <0.001 4.14 0.76 
both sides +ve       
one side +ve 2.55 (2.19 to 2.97) 142.02 <0.001 7.68 0.46 
Pupil 
both side -ve 7.32 (5.62 to 9.54) 217.55 <0.001 30.05 <0.01 
120-150mmHg       
<120 mmHg 1.63 (1.27 to 2.10) 14.89 <0.001 27.26 <0.01 
SBP 
>150 mmHg 1.46 (1.25 to 1.69) 23.73 <0.001 9.26 0.32 
85-110 mmHg       
<85 mmHg 1.44 (1.18 to 1.76) 12.73 <0.001 18.30 0.02 
MABP 
>110 mmHg 1.49 (1.22 to 1.83) 15.57 <0.001 10.83 0.21 
137-142 mmol/L       
<137 mmol/L 1.51 (1.30 to 1.75) 29.57 <0.001 5.79 0.45 
Sodium 
>142 mmol/L 1.27 (1.02 to 1.59) 4.44 0.035 11.09 0.09 
Age /24 years 2.06 (1.92 to 2.21) 379.72 <0.001 9.57 0.48 
pH /0.15 0.78 (0.71 to 0.87) 21.81 <0.001 4.26 0.37 
Haemoglobin/3.3 g/dL 0.69 (0.60 to 0.81) 22.50 <0.001 9.04 0.11 
Glucose /3.7 mmol/L 1.80 (1.61 to 2.00) 111.82 <0.001 9.00 0.11 
Haematocrit /10 % 0.69 (0.56 to 0.86) 11.16 0.001 2.57 0.28 
Platelets /100 x109/L 0.69 (0.59 to 0.81) 21.57 <0.001 0.88 0.83 
Prothrombin 
time 
/2 seconds 1.66 (1.34 to 2.06) 21.09 <0.001 3.60 0.17 
 
4.2.3 Dichotomous analysis - unfavourable outcome 
Table 4-4 shows the odds ratios and 95% confidence intervals for the conventional 
dichotomous split of the GOS grouping death, vegetative state and severe disability 
together and moderate recovery and good recovery together.  As with the previous 
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two dichotomies a similar pattern is seen between th  variables and outcome.  Older 
age, having a tSAH or a CT classification of swelling, shift or mass were very 
strongly associated with an unfavourable outcome.  Statistically significant 
heterogeneity was observed between studies for compressed or absent cisterns, 
contusions, shift>5mm, GCS 9-15 and some categories f the GCS components, and 
bilateral non reacting pupils. 
Table 4-4 Pooled random effects estimates of binary odds ratios for unfavourable outcome 
(unadjusted) 













male       Gender 
female 1.04 (0.93 to1.16) 0.40 0.526 11.14 0.35 
Caucasian       
Black 1.32 (1.00 to 1.73) 3.83 0.050 6.63 0.25 
Asian 1.15 (0.79 to 1.69) 0.54 0.461 2.42 0.66 
Race 
other 1.03 (0.81 to 1.31) 0.06 0.808 1.97 0.74 
0-8 years       
9-12 years 0.62 (0.37 to 1.03) 3.36 0.067 4.64 0.10 
Education 
> 12 years 0.59 (0.39 to 0.91) 5.63 0.018 3.17 0.20 
street/highway       
home 1.53 (1.14 to 2.06) 7.94 0.005 0.70 0.71 
work/school 1.43 (1.05 to 1.93) 5.31 0.021 1.40 0.50 
recreational 0.89 (0.59 to 1.35) 0.30 0.581 0.09 0.96 
Place Injury 
other 1.23 (0.86 to 1.75) 1.29 0.256 0.33 0.85 
domestic/fall       
road traffic accident 0.68 (0.60 to 0.76) 45.81 <0.001 7.39 0.69 
assault 0.65 (0.46 to 0.92) 5.95 0.015 20.66 0.02 
work-related 0.73 (0.54 to 1.00) 3.89 0.048 4.66 0.79 
sports/recreation 0.45 (0.29 to 0.71) 11.57 0.001 13.19 0.11 
Cause Injury 
other 0.95 (0.77 to 1.16) 0.26 0.611 3.61 0.94 
primary       Referral 
secondary 1.06 (0.91 to 1.23) 0.54 0.462 7.10 0.21 
 
Chapter 4 Analyses using IMPACT data 73 













no       Hypoxia 
suspected/definite 2.14 (1.72 to 2.67) 45.90 <0.001 15.55 0.03 
no       Hypotension 
suspected/definite 2.67 (2.18 to 3.28) 87.47 <0.001 15.95 0.04 
no       Hypothermia
suspected/definite 2.27 (1.66 to 3.11) 26.03 <0.001 7.49 0.11 
diffuse class II       
no visible pathology 0.35 (0.25 to 0.49) 39.90 <0.001 5.58 0.47 
swelling/shift 2.54 (2.06 to 3.14) 76.10 <0.001 9.76 0.14 
CT class 
mass 2.13 (1.69 to 2.67) 42.01 <0.001 15.88 0.01 
present       Cisterns 
compressed/absent 2.30 (1.71 to 3.11) 30.06 <0.001 22.27 <0.01 
no       
1-5 mm 1.34 (1.03 to 1.74) 4.75 0.029 13.42 0.04 
Shift 
> 5mm 2.10 (1.53 to 2.88) 20.86 <0.001 24.49 <0.01 
no       tSAH 
yes 2.70 (2.45 to 2.98) 388.40 <0.001 7.27 0.61 
no       EDH 
yes 0.60 (0.52 to 0.69) 51.30 <0.001 6.71 0.57 
no       SDH 
yes 2.16 (1.88 to 2.47) 122.58 <0.001 13.28 0.10 
no       Contusion 
yes 1.31 (1.06 to 1.60) 6.47 0.011 22.18 <0.01 
none       
pain/sound/ 
spontaneous 
0.35 (0.27 to 0.44) 75.41 <0.001 32.01 <0.01 
Eye 
missing/untestable 0.75 (0.54 to 1.04) 3.00 0.083 14.16 0.05 
none       
sounds-orientated 0.38 (0.30 to 0.48) 70.10 <0.001 26.00 <0.01 
Verbal 
missing/untestable 1.04 (0.81 to 1.35) 0.10 0.749 20.79 <0.01 
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localises/obeys       
none 5.35 (3.69 to 7.75) 78.54 <0.001 36.11 <0.01 
extension 8.90 (6.93 to 11.42)294.68 <0.001 19.89 0.03 
abnormal flexion 4.05 (2.95 to 5.57) 74.32 <0.001 37.8  <0.01 
normal flexion 1.94 (1.64 to 2.30) 58.34 <0.001 16.49 0.09 
Motor 
missing/untestable 2.26 (1.60 to 3.19) 21.30 <0.001 9.77 0.13 
6-8       
3-5 3.68 (3.04 to 4.45) 178.56 <0.001 19.38 0.04 
9-15 0.58 (0.42 to 0.81) 10.28 0.001 26.31 <0.01 
GCS 
missing/untestable 2.06 (1.71 to 2.48) 59.31 <0.001 9.38 0.23 
both sides +ve       
one side +ve 2.67 (2.21 to 3.23) 102.32 <0.001 12.61 0.13 
Pupil 
both side -ve 6.92 (5.03 to 9.52) 141.58 <0.001 38.26 <0.01 
120-150mmHg       
<120 mmHg 1.50 (1.28 to 1.75) 26.44 <0.001 12.13 0.15 
SBP 
>150 mmHg 1.47 (1.19 to 1.81) 12.65 <0.001 19.27 0.01 
85-110 mmHg       
<85 mmHg 1.23 (1.04 to 1.45) 6.07 0.014 14.72 0.06 
MABP 
>110 mmHg 1.45 (1.18 to 1.77) 12.81 <0.001 12.05 0.15 
137-142 mmol/L       
<137 mmol/L 1.43 (1.24 to 1.65) 25.14 <0.001 5.77 0.45 
Sodium 
>142 mmol/L 1.14 (0.95 to 1.36) 1.91 0.167 8.50 0.20 
Age /24 years 2.15 (2.00 to 2.31) 428.66 <0.001 9.10 0.52 
pH /0.15 0.83 (0.75 to 0.91) 15.80 <0.001 2.65 0.62 
Haemoglobin/3.3 g/dL 0.66 (0.55 to 0.78) 24.00 <0.001 12.69 0.03 
Glucose /3.7 mmol/L 1.69 (1.52 to 1.89) 93.01 <0.001 9.10 0.11 
Haematocrit /10 % 0.60 (0.50 to 0.74) 25.10 <0.001 2.18 0.34 
Platelets /100 x109/L 0.67 (0.58 to 0.78) 26.75 <0.001 2.90 0.41 
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/2 seconds 1.42 (1.04 to 1.95) 4.91 0.027 6.58 0.04 
 
4.2.4 Dichotomous analysis – not good outcome 
Table 4-5 below shows the odds ratios and 95% confide ce intervals for each 
covariate for the final binary split taking not a good outcome as ‘unfavourable’ i.e. 
comparing a not good recovery outcome with good recov ry.  A similar relationship 
between the covariates and outcome is observed as with the previous three 
dichotomies.  This pattern is shown both with the odds ratios and the tests for 
heterogeneity as would be expected.  For example, old r age and having a tSAH are 
very strongly associated with a not good outcome. 
 
Table 4-5 Pooled random effects estimates of binary odds ratios for not good outcome 
(unadjusted) 













male       Gender 
female 0.98 (0.88 to 1.09) 0.18 0.671 5.09 0.88 
Caucasian       
Black 1.41 (0.91 to 2.17) 2.38 0.123 10.06 0.07 
Asian 1.01 (0.67 to 1.51) 0.00 0.964 2.07 0.72 
Race 
other 1.12 (0.87 to 1.44) 0.74 0.388 1.72 0.79 
0-8 years       
9-12 years 0.88 (0.67 to 1.15) 0.91 0.341 1.64 0.44 
Education 
> 12 years 0.72 (0.53 to 0.99) 4.08 0.043 2.17 0.34 
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street/highway       
home 1.35 (0.98 to 1.85) 3.46 0.063 0.17 0.92 
work/school 1.40 (1.01 to 1.92) 4.15 0.042 1.83 0.40 
recreational 0.71 (0.47 to 1.07) 2.66 0.103 0.07 0.96 
Place Injury 
other 0.92 (0.63 to 1.33) 0.21 0.651 0.00 1.00 
domestic/fall       
road traffic accident 0.71 (0.63 to 0.81) 28.87 <0.001 8.32 0.60 
assault 0.71 (0.54 to 0.93) 6.33 0.012 11.83 0.30 
work-related 1.06 (0.71 to 1.60) .08 0.772 9.25 0.32 
sports/recreation 0.41 (0.25 to 0.66) 13.81 <0.001 15.02 0.06 
Cause Injury 
other 0.97 (0.76 to 1.23) 0.07 0.793 9.80 0.37 
primary       Referral 
secondary 1.06 (0.83 to 1.35) 0.22 0.640 17.29 <0.01 
no       Hypoxia 
suspected/definite 2.13 (1.70 to 2.67) 43.55 <0.001 12.31 0.09 
no       Hypotension 
suspected/definite 2.43 (2.00 to 2.95) 80.52 <0.001 11.07 0.20 
no       Hypothermia
suspected/definite 2.09 (1.43 to 3.06) 14.67 <0.001 7.85 0.10 
diffuse class II       
no visible pathology 0.42 (0.27 to 0.65) 14.79 0.001 14.75 0.02 
swelling/shift 2.19 (1.84 to 2.60) 79.40 <0.001 6.46 0.37 
CT class 
mass 1.97 (1.63 to 2.39) 49.27 <0.001 10.90 0.09 
present       Cisterns 
compressed/absent 2.17 (1.83 to 2.57) 80.78 <0.001 6.69 0.24 
no       
1-5 mm 1.14 (0.96 to 1.34) 2.30 0.130 4.44 0.62 
Shift 
> 5mm 2.02 (1.44 to 2.84) 16.48 <0.001 22.43 <0.01 
no       tSAH 
yes 2.41 (2.12 to 2.74) 176.26 <0.001 12.14 0.21 
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no       EDH 
yes 0.66 (0.57 to 0.75) 35.78 <0.001 2.81 0.95 
no       SDH 
yes 1.97 (1.62 to 2.39) 45.36 <0.001 21.60 0.01 
no       Contusion 
yes 1.44 (1.22 to 1.70) 19.18 <0.001 13.22 0.07 
none       
pain/sound/ 
spontaneous 
0.37 (0.29 to 0.47) 67.96 <0.001 34.50 <0.01 
Eye 
missing/untestable 0.87 (0.62 to 1.22) 0.64 0.424 12.30 0.09 
none       
sounds-orientated 0.42 (0.33 to 0.52) 57.22 <0.001 26.89 <0.01 
Verbal 
missing/untestable 1.08 (0.84 to 1.38) 0.35 0.552 15.54 0.03 
localises/obeys       
none 4.05 (2.86 to 5.75) 61.69 <0.001 27.08 <0.01 
extension 7.68 (6.02 to 9.80) 270.08 <0.001 12.86 0.23 
abnormal flexion 3.77 (2.68 to 5.29) 58.51 <0.001 34.74 <0.01 
normal flexion 1.69 (1.35 to 2.13) 20.61 <0.001 30.75 <0.01 
Motor 
missing/untestable 2.29 (1.67 to 3.15) 26.16 <0.001 8.02 0.24 
6-8       
3-5 3.16 (2.66 to 3.75) 169.95 <0.001 13.24 0.21 
9-15 0.55 (0.39 to 0.79) 10.55 0.001 37.65 <0.01 
GCS 
missing/untestable 1.83 (1.47 to 2.28) 29.13 <0.001 11.81 0.11 
both sides +ve       
one side +ve 3.13 (2.58 to 3.80) 132.43 <0.001 9.44 0.31 
Pupil 
both side -ve 6.96 (4.74 to 0.22) 97.93 <0.001 32.43 <0.01 
120-150mmHg       
<120 mmHg 1.44 (1.27 to 1.64) 31.15 <0.001 3.27 0.92 
SBP 
>150 mmHg 1.36 (1.12 to 1.65) 9.45 0.002 14.03 0.08 
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85-110 mmHg       
<85 mmHg 1.22 (1.08 to 1.38) 10.48 0.001 5.76 0.67 
MABP 
>110 mmHg 1.42 (1.09 to 1.86) .63 0.010 16.62 0.03 
137-142 mmol/L       
<137 mmol/L 1.32 (1.12 to 1.56) 10.58 0.001 6.94 0.33 
Sodium 
>142 mmol/L 1.09 (0.84 to 1.41) 0.42 0.516 14.18 0.03 
Age /24 years 2.15 (1.94 to 2.39) 215.14 <0.001 14.16 0.17 
pH /0.15 0.83 (0.74 to 0.92) 13.02 0.003 3.59 0.46 
Haemoglobin/3.3 g/dL 0.72 (0.63 to 0.81) 28.51 <0.001 6.79 0.24 
Glucose /3.7 mmol/L 1.57 (1.45 to 1.70) 121.67 <0.001 2.51 0.78 
Haematocrit /10 % 0.70 (0.55 to 0.88) 9.40 0.002 2.16 0.34 
Platelets /100 x109/L 0.74 (0.59 to 0.93) 6.97 0.008 4.90 0.18 
Prothrombin 
time 
/2 seconds 1.16 (0.63 to 2.14) 0.22 0.638 15.23 <0.01 
 
4.2.5 Discussion - dichotomies 
This is the first step before performing any proportional odds analysis as it allows 
judgement of whether the odds ratios under each of t e four dichotomies are broadly 
similar and hence if the assumption of proportional odds is likely to be met.  For 
example for gender the odds of an unfavourable outcome for men and women were 
very similar for all four dichotomies.  The four odds ratios and 95% confidence 
intervals were: 1.01 (0.90 to 1.13); 1.03 (0.93 to 1.15); 1.04 (0.93 to 1.16) and 0.98 
(0.88 to 1.09) for the mortality, dead/vegetative, unfavourable and not good 
dichotomies respectively.  Other variables showed a much stronger effect, for 
example having a tSAH was associated with a much poorer outcome for all four 
dichotomies.  Odds ratios and 95% confidence intervals are: 2.82 (2.52 to 3.16) for 
the mortality outcome; 3.00 (2.66 to 3.40) for the death/vegetative outcome; 2.70 
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(2.45 to 2.98) for the unfavourable outcome and 2.41 (2.12 to 2.74) for the not good 
outcome.  Again, all of these show a similar pattern fo  all four dichotomies. 
 
4.3 Proportional odds analysis on pooled data intro duction 
As the results from the four univariate analyses showed a similar pattern, the next 
stage was to fit a proportional odds model to these data.  Again the odds of an 
unfavourable outcome were modelled.  For this analysis the outcomes of death and 
vegetative state were pooled on both statistical and ethical grounds, as discussed 
previously.  Thus, the GOS was reduced to a 4-point ordinal scale for all proportional 
odds modelling. 
 
4.3.1 Unadjusted estimates – using proportional odds model 
Univariate results from the proportional odds regression are shown in Table 4-6 
below.  As with the univariate analysis on the binary outcomes many variables 
showed a strong univariate effect.  Particularly strong relationships were observed 
with age, CT class, tSAH, hypoxia and hypotension.  No differences in the odds of 
an unfavourable outcome were observed between genders or referral to neurosurgical 
unit.  Very little statistically significant heterogeneity was observed between studies.  
Only some of the CT parameters, cisterns, shift, contusion, some of the GCS 
components and prothrombin time showed statistically significant heterogeneity. 
 
Table 4-6 Pooled random effects estimates of the common odds ratios from proportional odds 
models (unadjusted) 













male       Gender 
female 1.01 (0.92 to 1.11) 0.06 0.805 7.17 0.71 
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Caucasian       
Black 1.30 (1.09 to 1.56) 8.15 0.004 4.11 0.53 
Asian 1.09 (0.78 to 1.51) 0.24 0.622 2.52 0.64 
Race 
other 1.08 (0.88 to 1.34) 0.56 0.453 2.43 0.66 
0-8 years       
9-12 years 0.78 (0.57 to 1.07) 2.36 0.125 2.70 0.26 
Education 
> 12 years 0.70 (0.52 to 0.94) 5.46 0.020 2.32 0.31 
street/highway       
home 1.51 (1.16 to 1.98) 9.27 0.002 1.01 0.60 
work/school 1.37 (0.99 to 1.89) 3.59 0.058 2.65 0.27 
recreational 0.72 (0.49 to 1.05) 2.92 0.088 0.15 0.93 
Place Injury 
other 1.13 (0.82 to 1.56) 0.58 0.447 0.08 0.96 
domestic/fall       
road traffic accident 0.66 (0.60 to 0.73) 65.32 <0.001 6.80 0.74 
assault 0.66 (0.52 to 0.84) 11.84 0.001 13.94 0.18 
work-related 0.88 (0.68 to 1.14) 0.96 0.327 2.63 0.96 
sports/recreation 0.45 (0.28 to 0.71) 11.71 0.001 20.07 0.01 
Cause Injury 
other 0.91 (0.76 to 1.09) 1.06 0.304 5.94 0.75 
primary       Referral 
secondary 1.02 (0.87 to 1.20) .05 0.817 10.35 0.07 
no       Hypoxia 
suspected/definite 2.08 (1.69 to 2.56) 4 .95 <0.001 17.45 0.01 
no       Hypotension 
suspected/definite 2.67 (2.09 to 3.41) 62.56 <0.001 28.00 <0.01 
no       Hypothermia 
suspected/definite 2.21 (1.56 to 3.15) 9.71 <0.001 11.71 0.02 
diffuse class II       
no visible pathology 0.45 (0.31 to 0.67) 16.14 <0.001 13.04 0.04 
swelling/shift 2.62 (2.13 to 3.21) 83.67 <0.001 11.89 0.06 
CT class 
mass 2.18 (1.83 to 2.61) 73.92 <0.001 12.44 0.05 
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present       Cisterns 
compressed/absent 2.45 (1.88 to 3.20) 43.20 <0.001 22.03 <0.01 
no       
1-5 mm 1.36 (1.09 to 1.68) 7.68 0.006 11.70 0.07 
Shift 
> 5mm 2.20 (1.64 to 2.96) 27.63 <0.001 26.30 <0.01 
no       tSAH 
yes 2.64 (2.42 to 2.89) 468.15 <0.001 8.30 0.50 
no       EDH 
yes 0.64 (0.56 to 0.72) 53.00 <0.001 4.43 0.82 
no       SDH 
yes 2.14 (1.87 to 2.45) 123.32 <0.001 15.92 0.04 
no       Contusion 
yes 1.34 (1.10 to 1.63) 8.34 0.004 25.68 <0.01 
none       
pain/sound/ 
spontaneous 
0.36 (0.28 to 0.46) 63.60 <0.001 47.76 <0.01 
Eye 
missing/untestable 0.74 (0.55 to 1.00) 3.85 0.050 15.07 0.04 
none       
sounds-orientated 0.38 (0.30 to 0.48) 70.49 <0.001 33.65 <0.01 
Verbal 
missing/untestable 0.99 (0.78 to 1.26) 0.00 0.949 23.40 <0.01 
localises/obeys       
none 5.30 (3.49 to 8.04) 61.42 <0.001 65.45 <0.01 
extension 7.48 (5.60 to 9.98) 186.33 <0.001 38.36 <0.01 
abnormal flexion 3.58 (2.71 to 4.73) 80.44 <0.001 38.79 <0.01 
normal flexion 1.74 (1.44 to 2.11) 32.41 <0.001 27.73 <0.01 
Motor 
missing/untestable 2.20 (1.66 to 2.92) 30.19 <0.001 9.11 0.17 
6-8       
3-5 3.67 (2.99 to 4.52) 151.85 <0.001 28.56 <0.01 
9-15 0.60 (0.41 to 0.88) 6.90 0.009 51.51 <0.01 
GCS 
missing/untestable 1.97 (1.65 to 2.34) 58.37 <0.001 10.45 0.16 
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both sides +ve       
one side +ve 2.71 (2.36 to 3.12) 194.30 <0.001 8.96 0.35 
Pupil 
both side -ve 7.31 (5.35 to 9.99) 156.11 <0.001 50.85 <0.01 
120-150mmHg       
<120 mmHg 1.53 (1.31 to 1.80) 27.72 <0.001 15.75 0.05 
SBP 
>150 mmHg 1.42 (1.20 to 1.68) 17.23 <0.001 14.96 0.06 
85-110 mmHg       
<85 mmHg 1.30 (1.12 to 1.51) 1.94 0.001 15.04 0.06 
MABP 
>110 mmHg 1.45 (1.19 to 1.76) 13.74 <0.001 13.74 0.09 
137-142 mmol/L       
<137 mmol/L 1.40 (1.22 to 1.60) 23.11 <0.001 6.80 0.34 
Sodium 
>142 mmol/L 1.14 (0.94 to 1.38) 1.88 0.171 11.34 0.08 
Age /24 years 2.14 (2.00 to 2.28) 546.10 <0.001 10.01 0.44 
pH /0.15 0.80 (0.74 to 0.88) 25.17 <0.001 4.05 0.40 
Haemoglobin /3.3 g/dL 0.69 (0.60 to 0.78) 31.84 <0.001 9.72 0.08 
Glucose /3.7 mmol/L 1.68 (1.54 to 1.83) 131.58 <0.001 8.18 0.15 
Haematocrit /10 % 0.68 (0.55 to 0.83) 13.51 <0.001 2.96 0.23 
Platelets /100 x109/L 0.70 (0.62 to 0.80) 28.52 <0.001 2.88 0.41 
Prothrombin 
time 
/2 seconds 1.41 (0.99 to 1.99) 3.72 0.054 11.23 <0.01 
 
4.3.2 Graphical illustration unadjusted estimates 
As an illustration of the results in Table 4-6 above, Figure 4-1 and Figure 4-2 below 
show forest plots for six selected variables.  Figure 4-1 shows referral, hypoxia, 
hypotension and hypothermia.  For all four variables a consistent pattern of effects is 
seen over all the studies.  Although there was statistically significant heterogeneity 
between studies for hypotension, looking at the figure it can be seen that estimates 
from all of the studies lie in the same direction.  Little difference is observed in the 
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odds of an unfavourable outcome between those who had a primary or secondary 
referral.  Those who had hypoxia, hypotension or hypothermia had a greater odds of 
a poorer outcome than those who did not in all studies. 
Figure 4-2 below shows forest plots for the CT categories and cisterns.  It can be 
seen that those with no visible pathology on the CT scan have a much more 
favourable outcome than those who had a diffuse injury.  Whereas, those who had a 
classification of mass or swelling/shift have a greater odds of an unfavourable 
outcome.  Statistically significant heterogeneity was observed with cisterns.  
However, looking at the figure shows that all of the estimates from the different 
studies lie in the same direction. 
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Figure 4-1 Forest plots of referral, hypoxia, hypotension and hypothermia 
 
 
Figure 4-2 Forest plots of CT class and cisterns 
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4.4 Multivariate analysis using proportional odds m odelling 
4.4.1 Introduction 
In order to perform multivariate analysis staff at the Rotterdam centre developed 
prognostic models based on the univariate proportional dds regression of the GOS 
(Steyerberg et al. 2008).  Four models were used: a simple three variable model 
containing age, motor score and pupils (the conventional covariates used in many 
analyses (Marmarou et al. 2007)); a four variable model containing CT in addition to 
age, motor and pupils (Maas et al. 2007); a more complex seven variable model 
which included the addition of tSAH, hypoxia and hypotension to the four variable 
model (Chesnut et al. 1993;Hukkelhoven et al. 2005;Maas et al. 2007;McHugh et al. 
2007b); and a nine variable model containing glucose and haemoglobin in addition to 
the parameters in the seven variable model (Van Beek et al. 2007).  The regression 
coefficients for a selection of the models have been published (Steyerberg et al. 
2011). 
 
Once all initial variables were extracted from each dataset and placed into the 
database an imputed version of the database was creted as detailed in Chapter 2.  
Values were imputed for any variables which had partially missing values within 
each study.  If a variable was wholly missing within a study it was not imputed.  
Outcome as measured by the GOS was not imputed.  For these multivariate analyses 
patients were included with complete data on age, baseline motor score and 6 month 
outcome.  In total 82% of the required values were available for a prognostic model 
with seven predictors (Murray et al. 2007) and 92% were available for a prognostic 
model with nine predictors (Steyerberg et al. 2008).  However, only four studies 
recorded lab values so the final nine covariate model is based only on these studies. 
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4.4.2 Results adjusted for three covariates 
Table 4-7 below shows the results of the multivariate analysis when each comparison 
was adjusted for age, motor score and pupil reactivity.  Strong associations with an 
unfavourable outcome were still observed with having a traumatic subarachnoid 
haemorrhage, higher glucose levels, having hypoxia, having hypotension, CT classes 
of swelling, shift or mass, lower pH, lower Haemoglobin, fewer platelets and longer 
prothrombin time.  Having an EDH, an eye response of pain/sound/spontaneous or a 
verbal response of sounds-orientated was strongly associated with a favourable 
outcome.  Statistically significant heterogeneity was observed between studies for 
referral and some categories of eye movement and GCS score.   
 
Table 4-7 Pooled random effects estimates of the common odds ratios from proportional odds 
models adjusted for 3 covariates 












male       Gender 
female 0.94 (0.85 to 1.04) 1.41 0.235 7.44 0.68 
Caucasian       
Black 1.44 (1.08 to 1.93) 6.11 0.013 7.77 0.17 
Asian 1.22 (0.84 to 1.78) 1.08 0.299 4.17 0.38 
Race 
other 1.11 (0.89 to 1.40) 0.87 0.350 1.55 0.82 
0-8 years       
9-12 years 0.87 (0.67 to 1.13) 1.08 0.298 0.98 0.61 
Education 
> 12 years 0.74 (0.56 to 0.97) 4.57 0.033 1.57 0.46 
street/highway       
home 0.82 (0.59 to 1.14) 1.43 0.232 2.36 0.31 
work/school 1.10 (0.74 to 1.66) 0.23 0.632 3.46 0.18 
recreational 0.75 (0.50 to 1.12) 1.98 0.159 0.31 0.86 
Place Injury 
other 0.87 (0.59 to 1.28) 0.51 0.476 2.35 0.31 
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domestic/fall       
road traffic accident 1.08 (0.96 to 1.21) 1.54 0.214 6.18 0.80 
assault 1.03 (0.76 to 1.40) .04 0.834 17.40 0.07 
work-related 1.21 (0.90 to 1.63) 1.67 0.196 5.62 0.69 
sports/recreation 0.74 (0.50 to 1.09) 2.30 0.129 9.60 0.29 
Cause Injury 
other 1.06 (0.87 to 1.29) 0.33 0.567 8.20 0.51 
primary       Referral 
secondary 1.14 (0.91 to 1.43) 1.37 0.241 16.11 0.01 
no       Hypoxia 
suspected/definite 1.65 (1.37 to 2.00) 26.46 <0.001 12.39 0.09 
no       Hypotension 
suspected/definite 2.06 (1.64 to 2.59) 37.77 <0.001 20.99 0.01 
no       Hypothermia 
suspected/definite 1.63 (1.11 to 2.40) 6.26 0.012 12.32 0.02 
diffuse class II       
no visible pathology 0.47 (0.32 to 0.70) 13.56 <0.001 11.39 0.08 
swelling/shift 2.23 (1.83 to 2.72) 63.18 <0.001 9.76 0.13 
CT class 
mass 1.48 (1.27 to 1.71) 26.06 <0.001 7.90 0.25 
present       Cisterns 
compressed/absent 1.83 (1.55 to 2.17) 48.70 <0.001 8.07 0.15 
no       
1-5 mm 1.31 (1.11 to 1.56) 9.88 0.002 6.97 0.32 
Shift 
> 5mm 1.38 (1.02 to 1.87) 4.33 0.038 23.91 <0.01 
no       tSAH 
yes 2.01 (1.83 to 2.21) 213.20 <0.001 6.95 0.64 
no       EDH 
yes 0.63 (0.55 to 0.72) 47.04 <0.001 2.09 0.98 
no       SDH 
yes 1.33 (1.21 to 1.47) 32.67 <0.001 7.55 0.48 
no       Contusion 
yes 1.40 (1.18 to 1.67) 14.19 <0.001 17.95 0.01 
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none       
pain/sound/ 
spontaneous 
0.65 (0.51 to 0.81) 13.74 <0.001 30.59 <0.01 
Eye 
missing/untestable 0.86 (0.56 to 1.32) 0.48 0.489 9.60 0.21 
none       
sounds-orientated 0.66 (0.55 to 0.80) 18.35 <0.001 19.02 0.04 
Verbal 
missing/untestable 1.00 (0.86 to 1.17) 0.00 0.999 4.80 0.68 
6-8       
3-5 1.37 (1.02 to 1.83) 4.52 0.0340 15.06 0.13 
9-15 0.72 (0.50 to 1.04) 3.00 0.083 39.49 <0.01 
GCS 
missing/untestable 1.13 (0.95 to 1.34) 1.79 0.181 6.63 0.47 
120-150mmHg       
<120 mmHg 1.28 (1.12 to 1.45) 14.22 <0.001 9.48 0.30 
SBP 
>150 mmHg 1.30 (1.08 to 1.57) .37 0.007 17.19 0.03 
85-110 mmHg       
<85 mmHg 1.14 (1.01 to 1.29) 4.80 0.029 9.26 0.32 
MABP 
>110 mmHg 1.27 (1.02 to 1.58) 4.47 0.035 15.20 0.06 
137-142 mmol/L       
<137 mmol/L 1.14 (0.91 to 1.43) 1.35 0.245 14.31 0.03 
Sodium 
>142 mmol/L 1.11 (0.96 to 1.27) 2.07 0.150 5.39 0.49 
pH /0.15 0.84 (0.76 to 0.92) 14.39 <0.001 1.87 0.76 
Haemoglobin /3.3 g/dL 0.76 (0.66 to 0.88) 14.68 <0.001 9.77 0.08 
Glucose /3.7 mmol/L 1.45 (1.36 to 1.55) 118.24 <0.001 4.13 0.53 
Haematocrit /10 % 0.83 (0.65 to 1.07) 2.05 0.152 3.38 0.18 
Platelets /100 x109/L 0.79 (0.69 to 0.91) 11.06 0.001 2.52 0.47 
Prothrombin 
time 
/2 seconds 1.63 (1.40 to 1.89) 40.40 <0.001 1.96 0.38 
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4.4.3 Results adjusted for four covariates 
Table 4-8 shows the results of the multivariate analysis when each level of each 
covariate was adjusted for age, motor score, pupil reactivity and CT class.  Even after 
adjustment for these four variables, a highly statiically significant relationship was 
observed between having a subarachnoid haemorrhage, igh r glucose levels and 
longer prothrombin time with an unfavourable outcome.  As with adjustment for 
three covariates, statistically significant heterogneity was only observed between 
studies for referral, shift >5mm and some eye and GCS categories. 
 
Table 4-8 Pooled random effects estimates of the common odds ratios from proportional odds 
models adjusted for 4 covariates 













male       Gender 
female 0.94 (0.85 to 1.03) 1.68 0.194 8.32 0.60 
Caucasian       
Black 1.45 (1.06 to 1.98) 5.31 0.021 8.68 0.12 
Asian 1.19 (0.83 to 1.73) 0.89 0.346 3.73 0.44 
Race 
other 1.09 (0.87 to 1.37) 0.60 0.437 2.55 0.64 
0-8 years       
9-12 years 0.86 (0.66 to 1.12) 1.26 0.263 1.54 0.46 
Education 
> 12 years 0.72 (0.54 to 0.95) .36 0.021 1.93 0.38 
street/highway       
home 0.73 (0.53 to 1.01) 3.71 0.054 2.17 0.34 
work/school 0.97 (0.60 to 1.57) 0.02 0.890 4.71 0.09 
recreational 0.71 (0.47 to 1.06) 2.85 0.091 0.17 0.92 
Place Injury 
other 0.80 (0.53 to 1.22) 1.04 0.308 2.73 0.25 
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domestic/fall       
road traffic accident 1.15 (1.03 to 1.30) 5.61 0.018 6.08 0.81 
assault 1.08 (0.78 to 1.50) .24 0.626 20.09 0.03 
work-related 1.25 (0.93 to 1.68) 2.19 0.139 5.71 0.68 
sports/recreation 0.76 (0.51 to 1.15) 1.70 0.193 10.23 0.25 
Cause Injury 
other 1.11 (0.90 to 1.37) 0.94 0.331 9.61 0.38 
primary       Referral 
secondary 1.12 (0.87 to 1.44) 0.77 0.380 20.52 <0.01 
no       Hypoxia 
suspected/definite 1.65 (1.39 to 1.95) 33.18 <0.001 9.82 0.20 
no       Hypotension 
suspected/definite 2.06 (1.64 to 2.57) 39.81 <0.001 19.45 0.01 
no       Hypothermia 
suspected/definite 1.62 (1.14 to 2.31) 7.25 0.007 10.22 0.04 
present       Cisterns 
compressed/absent 1.68 (1.28 to 2.20) 14.09 <0.001 13.64 0.02 
no       
1-5 mm 1.09 (0.93 to 1.28) 1.04 0.307 3.98 0.68 
Shift 
> 5mm 1.14 (0.77 to 1.71) 0.43 0.510 29.12 <0.01 
no       tSAH 
yes 1.90 (1.72 to 2.09) 174.53 <0.001 8.77 0.46 
no       EDH 
yes 0.50 (0.44 to 0.58) 91.64 <0.001 4.10 0.85 
no       SDH 
yes 1.17 (1.05 to 1.30) 7.88 0.005 7.66 0.47 
no       Contusion 
yes 1.34 (1.12 to 1.61) 10.52 0.001 18.03 0.01 
none       
pain/sound/ 
spontaneous 
0.63 (0.51 to 0.79) 15.78 <0.001 28.76 <0.01 
Eye 
missing/untestable 0.88 (0.55 to 1.42) 0.27 0.601 11.27 0.13 
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none       
sounds-orientated 0.66 (0.54 to 0.80) 17.36 <0.001 20.83 0.02 
Verbal 
missing/untestable 1.01 (0.86 to 1.17) 0.01 0.933 4.13 0.76 
6-8       
3-5 1.33 (0.97 to 1.82) 3.12 0.077 17.45 0.06 
9-15 0.69 (0.48 to 1.00) 3.80 0.051 37.72 <0.01 
GCS 
missing/untestable 1.11 (0.93 to 1.33) 1.33 0.249 7.22 0.41 
120-150mmHg       
<120 mmHg 1.27 (1.13 to 1.44) 14.56 <0.001 9.06 0.34 
SBP 
>150 mmHg 1.28 (1.06 to 1.54) 6.43 0.011 16.82 0.03 
85-110 mmHg       
<85 mmHg 1.14 (1.02 to 1.27) 5.28 0.022 7.03 0.53 
MABP 
>110 mmHg 1.26 (1.01 to 1.59) 4.08 0.043 16.02 0.04 
137-142 mmol/L       
<137 mmol/L 1.09 (0.86 to 1.39) 0.50 0.481 16.20 0.01 
Sodium 
>142 mmol/L 1.10 (0.96 to 1.26) 1.85 0.174 5.03 0.54 
pH /0.15 0.83 (0.76 to 0.91) 15.74 <0.001 2.44 0.66 
Haemoglobin /3.3 g/dL 0.76 (0.65 to 0.88) 13.56 <0.001 10.81 0.06 
Glucose /3.7 mmol/L 1.42 (1.33 to 1.52) 103.04 <0.001 3.62 0.60 
Haematocrit /10 % 0.82 (0.63 to 1.05) 2.50 0.114 3.44 0.18 
Platelets /100 x109/L 0.80 (0.69 to 0.92) 9.13 0.003 3.16 0.37 
Prothrombin 
time 
/2 seconds 1.60 (1.38 to 1.86) 37.47 <0.001 1.61 0.45 
 
4.4.4 Results adjusted for seven covariates 
Table 4-9 below shows the results of the multivariate analysis when estimates were 
adjusted for age, motor score, pupil reactivity, CT class, traumatic subarachnoid 
haemorrhage, hypoxia and hypotension.  Having higher lucose levels, lower 
haemoglobin and longer prothrombin time were strongly associated with an 
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unfavourable outcome.  Having an epidural haematoma, an eye response of 
pain/sound/spontaneous or a verbal response of sound -orientated was strongly 
associated with a favourable outcome.  Statistically significant heterogeneity was 
observed between studies for referral and one category each within shift, GCS and 
sodium. 
 
Table 4-9 Pooled random effects estimates of the common odds ratios from proportional odds 
models adjusted for 7 covariates 













male       Gender 
female 0.94 (0.85 to 1.04) 1.51 0.220 6.78 0.75 
Caucasian       
Black 1.48 (1.03 to 2.13) 4.58 0.032 10.74 0.06 
Asian 1.14 (0.73 to 1.78) 0.34 0.563 5.26 0.26 
Race 
other 1.07 (0.85 to 1.35) 0.35 0.555 2.00 0.74 
0-8 years       
9-12 years 0.87 (0.67 to 1.14) 1.03 0.310 1.89 0.39 
Education 
> 12 years 0.70 (0.46 to 1.05) 2.94 0.086 3.13 0.21 
street/highway       
home 0.76 (0.56 to 1.03) .06 0.080 1.23 0.54 
work/school 0.94 (0.57 to 1.56) 0.06 0.813 4.94 0.08 
recreational 0.72 (0.48 to 1.09) 2.45 0.118 0.12 0.94 
Place Injury 
other 0.81 (0.51 to 1.29) 0.81 0.369 3.31 0.19 
domestic/fall       
road traffic accident 1.16 (1.02 to 1.30) 5.56 0.018 6.83 0.74 
assault 1.17 (0.84 to 1.62) 0.88 0.349 19.48 0.03 
work-related 1.27 (0.94 to 1.72) .45 0.117 5.44 0.71 
sports/recreation 0.80 (0.52 to 1.24) 0.98 0.322 11.29 0.19 
Cause Injury 
other 1.15 (0.94 to 1.41) 1.87 0.172 8.38 0.50 
primary       Referral 
secondary 1.15 (0.87 to 1.50) .98 0.323 22.45 <0.01 
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no       Hypothermia 
suspected/definite 1.40 (1.02 to 1.91) 4.38 0.036 7.67 0.10 
present       Cisterns 
compressed/absent 1.64 (1.27 to 2.12) 4.39 <0.001 11.98 0.04 
no       
1-5 mm 1.10 (0.93 to 1.29) 1.19 0.276 3.80 0.70 
Shift 
> 5mm 1.18 (0.80 to 1.75) 0.71 0.401 27.59 <0.01 
no       EDH 
yes 0.53 (0.46 to 0.61) 76.70 <0.001 3.19 0.92 
no       SDH 
yes 1.17 (1.05 to 1.31) 7.99 0.005 6.70 0.57 
no       Contusion 
yes 1.26 (1.07 to 1.48) 7.73 0.005 14.30 0.05 
none       
pain/sound/ 
spontaneous 
0.65 (0.53 to 0.80) 16.17 <0.001 24.35 0.01 
Eye 
missing/untestable 0.89 (0.53 to 1.51) 0.19 0.663 12.81 0.08 
none       
sounds-orientated 0.67 (0.55 to 0.81) 17.37 <0.001 18.95 0.04 
Verbal 
missing/untestable 0.94 (0.80 to 1.10) 0.58 0.446 5.67 0.58 
6-8       
3-5 1.28 (0.93 to 1.77) 2.33 0.127 17.79 0.06 
9-15 0.71 (0.49 to 1.01) 3.55 0.060 35.44 <0.01 
GCS 
missing/untestable 1.03 (0.86 to 1.23) 0.11 0.746 6.98 0.43 
120-150mmHg       
<120 mmHg 1.18 (1.03 to 1.35) .83 0.016 9.70 0.29 
SBP 
>150 mmHg 1.33 (1.10 to 1.61) 8.49 0.004 16.96 0.03 
85-110 mmHg       
<85 mmHg 1.06 (0.95 to 1.19) 1.01 0.315 6.59 0.58 
MABP 
>110 mmHg 1.29 (1.03 to 1.61) 4.89 0.027 15.24 0.05 
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137-142 mmol/L       
<137 mmol/L 1.07 (0.81 to 1.41) 0.24 0.622 20.25 <0.01 
Sodium 
>142 mmol/L 1.05 (0.91 to 1.20) 0.41 0.522 2.90 0.82 
pH /0.15 0.89 (0.81 to 0.98) 5.89 0.015 2.57 0.63 
Haemoglobin /3.3 g/dL 0.76 (0.67 to 0.85) 20.78 <0.001 6.82 0.23 
Glucose /3.7 mmol/L 1.35 (1.26 to 1.45) 74.10 <0.001 2.89 0.72 
Haematocrit /10 % 0.89 (0.65 to 1.22) 0.50 0.479 4.77 0.09 
Platelets /100 x109/L 0.81 (0.70 to 0.93) 8.30 0.004 3.09 0.38 
Prothrombin 
time 
/2 seconds 1.55 (1.33 to 1.81) 31.63 <0.001 1.07 0.58 
 
4.4.5 Results adjusted for nine covariates 
Table 4-10 below shows the results of the multivariate analysis when estimates were 
adjusted for age, motor score, pupil reactivity, CT class, traumatic subarachnoid 
haemorrhage, hypoxia, hypotension, haemoglobin and glucose.  Here, as mentioned 
above, these estimates are only based on four studie .  Even after adjusting for these 
nine covariates, highly statistically significant associations with a favourable 
outcome were observed for those with an epidural haematoma, eye score being pain, 
sound or spontaneous and verbal score being between sounds to orientated inclusive.  
A highly statistically significant association between increased prothrombin time and 
an unfavourable outcome was observed.  Statistically significant heterogeneity was 
observed between the studies for the same variables s had statistically significant 
heterogeneity when estimates were adjusted for seven covariates. 
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Table 4-10 Pooled random effects estimates of the common odds ratios from proportional odds 
models adjusted for 9 covariates 













male       Gender 
female 0.88 (0.80 to 0.98) 5.50 0.019 9.49 0.49 
Caucasian       
Black 1.50 (1.02 to 2.20) 4.32 0.038 11.82 0.04 
Asian 1.13 (0.72 to 1.76) 0.28 0.594 5.23 0.26 
Race 
other 1.07 (0.85 to 1.34) 0.31 0.577 2.61 0.63 
0-8 years       
9-12 years 0.84 (0.65 to 1.10) 1.60 0.206 1.63 0.44 
Education 
> 12 years 0.69 (0.47 to 0.99) 3.95 0.047 2.69 0.26 
street/highway       
home 0.78 (0.58 to 1.07) 2.35 0.125 1.16 0.56 
work/school 0.91 (0.53 to 1.57) 0.11 0.739 5.53 0.06 
recreational 0.74 (0.49 to 1.11) 2.14 0.143 0.23 0.89 
Place Injury 
other 0.84 (0.52 to 1.37) 0.49 0.485 3.56 0.17 
domestic/fall       
road traffic accident 1.14 (1.01 to 1.28) 4.18 0.041 7.79 0.65 
assault 1.24 (0.90 to 1.70) 1.71 0.191 18.29 0.05 
work-related 1.26 (0.93 to 1.71) 2.23 0.135 5.10 0.75 
sports/recreation 0.81 (0.53 to 1.25) 0.87 0.350 11.06 0.20 
Cause Injury 
other 1.15 (0.92 to 1.43) 1.54 0.214 9.67 0.38 
primary       Referral 
secondary 1.14 (0.86 to 1.51) 0.84 0.359 24.34 <0.01 
no       Hypothermia 
suspected/definite 1.36 (0.96 to 1.93) 3.07 0.080 9.16 0.06 
present       Cisterns 
compressed/absent 1.63 (1.25 to 2.14) 2.60 <0.001 13.09 0.02 
no       
1-5 mm 1.08 (0.92 to 1.28) 0.88 0.348 4.36 0.63 
Shift 
> 5mm 1.21 (0.82 to 1.77) 0.90 0.344 26.17 <0.01 
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no       EDH 
yes 0.51 (0.44 to 0.59) 85.03 <0.001 4.12 0.85 
no       SDH 
yes 1.19 (1.07 to 1.33) 9.67 0.002 6.99 0.54 
no       Contusion 
yes 1.25 (1.06 to 1.48) 6.76 0.009 15.52 0.03 
none       
pain/sound/ 
spontaneous 
0.64 (0.52 to 0.80) 15.90 <0.001 25.64 <0.01 
Eye 
missing/untestable 0.83 (0.52 to 1.33) 0.58 0.444 10.59 0.16 
none       
sounds-orientated 0.66 (0.55 to 0.80) 18.38 <0.001 18.22 0.05 
Verbal 
missing/untestable 0.94 (0.81 to 1.10) 0.53 0.466 5.16 0.64 
6-8       
3-5 1.33 (0.97 to 1.81) 3.14 0.077 16.59 0.08 
9-15 0.70 (0.49 to 1.00) 3.76 0.052 35.26 <0.01 
GCS 
missing/untestable 1.03 (0.86 to 1.23) 0.11 0.744 6.26 0.51 
120-150mmHg       
<120 mmHg 1.09 (0.95 to 1.26) 1.60 0.206 10.20 0.25 
SBP 
>150 mmHg 1.33 (1.09 to 1.62) 8.23 0.004 17.36 0.03 
85-110 mmHg       
<85 mmHg 1.00 (0.90 to 1.13) 0.01 0.932 6.39 0.60 
MABP 
>110 mmHg 1.30 (1.03 to 1.65) 4.83 0.028 16.58 0.03 
137-142 mmol/L       
<137 mmol/L 1.03 (0.79 to 1.35) 0.06 0.812 18.77 <0.01 
Sodium 
>142 mmol/L 1.12 (0.97 to 1.29) 2.30 0.129 2.55 0.86 
pH /0.15 0.93 (0.85 to 1.03) 1.97 0.161 2.17 0.70 
Haematocrit /10 % 1.06 (0.70 to 1.59) 0.07 0.795 2.11 0.35 
Platelets /100 x109/L 0.80 (0.69 to 0.93) 8.18 0.004 3.03 0.39 
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/2 seconds 1.46 (1.25 to 1.71) 22.17 <0.001 0.64 0.73 
 
4.5 Discussion 
The first part of this chapter showed that using logistic regression to model the four 
binary outcomes similar odds ratios and overlapping confidence intervals were 
observed for each of the outcomes for most variables.  Using proportional odds 
modelling therefore seemed an appropriate summary.  The second part of the chapter 
firstly showed unadjusted results.  Subsequently four c variate sets (each containing 
respectively three, four, seven and nine covariates) w re adjusted for in multivariate 
proportional odds analysis.  Forest plots were alsoshown to illustrate the consistency 
of estimates across studies.  Little differences were observed between the three and 
four covariate models.  Therefore in subsequent chapters three covariate sets are used 
(three, seven and nine).  These analyses were all prformed using the IMPACT data 
and using each level of each covariate as though it was a treatment effect.  The next 
stage, shown in Chapter 5 and Chapter 6 is to use the IMPACT data to simulate 
treatment effects and compare different modelling strategies for ordinal outcomes. 
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5 Chapter 5 Comparison of different analysis strate gies – 
the sliding dichotomy 
5.1 Introduction 
Having shown that the proportional odds model was a reasonable summary of the 
four binary dichotomies using the IMPACT data in Chapter 4, the next stage was to 
compare different modelling strategies against the conventional dichotomous 
analysis.  This will show which gives the greatest r duction in sample size (RSS) 
under which circumstances.  Various scenarios and treatment effects were modelled 
using simulated data from the eleven IMPACT studies.  The methods for simulating 
the different treatment effects giving details of all of the scenarios are given in the 
first part of this chapter.  The sample size reduction for the different methods and 
scenarios studied are compared with recommendations made as to which methods of 
analysis are optimal under different treatment strategies.  In this chapter all 
simulation analysis strategies, the conventional anysis, the sliding dichotomy and 
the methodology for all of the simulation studies are described.   
The simulation studies were done in two parts: firstly the sliding dichotomy was 
refined, as shown in the second part of this chapter; th n the optimised version of the 
sliding dichotomy was taken forward to compare with the other modelling strategies.  
These results are shown in Chapter 6. 
Results are presented both by study and as overall median reductions in sample size 
in tables and graphs.  The figures show the unadjusted and adjusted analyses 
together. 
The sections describing the conventional analysis, sliding dichotomy and 
methodology below have almost all been published and the sections showing the 
results tables have partly been published (McHugh et al. 2010).  This paper discussed 
the three and seven covariate models with the 5% treatment effect. 
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5.2 Conventional analysis 
In evaluating novel analytical approaches, the conventional unadjusted Chi-squared 
analysis based on a dichotomisation of the GOS into u favourable versus favourable 
was used as a reference technique.  All other approches are compared back to this 
reference technique in terms of their relative efficiency, expressed as the percentage 
reduction in sample size, which preserves the statistical power of the novel analysis.  
This could also be thought of as obtaining narrower confidence limits and hence 
more precise estimates of the treatment effect for a given sample size.  It has 
previously been shown, using the IMPACT database, that the use of logistic 
regression to incorporate baseline covariates into the conventional analysis of the 
dichotomous GOS can yield sample size reductions of the order of 25% (Hernandez 
et al. 2006). 
To extend these earlier findings, and to allow direct comparisons with the results of 
ordinal analysis, three different sets of covariates w re used in adjusted dichotomous 
analyses.  These sets are as follows:  
3 covariate - age, motor and pupils 
7 covariate - age, motor, pupils, hypoxia, hypotension, tSAH and CT class 
9 covariate - age, motor, pupils, hypoxia, hypotension, tSAH, CT class, haemoglobin 
and glucose 
The covariate values were 94.6% complete for the three-covariate model, 81.6% 
complete for the seven-covariate model and 91.7% complete for the nine-covariate 
model.  As described in detail previously in Chapter 2, the missing covariate values 
were replaced using a single realisation of a multiple imputation procedure. 
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5.3 The sliding dichotomy 
A fundamental objection to the conventional dichotomous analysis of the GOS is that 
it gives absolute priority to one transition in the scale, namely, the change from 
severe disability to moderate disability, and ignores all other transitions, such as the 
change from vegetative state to severe disability or from moderate disability to good 
recovery.  This goes against clinical practice and lso lacks statistical sensitivity.  For 
a patient other than one with an intermediate prognosis, it is unlikely that a 
therapeutic intervention will alter prognosis sufficiently for the patient’s outcome to 
move from ‘unfavourable’ to ‘favourable’.  Therefore, when using the conventional 
dichotomous analysis, a substantial proportion of patients recruited into a clinical 
trial do not have the potential to demonstrate the eff ct of even a highly beneficial 
intervention (Machado, Murray, & Teasdale 1999).  This dilutes the observed effect 
of any beneficial (or indeed harmful) intervention a d so reduces statistical power. 
 
The ‘sliding dichotomy’ has been proposed to overcome this problem (Murray et al. 
2005).  The GOS is still dichotomised, but the point f dichotomy is tailored to each 
individual patient’s baseline prognosis.  For example, for a patient with an excellent 
prognosis, their outcome might only be regarded as being ‘favourable’ if they 
achieve good recovery, whereas a patient with a very poor prognosis might be 
regarded as having a ‘favourable’ outcome if they achieve severe disability or better.  
In effect, one is defining outcome to be favourable if it is better than would be 
expected, given the individual’s baseline prognosis. 
 
There are a number of operational issues to be decided when implementing the 
sliding dichotomy (Murray et al. 2005).  One needs to use a baseline prognostic 
model, but does a sophisticated model offer substantial advantages over a simple 
model?  Given the predicted prognostic risk, the patients need to be ordered by risk 
and then banded into prognostic groups.  Should this be done to give roughly equal 
number of patients in each band, or so that each band is defined by a range of 
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prognostic risk?  How many bands should be used?  After the baseline covariates 
have been incorporated into the prognostic model, can they be used again to 
undertake an adjusted analysis?  Each of these issus i  explored in this chapter. 
 
5.4 Simulating treatment effects - methods 
5.4.1 Design of the Simulation Study 
The simulation study began by fitting an overall multinomial generalised logit 
regression model for a nominal response to the entire IMPACT database to predict 
the probability of each possible outcome as a functio  of a patient’s baseline 
covariates.  This was done separately for the three, seven and nine covariate sets 
described previously, using the SAS procedure PROC L GISTIC.  As with the 
proportional odds analysis shown in Chapter 4, death and vegetative state were 
pooled on both statistical and ethical grounds.  Thus, the GOS was reduced to a 4-
point ordinal scale for all the analyses.  The SAS programs for the initial simulations 
were written jointly by Dr Butcher (Edinburgh) and me.  Subsequent programs to 
model the simulation data were written by me. 
 
The 11 constituent studies within the IMPACT database were used as examples of 
typically selected head injury populations.  For a single simulation with any one of 
the 11 IMPACT data sets, 400 subjects were sampled at random with replacement.  
For each individual, their predicted outcome was modelled in terms of their baseline 
covariates.  For example, the modelled probabilities of the outcome for a given 
individual being death/vegetative state (D/V), sever  disability (SD), moderate 
disability (MD), or good recovery (GR) might be 40%, 20%, 30%, and 10%, 
respectively.  Using these estimated probabilities, an actual outcome was simulated, 
yielding a random sample of 400 patients reflecting he baseline severity of the study 
in question, and with simulated outcomes.  These represented the placebo group in a 
trial.  Still as part of this single simulation, a further 400 subjects were sampled at 
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random with replacement, to generate the intervention group.  When simulating the 
outcomes for the intervention group, the predicted probabilities coming from the 
multinomial model were adjusted to incorporate a tre tment effect. 
Two treatment effects were fitted, 5% and 8%, both increasing the proportion of 
favourable outcomes.  Eight percent was chosen as this is typically the treatment 
difference looked for in head injury trials.  Five p rcent was also chosen to reflect a 
more modest, and perhaps more realistic, treatment benefit. 
Two different models were used for the treatment effect, ‘uniform’ and ‘mortality’.  
For the ‘uniform’ treatment effect, it was assumed that the impact of the treatment 
followed precisely a proportional odds model.  The common odds ratio that was used 
was calibrated so that overall, there was a 5% or 8% absolute increase in the 
proportion of patients with a favourable outcome.  For the ‘mortality’ model, it was 
assumed that the effect of treatment was to reduce the risk of D/V, but that the 
relative probability of SD to MD to GR was unaltered.  Again, the reduction in 
mortality was calibrated so that overall, there was a 5% or 8% absolute increase in 
the proportion of patients with a favourable outcome.  The technical details of this 
procedure are given below. 
 
5.4.1.1 Algorithms used for the simulated treatment effects 
Proportional odds model 
Step 1: For a simulated patient from the treatment group with given covariate values, 
the global multinomial model will give initial ‘placebo’ probabilities p1, p2, p3, p4 for 
the four possible outcomes D/V, SD, MD, and GR, respectively (where 
p1+p2+p3+p4=1). 
Step 2: The odds ratios are calculated for each possible dichotomisation of the scale 
as follows:  
OR4= p4/(1-p4) 
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OR34 = (p3+p4)/(1-p3-p4) 
OR234 = (p2+p3+p4)/(1-p2-p3-p4) 
Step 3: The odds ratios are each multiplied by the treatment effect parameter k. 
Step 4: The scaled odds ratios are back transformed to give the new ‘treatment’ 





The calibration is achieved by taking the overall distribution over D/V, SD, MD, and 
GR for the study in question and applying the algorithm above.  The treatment 
parameter is obtained by solving t3+t4=p3+p4+δ for k, where δ was set to 0.05 or 
0.08.  This was performed using the Microsoft Excel add on Tool, Solver. 
 
Mortality model 
The algorithm is a simplified version of the above.  The treated probability of D/V is 
reduced by scaling and then back transforming the corresponding odds ratio.  The 
probabilities for SD, MD, and GR are scaled linearly so that the four treatment 
probabilities sum to one.  The calibration is achieved as described above. 
 
5.4.1.2 Illustration for the simulated treatment effects 
As an illustration, the overall distribution of outcome in the selected study might be 
20% D/V, 30% SD, 25% MD, and 25% GR.  With a proportional odds model, a 
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common odds ratio of (55/45)/(50/50), that is, 1.22, leads to a 5% absolute increase 
in the proportion of patients with an outcome of MD or GR.  Under this uniform 
model, the full outcome distribution in the intervention group would be 17% D/V, 
28% SD, 26% MD, and 29% GR.  Under the mortality model, the proportion of 
patients with outcomes of SD, MD, and GR remain in the ratio 30:25:25.  To achieve 
this, with an absolute increase of 5% in the proportion of patients with an outcome of 
MD or GR requires an overall outcome distribution of 12% D/V, 33% SD, 27.5% 
MD, and 27.5% GR.  With this distribution, the odds ratio for D/V versus better is 
1.83, the odds ratio for D/V or SD versus better is 1.22 (as for the proportional odds 
model), and the odds ratio for D/V or SD or MD versus better is 1.14.  Thus, as 
intended, the mortality model deviates substantially from the proportional odds 
model.  Fitting a proportional odds model to these data under the mortality model 
gives an estimated common odds ratio of 1.30. 
 
5.4.1.3 Modelling the simulated treatment effects 
This process therefore generated a sample of 800 subjects, representing 400 patients 
from the placebo group and 400 from the intervention group.  The total size of 800 
was chosen to be representative of a typical Phase III trial in head injury.  Once the 
data were generated, they were analysed by the different approaches, which were to 
be compared, yielding either a ‘significant’ or a ‘nonsignificant’ outcome.  For the 
analyses based on the sliding dichotomy approach, the parameters for the underlying 
prognostic model were estimated separately for eachsimulation by fitting a binary 
logistic regression model with a conventional favourable/unfavourable dichotomy of 
the GOS as the response variable.  The entire process was then repeated 1000 times, 
and the power of each statistical approach was estimated as the proportion of the 
1000 analyses, which yielded a significant result at the 5% level (two-sided).  With 
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For ease of interpretation, the power was then converted into a measure of the 
efficiency of each analytical approach relative to the reference approach of the 
conventional dichotomy without covariate adjustment.  Thus, each method is 
reported in terms of the reduction in sample size, which can be achieved while 
preserving the power of the analysis.  “The formula used was: 100-100*[(mean of Z 
score for reference model)/(mean of Z score for adjusted model)]2 (Hernandez, 
Steyerberg, & Habbema 2004) where Z score is equal to the Wald statistic of the 
treatment effect coefficient” (Hernandez et al. 2006). 
 
In total, the simulations covered 11x3x2x2 scenarios – every combination of the 11 
constituent studies with the three sets of covariates (three, seven or nine) with the 
two treatment effect models (uniform or mortality) and the two treatment effects (5% 
and 8%). 
 
In total, 16 different analytical approaches were compared: 
• The conventional dichotomous analysis, as the reference technique. 
• The sliding dichotomy with each combination of three, four, or five 
prognostic bands; the prognostic bands determined either by having equal 
numbers of patients per band or by having equal bands for p(fav), the 
predicted probability of a favourable outcome (e.g., for four equal bands, the 
bands would be defined by p(fav) lying in the ranges 0–25%, 25–50%, 50–
75%, and 75–100%); and with and without covariate adjustment (3x2x2=12 
combinations). 
• The conventional dichotomous analysis, with covariates. 
• The proportional odds model, without covariates. 
• The proportional odds model, with covariates. 
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The different approaches to the sliding dichotomy analysis were compared first, as 
shown in this chapter, and a single optimised version was taken forward to compare 
with the other methods, as shown in Chapter 6. 
 
For a limited number of scenarios representing the conventional binary logistic 
regression analysis, the proportional odds analysis and the sliding dichotomy 
analysis; the entire process of running 1000 simulations for each of the 11 data sets 
was repeated 10 times, to allow the standard error of the differences between 
methods in percentage sample size reduction to be estimated.  Similarly, for a 
number of representative scenarios, a very large number of simulations were run with 
a null treatment effect to assess whether the actual significance level was close to the 
nominal value of 5%.  These gave the following results.  Significance level: the 95% 
confidence intervals for the significance level achieved with the logistic regression, 
the sliding dichotomy, and the proportional odds model were, 5.10–5.22%, 4.95–
5.06%, and 5.08–5.21% respectively.  Precision: the estimated standard error for the 
difference between methods in terms of the percentag  reduction in sample size 
ranged from 1.5% to 5% with a mean of 3.5%. 
 
5.5 Sliding dichotomy modelling 
It was firstly of interest to compare the different sliding dichotomy strategies.  The 
tables below show the sample size reduction achieved when the sliding dichotomy 
strategy is applied.  Each table shows all of the sliding dichotomy scenarios 
separately for the combinations of the three covariate sets (three, seven and nine 
covariates), two treatment effects (uniform and mortality) and the two treatment 
effects (5% and 8%).  For all of the tables the table cells are the percentage 
reductions in sample size, which can be achieved while preserving the power relative 
to the conventional unadjusted analysis of the dichotomised outcome scale 
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5.5.1 Sliding dichotomy modelling – uniform treatment effect 
Here the treatment effect followed a proportional odds model. 
5.5.1.1 Three covariate model 
5% treatment effect 
Table 5-1 below shows the results from the 5% treatm n  effect.  Greater reductions 
in sample size are observed, in general, using the bands with equal splits rather than 
the bands based on p(fav).  Using five bands, equal splits with and without covariates 
performs poorly for all studies.  Using five bands equal splits with TINT gives an 
increase in sample size compared with the conventional dichotomy.  The addition of 
covariates gives a modest increase in efficiency for all of the scenarios. 
Table 5-1 Sliding Dichotomy comparison: Median and by trial reductions in sample size. 
Uniform treatment scenario, 5% treatment effect, three covariate model for all subjects5 
 TINT TIUS SLIN SAP PEG HITI UK4 TCDB SKB EBIC HITII  Median 
Conventional 
no cov 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
3 bands, equal 
splits 
16.2 30.2 26.1 25.6 36.5 28.6 28.9 45.3 29.9 38.5 33.3 29.9 
4 bands, equal 
splits 
22.6 35.5 29.3 33.7 34.6 27.5 33.8 44.5 30.7 37.0 38.2 33.8 
5 bands, equal 
splits 
-4.1 18.2 8.7 17.3 21.4 15.6 26.8 41.0 18.3 29.9 24.6 18.3 
3 bands, equal 
splits +cov 
19.8 32.5 29.5 27.9 38.5 31.6 36.6 48.7 30.3 43.9 32.3 32.3 
                                                
5 Table cells are the percentage reductions in sample size, which can be achieved while preserving the 
power relative to the conventional unadjusted analysis of the dichotomised outcome scale. ‘Equal 
splits’ means prognostic bands chosen to contain equal numbers of patients. ‘p(fav)’ means prognostic 
bands chosen with specific ranges of the predicted probability of a favourable outcome. ‘no cov’ 
means that the final analysis was not covariate adjusted. ‘+cov’ means that the final analysis was 
covariate adjusted. 
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 TINT TIUS SLIN SAP PEG HITI UK4 TCDB SKB EBIC HITII  Median 
4 bands, equal 
splits +cov 
24.4 35.7 30.3 33.4 36.3 32.3 36.7 46.3 35.0 40.4 39.1 35.7 
5 bands, equal 
splits +cov 
-1.5 17.7 12.2 17.6 24.8 16.1 26.6 41.2 20.6 31.3 25.6 20.6 
3 bands, 
p(fav) splits 
18.5 29.0 28.9 29.2 33.2 26.4 33.2 42.1 20.9 34.4 32.9 29.2 
4 bands, 
p(fav) splits 
14.1 29.2 22.3 27.0 29.7 21.6 31.1 43.8 24.2 31.7 28.1 28.1 
5 bands, 
p(fav) splits 












18.5 34.4 21.6 28.6 35.8 22.3 36.9 45.3 27.7 38.9 34.6 34.4 
 
8% treatment effect 
All of the sliding dichotomy strategies gave a reduction in sample size compared 
with the conventional dichotomy for all studies using the 8% treatment effect as 
shown in Table 5-2 below.  Using five bands equal splits with and without covariates 
again gave the smallest reductions in sample size compared with the other strategies.  
Similar results were observed both when having equal n mbers of patients per band 
and when banding by the proportion of favourable outc mes. 
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Table 5-2 Sliding Dichotomy comparison: Median and by trial reductions in sample size. 
Uniform treatment scenario, 8% treatment effect, three covariate model for all subjects5 
 TINT TIUS SLIN SAP PEG HITI UK4 TCDB SKB EBIC HITII  Median 
Conventional 
no cov 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
3 bands, equal 
splits 
26.5 29.8 28.1 27.5 29.8 29.4 34.2 38.2 26.2 35.9 32.7 29.8 
4 bands, equal 
splits 
27.6 29.8 26.2 28.4 29.5 21.7 36.5 38.7 21.2 36.7 31.8 29.5 
5 bands, equal 
splits 
14.1 12.3 12.6 16.1 19.0 7.0 27.5 30.9 10.0 27.4 19.4 16.1 
3 bands, equal 
splits +cov 
27.4 32.8 29.7 28.0 31.4 29.6 38.7 42.4 26.0 39.5 33.9 31.4 
4 bands, equal 
splits +cov 
29.7 31.4 29.4 29.5 33.1 25.0 38.2 43.2 24.0 40.8 32.0 31.4 
5 bands, equal 
splits +cov 
16.3 14.1 14.7 17.5 21.6 7.0 28.6 34.9 8.9 28.9 20.5 17.5 
3 bands, 
p(fav) splits 
28.8 28.4 26.5 28.2 28.7 18.3 36.0 39.2 17.6 35.2 29.9 28.7 
4 bands, 
p(fav) splits 
25.6 25.7 21.8 23.1 26.8 14.7 34.2 38.4 13.8 32.8 24.0 25.6 
5 bands, 
p(fav) splits 












30.4 30.0 25.8 28.0 33.7 19.9 37.6 42.3 20.2 39.0 28.5 30.0 
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5.5.1.2 Seven covariate model 
For both the 5% and 8% treatment effects, all sliding dichotomy scenarios showed a 
reduction in sample size compared with the conventional analysis as shown in Table 
5-3 and Table 5-4 respectively. 
 
5% treatment effect 
Here, typically, using the scenarios based on having equal numbers of patients per 
band gave slightly greater reductions in sample sizthan using the scenarios which 
banded by the probability of a favourable outcome.  For all scenarios, using 
covariates gave a modest increase in efficiency.  Using five bands with equal splits 
gave the smallest reductions in sample size. 
 
Table 5-3 Sliding Dichotomy comparison: Median and by trial reductions in sample size. 
Uniform treatment scenario, 5% treatment effect, seven covariate model for all subjects5 
 TINT TIUS SLIN SAP PEG HITI UK4 TCDB SKB EBIC HITII  Median 
Conventional 
no cov 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.00.0 
3 bands, equal 
splits 
24.7 33.1 25.7 33.2 39.6 41.5 39.9 42.1 27.6 29.2 30.133.1 
4 bands, equal 
splits 
29.2 39.8 27.1 33.3 41.6 36.8 41.7 34.2 26.0 28.4 28.133.3 
5 bands, equal 
splits 
7.3 28.2 10.2 11.6 28.9 25.6 33.0 27.4 17.8 27.5 16.925.6 
3 bands, equal 
splits +cov 
24.9 39.8 28.1 36.8 43.8 42.8 44.9 50.6 31.9 40.0 34.139.8 
4 bands, equal 
splits +cov 
32.3 49.1 26.9 42.8 44.6 40.5 43.6 43.0 30.6 37.8 31.740.5 
5 bands, equal 
splits +cov 
15.8 35.5 11.8 30.8 31.6 23.1 37.7 32.9 13.5 29.9 15.029.9 
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 TINT TIUS SLIN SAP PEG HITI UK4 TCDB SKB EBIC HITII  Median 
3 bands, 
p(fav) splits 
25.6 37.8 23.2 33.3 36.4 38.2 44.0 35.6 20.2 28.7 29.333.3 
4 bands, 
p(fav) splits 
25.4 35.5 13.2 18.6 34.8 31.6 37.3 30.9 5.5 24.4 24.625.4 
5 bands, 
p(fav) splits 












31.7 47.0 22.8 36.1 41.3 35.7 44.4 42.9 23.3 39.4 27.436.1 
 
8% treatment effect 
As with the 5% treatment effect, using five bands with equal splits gave the smallest 
reductions in sample size although the reductions with the 8% treatment effect were 
greater than those with the 5% treatment effect.  Using banding based on the 
probability of a favourable outcome gave slightly greater increases in sample size 
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Table 5-4 Sliding Dichotomy comparison: Median and by trial reductions in sample size. 
Uniform treatment scenario, 8% treatment effect, seven covariate model for all subjects5 
 TINT TIUS SLIN SAP PEG HITI UK4 TCDB SKB EBIC HITII  Median 
Conventional 
no cov 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
3 bands, equal 
splits 
29.1 38.1 20.4 32.4 35.0 31.2 36.5 42.4 30.3 39.6 34.7 34.7 
4 bands, equal 
splits 
44.5 44.3 36.3 40.3 42.4 38.5 38.5 39.7 26.9 43.5 29.8 39.7 
5 bands, equal 
splits 
22.9 34.7 1.7 24.4 21.8 17.4 32.1 43.7 30.9 39.6 21.7 24.4 
3 bands, equal 
splits +cov 
34.2 41.1 22.4 33.9 38.9 35.2 43.7 48.4 32.6 46.5 39.1 38.9 
4 bands, equal 
splits +cov 
46.9 44.2 37.0 34.0 46.1 42.2 37.5 46.1 30.7 40.7 32.7 40.7 
5 bands, equal 
splits +cov 
29.8 30.3 22.4 19.6 32.3 23.9 31.6 38.7 15.9 32.8 15.9 29.8 
3 bands, 
p(fav) splits 
38.4 45.1 22.2 40.1 33.3 30.1 38.6 50.4 39.0 41.7 42.1 39.0 
4 bands, 
p(fav) splits 
33.3 41.2 15.9 34.2 31.7 28.4 35.1 47.2 35.4 43.1 34.3 34.3 
5 bands, 
p(fav) splits 












44.3 41.8 35.1 33.9 45.6 38.1 38.9 44.7 28.0 40.1 32.3 38.9 
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5.5.1.3 Nine covariate model 
5% and 8% treatment effects 
A similar pattern was observed both for the 5% and 8% treatment effects.  Using 
nine covariates, all sliding dichotomy strategies gave a reduction in sample size of 
typically 30-40% compared with the conventional dichotomous analysis, as shown in 
Table 5-5 and Table 5-6 below.  Using four bands, when banding by sample size, 
gave the greatest reductions in sample size with smaller reductions observed with 
using three and then five bands.  Those scenarios that used the proportion of 
favourable outcomes to group subjects showed a similar picture with the three, four 
and five bands, with here the three band scenarios typically performing the best. 
 
Table 5-5 Sliding Dichotomy comparison: Median and by trial reductions in sample size. 
Uniform treatment scenario, 5% treatment effect, nine covariate model for all subjects5 
 TINT TIUS SLIN SAP PEG HITI UK4 TCDB SKB EBIC HITII  Median 
Conventional 
no cov 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
3 bands, equal 
splits 
35.1 43.6 20.3 28.3 30.7 35.0 40.4 37.5 35.8 36.2 32.6 35.1 
4 bands, equal 
splits 
39.6 49.3 29.8 30.4 29.0 32.0 42.4 37.9 37.9 36.2 22.3 36.2 
5 bands, equal 
splits 
16.4 42.0 16.9 8.0 22.4 22.9 32.6 31.8 26.8 37.0 9.9 22.9 
3 bands, equal 
splits +cov 
39.8 47.8 23.9 32.1 35.8 38.7 45.2 47.4 37.6 44.7 35.1 38.7 
4 bands, equal 
splits +cov 
41.8 50.6 30.5 32.3 32.6 35.6 41.9 47.8 39.2 43.5 30.6 39.2 
5 bands, equal 
splits +cov 
28.8 43.3 16.4 12.5 23.6 24.8 30.8 36.9 28.6 36.8 12.3 28.6 
3 bands, 
p(fav) splits 
31.7 48.4 28.4 29.3 27.6 31.2 41.1 35.9 27.6 36.0 28.2 31.2 
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 TINT TIUS SLIN SAP PEG HITI UK4 TCDB SKB EBIC HITII  Median 
4 bands, 
p(fav) splits 
32.5 46.4 20.5 24.5 27.8 27.7 34.8 33.2 23.8 34.5 16.9 27.8 
5 bands, 
p(fav) splits 












40.5 50.2 30.3 27.5 36.7 32.2 39.1 45.0 32.8 39.6 25.2 36.7 
 
Table 5-6 Sliding Dichotomy comparison: Median and by trial reductions in sample size. 
Uniform treatment scenario, 8% treatment effect, nine covariate model for all subjects5 
 TINT TIUS SLIN SAP PEG HITI UK4 TCDB SKB EBIC HITII  Median 
Conventional 
no cov 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
3 bands, equal 
splits 
24.0 39.4 21.3 29.8 30.9 32.1 41.5 40.4 34.4 38.9 29.4 32.1 
4 bands, equal 
splits 
39.9 42.5 36.2 36.6 46.6 43.6 40.2 42.2 31.6 29.1 28.3 39.9 
5 bands, equal 
splits 
24.0 30.7 19.0 14.6 30.1 24.0 34.6 42.3 32.0 30.3 22.5 30.1 
3 bands, equal 
splits +cov 
28.5 44.1 23.6 34.9 37.2 35.8 47.8 45.1 37.1 43.7 33.7 37.1 
4 bands, equal 
splits +cov 
43.8 53.8 38.3 41.8 48.9 46.4 54.2 48.2 36.8 45.3 32.8 45.3 
5 bands, equal 
splits +cov 
27.0 40.0 22.4 26.9 34.2 30.1 42.8 40.1 27.0 40.1 22.7 30.1 
3 bands, 
p(fav) splits 
38.6 41.9 36.0 33.1 45.6 40.3 39.6 45.7 40.3 33.6 38.0 39.6 
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 TINT TIUS SLIN SAP PEG HITI UK4 TCDB SKB EBIC HITII  Median 
4 bands, 
p(fav) splits 
36.2 38.3 30.2 30.4 40.3 34.6 38.4 44.0 37.1 30.1 34.4 36.2 
5 bands, 
p(fav) splits 












43.6 52.6 38.1 41.1 46.2 43.8 54.6 48.9 31.3 46.4 33.9 43.8 
 
5.5.1.4 Uniform treatment effect graphical comparison 
Figure 5-1, Figure 5-2 and Figure 5-3 below show the results by trial for the Uniform 
5% treatment effect when banding by sample size for three, four and five bands 
respectively.  The figures show the three covariate models (three, seven and nine), 
both unadjusted and adjusted.  The studies are ordered with the trials together then 
the three surveys, UK4, TCDB and EBIC.  Similar reductions in sample size are 
observed using three and four bands, with five bands giving smaller reductions.  For 
most studies the addition of covariates gave additional sample size reductions, the 
adjusted results.  Using models based on seven or ni e covariates generally gave 
greater sample size reductions than using three covariates although this was not 
consistent over all studies. 
 
Graphs showing the results by trial banded by the probability of a favourable 
outcome for a Uniform 5% treatment effect are shown in Figure 5-4, Figure 5-5 and 
Figure 5-6 for the three, four and five bands respectiv ly.  For all studies using either 
three, four or five bands and banding by the probability of a favourable outcome 
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gives a reduction in sample size compared with the conventional dichotomous 
analysis.  Here, the addition of covariates gives a modest additional gain for all three 
models.  A similar pattern of results is observed over three, four and five bands.  This 
is different to the results observed when banding was done by sample size, where 
using five bands gave smaller reductions in sample siz  than using three or four 
bands. 
 
Figure 5-7, Figure 5-8 and Figure 5-9 below show the results by trial for the sliding 
dichotomy simulations for the Uniform 8% treatment ffect when banding by sample 
size for three, four and five bands respectively.  For all studies banding by three, four 
or five bands gave a reduction in sample size compared with the conventional 
dichotomy.  Using five bands gave the smallest reductions in sample size.  Using 
three or four bands gave similar reductions.  For mst studies using the seven or nine 
covariate models gave greater reductions than the thre  covariate model. 
 
As with the 5% treatment effect, banding by the probability of a favourable outcome 
gave a reduction in sample size for all studies modelling the 8% treatment effect, as 
shown in Figure 5-10, Figure 5-11 and Figure 5-12.  The adjusted models typically 
gave greater reductions than the unadjusted models.  However, using the nine 
covariate model did not consistently give greater reductions than the seven covariate 
model. 
 
Figure 5-13 and Figure 5-14 show the median reductions n sample size over all trials 
by prognostic banding group for the Uniform 5% and 8% treatment effects 
respectively.  These show that using either three, four or five bands and banding by 
sample size or by the probability of a favourable outc me, all covariate models show 
a reduction in sample size compared with the conventional dichotomous model.  
When banding by the probability of a favourable outc me a similar pattern is 
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observed when using three, four or five bands.  When banding by sample size using 
five bands gives smaller reductions than either three or four bands. 
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Key: 3 covariate model unadjusted (red), 3 covariate model adjusted (dark blue), 7 covariate model 
unadjusted (green), 7 covariate model adjusted (yellow), 9 covariate model unadjusted (purple), 9 
covariate model adjusted (pink) 
                                                
6 Bars are the percentage reductions in sample size which can be achieved while preserving the power 
relative to the conventional unadjusted analysis of the dichotomised outcome scale. ‘Equal splits’ 
means prognostic bands chosen to contain equal numbers of patients. ‘p(fav)’ means prognostic bands 
chosen with specific ranges of the predicted probability of a favourable outcome. 
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Key: 3 covariate model unadjusted (red), 3 covariate model adjusted (dark blue), 7 covariate model 
unadjusted (green), 7 covariate model adjusted (yellow), 9 covariate model unadjusted (purple), 9 
covariate model adjusted (pink) 
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Key: 3 covariate model unadjusted (red), 3 covariate model adjusted (dark blue), 7 covariate model 
unadjusted (green), 7 covariate model adjusted (yellow), 9 covariate model unadjusted (purple), 9 
covariate model adjusted (pink) 
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Key: 3 covariate model unadjusted (red), 3 covariate model adjusted (dark blue), 7 covariate model 
unadjusted (green), 7 covariate model adjusted (yellow), 9 covariate model unadjusted (purple), 9 
covariate model adjusted (pink) 
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Figure 5-13 Sliding Dichotomy: Median reductions in sample size by prognostic banding group. 

















Figure 5-14 Sliding Dichotomy: Median reductions in sample size by prognostic banding group. 


















Key: 3 covariate model unadjusted (red), 3 covariate model adjusted (dark blue), 7 covariate model 
unadjusted (green), 7 covariate model adjusted (yellow), 9 covariate model unadjusted (purple), 9 
covariate model adjusted (pink) 
                                                
7 Bars are the percentage reductions in sample size which can be achieved while preserving the power 
relative to the conventional unadjusted analysis of the dichotomised outcome scale. ‘Equal’ means 
prognostic bands chosen to contain equal numbers of patients. ‘p(fav)’ means prognostic bands chosen 
with specific ranges of the predicted probability of a favourable outcome. The number refers to the 
number of bands. 
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5.5.2 Sliding dichotomy modelling - mortality treatment effect 
5% and 8% treatment effects 
Here the treatment effect is a reduction in mortality.  No sliding dichotomy strategy 
gave a reduction in sample size for SLIN for both the 5% and 8% treatment effects. 
5.5.2.1  Three covariate model 
5% treatment effect 
Table 5-7 below shows that, with the exception of the three series (UK4, TCDB and 
EBIC), using five bands equal splits both with and without covariates gave an 
increase in sample size compared with the conventional dichotomous analysis for all 
studies.  All other scenarios showed a reduction in sample size for all studies except 
TINT and SLIN.  In general greater reductions were observed when equal splits were 
used as opposed to banding by the probability of a favourable outcome although the 
reductions were similar overall. 
 
Table 5-7 Sliding Dichotomy comparison: Median and by trial reductions in sample size. 
Mortality treatment scenario, 5% treatment effect, three covariate model for all subjects5 
 TINT TIUS SLIN SAP PEG HITI UK4 TCDB SKB EBIC HITII  Median 
Conventional 
no cov 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
3 bands, equal 
splits 
15.1 21.9 -47.1 34.0 35.1 36.9 42.9 34.6 38.0 37.3 40.3 35.1 
4 bands, equal 
splits 
18.5 24.4 -14.8 16.5 32.5 23.9 52.4 49.8 28.8 32.8 3.1 24.4 
5 bands, equal 
splits 
-119.6 -87.6 -115.7 -75.8 -9.2 -14.2 15.1 14.4 -27.8 6.3 -42.3 -27.8 
3 bands, equal 
splits +cov 
18.8 23.6 -52.4 35.6 38.0 36.6 44.7 37.9 36.6 40.5 40.5 36.6 
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 TINT TIUS SLIN SAP PEG HITI UK4 TCDB SKB EBIC HITII  Median 
4 bands, equal 
splits +cov 
17.6 25.2 -12.8 20.2 33.2 26.9 54.3 52.9 31.6 38.1 23.3 26.9 
5 bands, equal 
splits +cov 
-109.8 -84.4 -115.7 -56.1 -10.0 -14.7 14.8 17.1 -29.4 4.4 -45.5 -29.4 
3 bands, 
p(fav) splits 
3.4 9.8 -24.5 10.5 27.7 16.7 44.0 43.1 9.7 26.0 21.5 6.7 
4 bands, 
p(fav) splits 
-14.5 14.2 -64.2 11.7 29.9 29.4 47.8 45.7 30.1 34.2 19.4 29.4 
5 bands, 
p(fav) splits 












3.0 19.4 -25.8 21.4 37.4 33.5 51.4 50.3 30.7 41.5 28.2 30.7 
 
8% treatment effect 
In general, using 3 or 4 bands, equal splits with covariates gave the greatest 
reductions.  With TINT the only very modest advantage over the conventional 
analysis was seen when using 4 bands equal splits.  All other scenarios showed a 
disadvantage of using the sliding dichotomy with increases in the sample size 
required from 7% up to 148% as shown in Table 5-8. 
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Table 5-8 Sliding Dichotomy comparison: Median and by trial reductions in sample size. 
Mortality treatment scenario, 8% treatment effect, three covariate model for all subjects5 
 TINT TIUS SLIN SAP PEG HITI UK4 TCDB SKB EBIC HITII  Median 
Conventional 
no cov 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
3 bands, 
equal splits 
-25.5 5.1 -65.6 31.3 42.3 37.2 36.5 38.1 33.5 38.0 36.5 36.5 
4 bands, 
equal splits 
5.9 16.6 -41.4 26.4 35.5 25.9 43.9 43.2 19.1 24.2 19.8 24.2 
5 bands, 
equal splits 












-138.1 -180.2 -175.6 -67.9 -7.7 -40.9 13.3 6.0 -60.7 -3.3 -71.3 -60.7 
3 bands, 
p(fav) splits 
-12.1 -2.4 -28.0 20.0 32.8 22.6 39.6 35.5 7.3 27.4 16.7 20.0 
4 bands, 
p(fav) splits 
-33.6 -5.4 -78.8 13.9 41.4 25.3 46.2 41.6 5.2 30.2 13.1 13.9 
5 bands, 
p(fav) splits 












-6.9 9.4 -46.1 25.0 44.1 29.1 49.5 49.2 12.8 38.2 23.4 25.0 
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5.5.2.2 Seven covariate model 
5% treatment effect 
For most studies using three or four bands with equal splits resulted in greater 
reductions in sample size than banding by the proportion of favourable outcomes as 
shown in Table 5-9 below.  Using five bands with equal splits however gave an 
increase in sample size compared with the conventional analysis for seven of the 
eleven studies.  Using covariates gave a modest increase in efficiency. 
 
Table 5-9 Sliding Dichotomy comparison: Median and by trial reductions in sample size. 
Mortality treatment scenario, 5% treatment effect, seven covariate model for all subjects5 
 TINT TIUS SLIN SAP PEG HITI UK4 TCDB SKB EBIC HITII  Median 
Conventional 
no cov 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
3 bands, 
equal splits 
29.5 32.9 23.7 36.4 38.1 40.2 38.0 41.7 43.2 39.3 37.2 38.0 
4 bands, 
equal splits 
24.9 24.8 12.0 16.6 13.6 23.9 52.9 56.6 56.4 40.4 29.2 24.9 
5 bands, 
equal splits 












-83.8 -138.2 -126.6 -102.7 -20.0 -89.6 10.8 29.3 29.4 6.1 -29.7 -29.7 
3 bands, 
p(fav) splits 
13.6 19.1 14.0 13.0 24.5 24.6 45.0 44.6 41.7 34.7 28.1 24.6 
4 bands, 
p(fav) splits 
19.4 20.1 -7.8 12.5 27.4 19.9 49.0 47.8 51.6 38.1 21.8 21.8 
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 TINT TIUS SLIN SAP PEG HITI UK4 TCDB SKB EBIC HITII  Median 
5 bands, 
p(fav) splits 












22.0 20.4 -8.2 23.1 33.8 31.2 52.5 57.6 54.8 45.8 35.7 33.8 
 
8% treatment effect 
For all studies using three or four bands with equal splits both with and without 
covariates gave the greatest reductions in sample size a  shown in Table 5-10.  As 
with the 5% treatment effect using five bands with equal splits gave an increase in 
sample size compared with the conventional dichotomy for seven of the eleven 
studies.  In general using the equal splits gave greate  reductions than banding by the 
probability of a favourable outcome. 
 
Table 5-10 Sliding Dichotomy comparison: Median and by trial reductions in sample size. 
Mortality treatment scenario, 8% treatment effect, seven covariate model for all subjects5 
 TINT TIUS SLIN SAP PEG HITI UK4 TCDB SKB EBIC HITII  Median 
Conventional 
no cov 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
3 bands, 
equal splits 
17.2 28.0 7.3 39.6 40.8 41.9 40.7 45.7 39.2 42.1 37.1 39.6 
4 bands, 
equal splits 
21.9 31.7 28.9 19.3 23.7 36.4 43.1 50.7 44.0 35.4 29.8 31.7 
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 TINT TIUS SLIN SAP PEG HITI UK4 TCDB SKB EBIC HITII  Median 
5 bands, 
equal splits 












-154.6 -120.4 -118.1 -78.3 -45.6 -66.0 12.8 23.7 7.7 14.2 -72.9 -66.0 
3 bands, 
p(fav) splits 
12.3 23.1 11.7 12.4 32.4 32.1 39.6 50.5 33.0 40.4 25.7 32.1 
4 bands, 
p(fav) splits 
-5.0 17.1 -36.4 11.5 37.9 24.8 43.1 52.2 42.4 41.3 13.9 24.8 
5 bands, 
p(fav) splits 












-0.9 24.7 -1.9 20.5 40.0 32.4 50.7 5 .5 41.7 50.7 26.1 32.4 
 
5.5.2.3 Nine covariate model 
5% treatment effect 
For the scenarios using three and four bands using ba ding based on sample size 
resulted in slightly greater reductions in sample siz than using banding based on the 
probability of a favourable outcome as shown in Table 5-11 below.  Five bands equal 
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splits both with and without covariates performed poorly again resulting in an 
increase in sample size compared to the conventional dichotomy for most studies.  
Banding by the probability of a favourable outcome and using four or five bands 
gave a reduction in sample size compared with the conventional dichotomy for all 
studies except SLIN. 
 
Table 5-11 Sliding Dichotomy comparison: Median and by trial reductions in sample size. 
Mortality treatment scenario, 5% treatment effect, nine covariate model for all subjects5 
 TINT TIUS SLIN SAP PEG HITI UK4 TCDB SKB EBIC HITII  Median 
Conventional 
no cov 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
3 bands, 
equal splits 
33.5 25.2 20.7 42.0 38.9 40.1 33.2 32.3 40.2 37.7 40.4 37.7 
4 bands, 
equal splits 
17.6 26.8 21.5 29.7 33.8 10.2 47.1 45.7 50.3 45.9 24.6 29.7 
5 bands, 
equal splits 












-129.3 -96.0 -80.1 -48.5 -11.7 -88.9 13.5 9.6 28.4 14.5 -29.3 -29.3 
3 bands, 
p(fav) splits 
2.5 18.2 -3.7 22.6 31.8 15.1 38.2 37.4 40.6 38.8 31.0 31.0 
4 bands, 
p(fav) splits 
-6.3 12.4 -48.4 27.7 39.2 19.4 42.9 40.7 52.9 42.4 31.4 31.4 
5 bands, 
p(fav) splits 
3.7 21.0 -14.4 32.6 45.3 23.7 47.1 44.4 54.1 47.3 35.9 35.9 
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16.1 26.6 3.1 38.9 49.2 23.5 51.1 49.1 53.6 45.1 33.9 8.9 
 
8% treatment effect 
As with the 5% treatment effect using five bands equal splits resulted in greater 
sample sizes than the conventional dichotomy as shown in Table 5-12 below.  Here 
though greater sample size reductions were observed, in general, for the strategies 
based on banding the proportion of favourable outcomes rather than having equal 
splits based on sample size. 
 
Table 5-12 Sliding Dichotomy comparison: Median and by trial reductions in sample size. 
Mortality treatment scenario, 8% treatment effect, nine covariate model for all subjects5 
 TINT TIUS SLIN SAP PEG HITI UK4 TCDB SKB EBIC HITII Median 
Conventional 
no cov 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
3 bands, 
equal splits 
20.8 25.1 0.5 40.6 43.6 37.0 36.9 39.8 40.9 45.5 38.4 38.4 
4 bands, 
equal splits 
26.5 32.4 11.3 26.3 34.7 20.8 44.7 44.6 50.1 37.5 19.3 32.4 
5 bands, 
equal splits 




22.8 28.7 2.7 43.2 46.4 38.3 40.6 42.8 42.6 50.2 40.1 40.6 
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-110.8 -126.8 -121.6 -94.0 -17.2 -78.3 9.0 15.9 18.3 18.9 -70.5 -70.5 
3 bands, 
p(fav) splits 
6.7 22.5 4.9 18.1 34.8 15.9 39.9 47.0 48.9 41.1 33.7 33.7 
4 bands, 
p(fav) splits 
-10.5 13.0 -35.8 7.7 39.7 9.4 45.7 51.5 53.7 39.8 27.9 27.9 
5 bands, 
p(fav) splits 












10.5 24.2 -15.8 20.9 45.0 24.3 52.0 50.0 50.1 54.7 29.8 29.8 
 
5.5.2.4 Mortality treatment effect graphical comparison 
Figure 5-15, Figure 5-16 and Figure 5-17 below show the results by trial obtained 
when banding by sample size with three, four and five bands respectively using the 
5% treatment effect.  Using three or four bands gave reductions in sample size for the 
three covariate models both unadjusted and adjusted, for all studies except SLIN.  
Using five bands however gave much larger sample sizes for all of the trials except 
SKB seven and nine covariate models.  For the three and four band models, using 
covariates gave a small additional benefit.  The seven and nine covariate model gave 
greater sample size reductions than the three covariate model using four bands.  
However, using three bands little difference was oberved between the three 
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covariate models.  A very similar pattern was also observed using the 8% treatment 
effect as shown in Figure 5-21, Figure 5-22 and Figure 5-23.   
 
Banding by the probability of a favourable outcome did show a reduction in sample 
size for almost all studies for three, four and five bands, with the 5% treatment effect, 
as shown in Figure 5-18, Figure 5-19 and Figure 5-20.  SLIN showed an increase in 
sample size for almost all scenarios and TINT also showed an increase in sample size 
for some of the four band covariate models.  Greate reductions in sample size were 
typically observed for the observational studies rather than the trials.  As with the 
Uniform model, a similar pattern was observed over using three, four or five bands 
when banding by the proportion of favourable outcomes. 
 
Modelling an 8% treatment effect and banding by the probability of a favourable 
outcome gave similar results to modelling the 5% treatment effect, as shown in 
Figure 5-24, Figure 5-25 and Figure 5-26 below.  For SLIN and TINT using four 
bands gave an increase in sample size compared with using the conventional 
dichotomy for most of the covariate models.  Again, the observational studies 
typically had greater reductions than the trials. 
 
Figure 5-27 and Figure 5-28 below show the median reductions in sample size when 
banding both by sample size and by the probability of a favourable outcome for the 
5% and 8% treatment effects respectively.  Banding by the probability of a 
favourable outcome gave median reductions in sample size of around 40% 
irrespective of whether three, four or five bands were used.  When banding by 
sample size using three or four bands also gave reductions of around 40% however 
using five bands consistently gave an increase in sample size of 40 to 60% when 
compared with the conventional dichotomy. 
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Key: 3 covariate model unadjusted (red), 3 covariate model adjusted (dark blue), 7 covariate model 
unadjusted (green), 7 covariate model adjusted (yellow), 9 covariate model unadjusted (purple), 9 
covariate model adjusted (pink) 
 
 
Chapter 5 Comparison of different analysis strategies – the sliding dichotomy 134 

























































Key: 3 covariate model unadjusted (red), 3 covariate model adjusted (dark blue), 7 covariate model 
unadjusted (green), 7 covariate model adjusted (yellow), 9 covariate model unadjusted (purple), 9 
covariate model adjusted (pink) 
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Key: 3 covariate model unadjusted (red), 3 covariate model adjusted (dark blue), 7 covariate model 
unadjusted (green), 7 covariate model adjusted (yellow), 9 covariate model unadjusted (purple), 9 
covariate model adjusted (pink) 
 
Chapter 5 Comparison of different analysis strategies – the sliding dichotomy 136 

























































Key: 3 covariate model unadjusted (red), 3 covariate model adjusted (dark blue), 7 covariate model 
unadjusted (green), 7 covariate model adjusted (yellow), 9 covariate model unadjusted (purple), 9 
covariate model adjusted (pink) 
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Figure 5-27 Sliding Dichotomy: Median reductions in sample size by prognostic banding group. 




















Figure 5-28 Sliding Dichotomy: Median reductions in sample size by prognostic banding group. 





















Key: 3 covariate model unadjusted (red), 3 covariate model adjusted (dark blue), 7 covariate model 
unadjusted (green), 7 covariate model adjusted (yellow), 9 covariate model unadjusted (purple), 9 
covariate model adjusted (pink) 
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5.6 Discussion 
This chapter has shown that when modelling the sliding ichotomy a consistent 
pattern is observed.  Banding by sample size, either thr e or four bands, with the 
addition of covariates gave typically the greatest sample size reductions.  The sliding 
dichotomy performed poorly when using five splits based on sample size as shown 
both in the tables and in the graphs.  Perhaps studie  of 800 subjects are too small to 
show such refinement.  Using the sliding dichotomy also depends on the constituent 
properties of the study sampled.  For SLIN in particular, using the sliding dichotomy 
or the sliding dichotomy plus covariates resulted in an increase in sample size of 
30% to 40% compared with using the conventional tretm nt only strategy.  This is 
because subjects in the ‘poor’ prognosis band using the sliding dichotomy had a wide 
range of actual outcomes from poor to good, as illutrated below.  Table 5-13 below 
shows the probability of a favourable outcome, p(fav), for each of the three bands of 
the sliding dichotomy for SLIN and EBIC.  It can bes en for SLIN that for those in 
the poor prognosis band their probability of a favourable outcome ranges from 0.28 
to 0.60.  Whereas for EBIC, for those in the poor pr gnosis band their probability of 
a favourable outcome ranges from 0.22 to 0.46, a much narrower range. 
Table 5-13 Probability of a favourable outcome for 3 bands for SLIN and EBIC 
 SLIN  EBIC 
 p(fav)  p(fav) 
Poor prognosis 0.28 to 0.60  0.22 to 0.46 
Mid prognosis 0.60 to 0.72  0.46 to 0.67 
Best prognosis 0.72 to 0.82  0.67 to 0.84 
 
Table 5-14 and Table 5-15 below show the percentage of subjects in each of the three 
sliding dichotomy bands for SLIN and EBIC respectively.  These percentages are the 
numbers with the simulated GOS, simGOS.  The line show  where the dichotomy 
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which gives closest to a 50:50 split is made within each prognosis group.  It can be 
seen with EBIC data, Table 5-15, that the split is optimal for each of the three bands.  
However for SLIN, Table 5-14, it can be seen that for those in the best and mid 
prognosis bands the dichotomy is between good recovery versus everything else.  For 
those in the poorest prognostic band the dichotomy is between severe and moderate. 
Table 5-14 SLIN, percentage of subjects in each sliding dichotomy band 
SLIN         
 simGOS %  simGOS %  simGOS % 
 D/V 7  D/V 18  D/V 31 
Best S 17 Mid S 18 Poor S 23 
 M 25  M 28  M 23 
 G 51  G 36  G 23 
 
Table 5-15 EBIC, percentage of subjects in each sliding dichotomy band 
EBIC         
 simGOS %  simGOS %  simGOS % 
 D/V 12  D/V 17  D/V 38 
Best S 15 Mid S 24 Poor S 27 
 M 29  M 27  M 19 
 G 43  G 33  G 16 
 
The next stage in modelling, as shown in Chapter 6 is to take forward the optimised 
version of the sliding dichotomy for each of the covariate sets, treatment effect 
models and treatment effects and compare with the ot r strategies for analysing 
ordinal data. 
 
Chapter 6 Comparing different modelling strategies 140 
6 Chapter 6 Comparing different modelling strategie s 
6.1 Introduction 
Having refined the sliding dichotomy, as shown in Chapter 5, the next stage was to 
compare the sliding dichotomy against different modelling strategies to see which 
gives the greatest reduction in sample size (RSS) under which circumstances.  These 
will include, amongst others, fitting a proportional odds models with a common odds 
ratio, modelling a reduction in mortality, modelling a proportional odds model with 
different odds ratios in different clinical subgroups and also different prognostic 
subgroups. 
As previously three covariate sets (three, seven and nine covariates), two treatment 
scenarios Uniform and Mortality and two treatment effects 5% and 8% were 
modelled. 
The optimised sliding dichotomy, the conventional analysis with covariates and the 
proportional odds model with and without covariates are all compared with the 
conventional dichotomy in the first part of this chapter. 
In the second part it was of interest to see if the same pattern of results was observed 
when improvement was restricted to certain groups (both prognostic and physical) or 
when groups were targeted for improvement (again based on prognosis or a physical 
characteristic).  As in Chapter 5, results are shown both by trial and as a median 
reduction in sample size over all trials. 
 
6.1.1 Restricting improvement and targeting - methods 
Restricting improvement 
Two separate scenarios were explored using all subjects: restricting improvement to 
patients with an intermediate prognosis and restricting improvement to patients with 
a mass lesion.  That is only applying a treatment effect to these patients. 
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For the improvement restricted to patients with an intermediate prognosis the 
treatment effect (5% or 8%) was only applied to those subjects with an individual 
probability of a favourable outcome between 0.2 and 0.8 inclusive.  This was 
obtained by fitting a conventional binary logistic regression model with the 
conventional favourable/unfavourable dichotomy of the GOS as the response 
variable.  The modelling of the uniform and mortality treatment effects is as 
previously described in Chapter 5.  For those subjects with either a low (<0.2) or 
high (>0.8) probability of a favourable outcome then the probabilities remained as 
the original probabilities from the multinomial model, i.e. no treatment effect was 
applied. 
Restricting improvement to patients with a mass lesion was done in a very similar 
way.  Here, only patients who had a mass lesion had t e treatment effect applied with 
all other subject’s probabilities remaining as originally modelled. 
 
Targeting 
Here also two separate scenarios were explored: targeting only patients with an 
intermediate prognosis and targeting only patients with a mass lesion.  That is only 
using these patients in the analysis. 
For the first, targeting only patients with an interm diate prognosis, the different 
strategies were compared only for subjects with an intermediate prognosis of a 
favourable outcome, between 0.2 and 0.8 inclusive.  The numbers available for 
analysis were therefore: 6279 for the three covariate model; 5636 for the seven 
covariate model and 5464 for the nine covariate model. 
 
For the second scenario, targeting only patients with a mass lesion, only subjects 
with this were analysed.  As the seven and nine covariate models both contained CT 
only the three covariate model could be fitted.  Analysis here was performed on 2974 
subjects. 
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6.2 All subjects – comparing different modelling st rategies 
For all tables, the table cells are the percentage reductions in sample size, which can 
be achieved while preserving the power relative to the conventional unadjusted 
analysis of the dichotomised outcome scale 
 
6.2.1 Comparing strategies - uniform treatment effect 
Here the treatment effect followed a proportional odds model. 
6.2.1.1 Three covariate model 
5% treatment effect 
Across all trials the greatest reduction in sample siz was under the proportional odds 
plus covariates strategy, typically around 40%, although all strategies did show an 
improvement over the conventional modelling strategy.  Using the sliding dichotomy 
with four bands and covariates gave the next largest reduction in sample size as 
shown in Table 6-1 below. 
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Table 6-1 All subjects. Median and by trial reductions in sample size. Uniform treatment 
scenario, 5% treatment effect, three covariate model8 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
21.2 20.1 11.7 18.4 27.2 18.3 26.8 30.9 14.6 28.9 23.9 21.2 
Proportional 
Odds: no cov 
21.9 22.7 22.7 23.2 4.3 19.0 18.1 24.0 23.7 16.3 22.9 22.7 
Proportional 
Odds: + cov 
40.2 44.7 36.3 41.9 45.6 39.2 48.6 53.5 37.2 50.3 45.3 44.7 
SD 4 bands, 
equal splits 
+cov 
24.4 35.7 30.3 33.4 36.3 32.3 36.7 46.3 35.0 40.4 39.1 35.7 
 
8% treatment effect 
Table 6-2 below, shows that, as with the 5% treatmen  effect, the greatest reduction 
in sample size occurred using the proportional odds plu  covariates strategy with the 
sliding dichotomy plus covariates strategy again givin  the next greatest reduction in 
sample size.  In general, both treatment effects, 5% and 8%, showed similar results 
with all strategies showing an improvement over the conventional dichotomous 
treatment strategy. 
 
                                                
8 Table cells are the percentage reductions in sample size, which can be achieved while preserving the 
power relative to the conventional unadjusted analysis of the dichotomised outcome scale. ‘SD’ means 
sliding dichotomy. ‘Equal splits’ means prognostic bands chosen to contain equal numbers of patients. 
‘p(fav)’ means prognostic bands chosen with specific ranges of the predicted probability of a 
favourable outcome. ‘no cov’ means that the final analysis was not covariate adjusted. ‘+cov’ means 
that the final analysis was covariate adjusted. 
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Table 6-2 All subjects. Median and by trial reductions in sample size. Uniform treatment 
scenario, 8% treatment effect, three covariate model8 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
15.9 17.3 14.4 18.2 0.9 17.6 22.1 26.1 10.2 24.3 22.2 18.2 
Proportional 
Odds: no cov 
22.1 24.9 26.9 22.3 17.5 17.0 22.6 20.6 21.2 20.5 22.9 22.1 
Proportional 
Odds: + cov 
40.9 42.7 40.2 42.0 41.4 39.9 47.8 48.0 38.2 46.3 44.8 42.0 
SD 3 bands, 
equal splits 
+cov 
27.4 32.8 29.7 28.0 31.4 29.6 38.7 42.4 26.0 39.5 33.9 31.4 
 
6.2.1.2 Seven covariate model 
For both the 5% and 8% treatment effects, shown in Table 6-3 and Table 6-4 
respectively below, all modelling strategies showed an improvement over the 
conventional dichotomous modelling strategy.  For both treatment effects the 
proportional odds plus covariates strategy gave the greatest reduction in sample size, 
of around 40-50% with again the sliding dichotomy plus covariates giving the next 
largest decrease.  For the 5% treatment effect the conventional plus covariates 
strategy gave a similar result to the proportional odds treatment only strategy.  
However, for the 8% treatment effect the conventional plus covariates strategy 
showed a greater reduction in sample size, for most studies, than the proportional 
odds treatment only strategy. 
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Table 6-3 All subjects. Median and by trial reductions in sample size. Uniform treatment 
scenario, 5% treatment effect, seven covariate model8 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
20.0 26.8 19.4 25.3 27.3 26.3 29.3 33.6 13.5 28.9 22.7 26.3 
Proportional 
Odds: no cov 
20.5 27.0 25.5 23.2 7.1 28.3 21.7 22.9 15.1 17.8 21.0 22.9 
Proportional 
Odds: + cov 
44.6 50.9 41.5 46.5 3.2 50.0 55.6 57.4 41.0 48.7 48.1 48.7 
SD 4 bands, 
equal splits 
+cov 
32.3 49.1 26.9 42.8 44.6 40.5 43.6 43.0 30.6 37.8 31.7 40.5 
 
Table 6-4 All subjects. Median and by trial reductions in sample size. Uniform treatment 
scenario, 8% treatment effect, seven covariate model8 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
23.1 29.1 16.7 24.6 26.5 24.1 29.9 32.6 20.5 33.6 24.4 24.6 
Proportional 
Odds: no cov 
25.6 22.6 25.2 22.3 19.9 28.1 22.6 23.3 18.3 22.5 25.8 22.6 
Proportional 
Odds: + cov 
47.7 51.3 38.6 46.6 50.0 49.1 50.9 55.1 40.4 52.5 53.3 50.0 
SD 3 bands, 
p(fav) splits 
+cov 
47.2 42.3 35.1 36.6 45.8 40.1 39.4 46.1 32.0 44.1 30.7 40.1 
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6.2.1.3 Nine covariate model 
As with the three and seven covariate models, all modelling strategies showed an 
improvement over the conventional dichotomous treatm nt split.  This was observed 
over all studies for both the 5% and 8% treatment effects as shown in Table 6-5 and 
Table 6-6 respectively below.  The proportional odds plus covariates strategy gave 
the greatest reduction in sample size.  The conventional plus covariates strategy gave 
a similar, or better in some cases, reduction in sample size as the proportional odds 
treatment only strategy. 
 
Table 6-5 All subjects. Median and by trial reductions in sample size. Uniform treatment 
scenario, 5% treatment effect, nine covariate model8 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
25.8 38.6 17.9 22.2 1.0 27.7 26.9 29.7 22.4 31.0 21.9 25.8 
Proportional 
Odds: no cov 
28.4 27.1 22.3 22.0 16.0 26.2 25.4 16.6 21.5 14.4 19.0 22 
Proportional 
Odds: + cov 
52.0 55.6 43.8 45.0 44.3 48.9 55.1 55.3 43.9 52.7 46.1 48.9 
SD 4 bands, 
equal splits 
+cov 
41.8 50.6 30.5 32.3 2.6 35.6 41.9 47.8 39.2 43.5 30.6 39.2 
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Table 6-6 All subjects. Median and by trial reductions in sample size. Uniform treatment 
scenario, 8% treatment effect, nine covariate model8 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
19.6 27.9 17.8 26.7 27.5 21.0 32.8 31.3 22.1 29.8 20.6 26.7 
Proportional 
Odds: no cov 
21.9 27.9 24.4 25.8 21.6 26.1 26.3 22.0 22.8 21.0 23.7 23.7 
Proportional 
Odds: + cov 
44.5 53.5 42.5 50.0 46.1 48.5 55.6 55.1 47.9 52.6 47.6 48.5 
SD 3 bands, 
p(fav) splits 
+cov 
44.0 51.5 39.0 43.3 50.0 44.1 54.2 50.1 34.0 47.2 34.6 44.1 
 
6.2.2 Comparing strategies – mortality treatment effect 
The mortality treatment effect was next explored.  This assumes that the effect of 
treatment is to reduce the risk of death or vegetative state but that the relative 
probability of severe disability to moderate disability to good recovery is unaltered. 
6.2.2.1 Three covariate model 
For both the 5% and 8% treatment effects for SLIN and the 8% treatment effect for 
TINT using the sliding dichotomy strategy resulted in an increase in sample size 
compared to the conventional treatment only strategy.  The proportional odds plus 
covariates strategy resulted in the largest reduction in sample size for all studies.  The 
sliding dichotomy plus covariates strategy resulted in the next largest reduction in 
sample size for most studies.  The proportional odds treatment only strategy showed 
a greater reduction in sample size for all studies, except TIUS, than the conventional 
plus covariates strategy.  Using covariates with the conventional dichotomy and with 
the proportional odds model gave greater reductions than the strategies without 
covariates as shown in Table 6-7 and Table 6-8 below. 
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Table 6-7 All subjects. Median and by trial reductions in sample size. Mortality treatment 
scenario, 5% treatment effect, three covariate model8 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
18.5 21.9 13.5 18.6 23.7 20.0 25.6 22.5 19.1 24.3 21.3 21.3 
Proportional 
Odds: no cov 
20.6 15.5 15.3 32.7 35.4 35.4 42.1 37.2 38.7 35.4 37.1 35.4 
Proportional 
Odds: + cov 
42.0 44.2 31.8 45.6 50.8 50.2 58.9 54.7 49.2 53.2 50.3 50.2 
SD 3 bands, 
equal splits 
+cov 
18.8 23.6 -52.4 35.6 38.0 36.6 44.7 37.9 36.6 40.5 40.5 36.6 
 
Table 6-8 All subjects. Median and by trial reductions in sample size. Mortality treatment 
scenario, 8% treatment effect, three covariate model8 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
13.8 18.1 11.3 14.3 23.3 18.1 19.0 27.0 13.2 23.8 18.8 18.1 
Proportional 
Odds: no cov 
18.6 17.0 13.5 28.8 36.7 36.7 37.2 35.2 32.6 35.7 34.2 34.2 
Proportional 
Odds: + cov 
38.9 42.2 29.3 44.5 6.0 52.2 52.4 58.1 46.7 52.7 49.6 49.6 
SD 3 bands, 
equal splits 
+cov 
-22.3 5.5 -61.8 32.9 43.0 38.0 37.7 42.5 34.0 39.9 37.5 37.5 
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6.2.2.2 Seven covariate model 
For all studies all strategies showed an improvement over the conventional treatment 
only strategy.  As with the three covariate model th  greatest reductions in sample 
size were observed using the proportional odds plus covariates strategy.  Similar 
results were observed both with the 5% and 8% treatm nt effects as shown in Table 
6-9 and Table 6-10 below. 
 
Table 6-9 All subjects. Median and by trial reductions in sample size. Mortality treatment 
scenario, 5% treatment effect, seven covariate model8 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
24.4 26.5 15.6 17.4 22.0 20.8 25.3 31.8 24.9 30.9 21.5 24.4 
Proportional 
Odds: no cov 
21.4 30.0 29.2 28.7 31.4 31.2 40.0 40.3 46.9 35.4 32.0 31.4 
Proportional 
Odds: + cov 
48.5 50.1 41.1 47.1 51.6 51.5 58.8 62.9 58.6 57.6 51.3 51.5 
SD 3 bands, 
equal splits 
+cov 
33.6 34.2 24.4 37.9 41.3 42.9 39.8 47.9 43.9 42.5 38.9 39.8 
 
Table 6-10 All subjects. Median and by trial reductions in sample size. Mortality treatment 
scenario, 8% treatment effect, seven covariate model8 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
19.3 22.4 17.7 16.6 19.2 19.9 20.2 25.9 22.2 30.9 22.7 20.2 
Proportional 
Odds: no cov 
21.9 24.9 29.4 30.3 5.3 32.1 42.0 41.3 43.7 37.1 34.0 34.0 
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Study Scenario 
TINT  TIUS SLIN SAP PEG HITI  UK4 TCDB SKB EBIC HITII  
Median 
Proportional 
Odds: + cov 
44.8 52.2 46.7 51.1 53.1 50.7 57.8 63.6 58.1 61.4 53.7 53.1 
SD 4 bands, 
equal splits 
+cov 
25.5 33.5 28.5 23.0 27.4 37.2 50.9 55.8 41.9 39.8 32.2 33.5 
 
6.2.2.3 Nine covariate model 
All strategies showed an improvement over the conventional treatment only strategy 
for all studies as shown in Table 6-11 and Table 6-12 below.  As with the three and 
seven covariate models, using the proportional odds plus covariates strategy gave the 
greatest reductions in sample size.  The results from all three covariate models 
showed a similar pattern with, typically, slightly greater magnitudes of reduction 
going from the three to seven to nine covariate models. 
 
Table 6-11 All subjects. Median and by trial reductions in sample size. Mortality treatment 
scenario, 5% treatment effect, nine covariate model8 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
21.3 30.3 16.1 22.9 21.1 20.7 16.9 22.5 19.8 29.5 22.3 21.3 
Proportional 
Odds: no cov 
31.6 28.6 31.3 32.4 34.3 27.9 33.5 34.7 44.6 37.7 34.7 33.5 
Proportional 
Odds: + cov 
51.0 52.3 43.2 53.3 56.3 52.5 54.9 57.3 59.6 59.5 53.7 53.7 
SD 3 bands, 
equal splits 
+cov 
37.5 29.1 23.3 42.8 43.3 42.9 36.6 38.1 42.8 43.8 42.5 42.5 
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Table 6-12 All subjects. Median and by trial reductions in sample size. Mortality treatment 
scenario, 8% treatment effect, nine covariate model8 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
19.9 23.5 15.3 20.4 24.0 21.1 19.9 27.4 22.7 28.6 22.7 22.7 
Proportional 
Odds: no cov 
26.0 20.7 30.6 30.9 34.8 31.2 38.0 41.0 49.5 42.8 35.5 34.8 
Proportional 
Odds: + cov 
47.1 51.5 43.4 51.2 55.8 50.6 56.5 58.5 58.8 62.6 53.0 53.0 
SD 3 bands, 
equal splits 
+cov 
22.8 28.7 2.7 43.2 46.4 38.3 40.6 42.8 42.6 50.2 40.1 40.6 
 
6.2.3 Graphical comparison – all subjects 
The tabulated results showed that the proportional dds model and the sliding 
dichotomy model with covariates gave the greatest reductions in sample sizes when 
the treatment effect followed a proportional odds model and when the treatment 
effect is a reduction in mortality.  It is of interest to examine these patterns 
graphically looking across all of the covariate models together.  In the graphs the 
trials are presented side by side as are the three obs rvational series. 
 
Figure 6-1 and Figure 6-2 below show the results by trial for the 5% and 8% 
treatment effect respectively when the treatment effect ollowed a proportional odds 
model (the Uniform treatment comparison).  No clear p ttern is observed looking at 
the sliding dichotomy with the 5% treatment effect.  The 8% treatment effect does 
show, for all studies except HITII, a greater reduction in sample size with the seven 
and nine covariate models compared with the three covariate models for the sliding 
dichotomy strategies. 
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With the proportional odds strategies, using seven or ine covariates almost always 
shows a greater reduction than with using three covariates both for the 5% and 8% 
treatment effects.  Also, using seven and nine covariates with the proportional odds 
strategies gave similar or greater reductions in sample size than the sliding 
dichotomy with three, seven or nine covariates. 
 
Figure 6-3 and Figure 6-4 show the results by trialof the sliding dichotomy and 
proportional odds models for all three covariate sets when the treatment effect was a 
reduction in mortality (the Mortality treatment comparison).  Again no clear patterns 
were observed for the sliding dichotomy strategies.  U ing seven and nine covariates 
with the proportional odds model typically resulted in greater reductions than using 
the three covariate model. 
 
Figure 6-5 shows the median reductions in sample size over all trials for the four 
treatment effects (Uniform 5% and 8% and Mortality 5% and 8%).  These show very 
consistent results both when the treatment effect followed a proportional odds model 
and when it did not.  For almost all models adding covariates gave a small additional 
benefit.  This gave in some cases sample size reductions of just over 50% compared 
with the conventional dichotomy. 
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Key: Sliding Dichotomy 3 covariates (red), Sliding Dichotomy 7 covariates (dark blue), Sliding 
Dichotomy 9 covariates (green), Proportional odds 3 covariates (yellow), Proportional odds 7 
covariates (purple), Proportional odds 9 covariates (pink) 
                                                
9 Bars are the percentage reductions in sample size which can be achieved while preserving the power 
relative to the conventional unadjusted analysis of the dichotomised outcome scale. 
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Key: Sliding Dichotomy 3 covariates (red), Sliding Dichotomy 7 covariates (dark blue), Sliding 
Dichotomy 9 covariates (green), Proportional odds 3 covariates (yellow), Proportional odds 7 
covariates (purple), Proportional odds 9 covariates (pink)
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Figure 6-5 Median reductions in sample size for all subjects. Comparison of Sliding Dichotomy 






























Key: Sliding Dichotomy 3 covariates (red), Sliding Dichotomy 7 covariates (dark blue), Sliding 
Dichotomy 9 covariates (green), Proportional odds 3 covariates (yellow), Proportional odds 7 
covariates (purple), Proportional odds 9 covariates (pink)
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6.2.4 Discussion 
For both the 5% and 8% treatment effects and the three, seven and nine covariate 
models using the proportional odds model with covariates gave the greatest 
reductions in sample size.  This was true both when t  data followed a proportional 
odds model (the Uniform treatment scenario) and when t y deviated strongly from a 
proportional odds model (the Mortality treatment scenario). 
 
6.3 Improvement restricted to patients with an inte rmediate prognosis 
Having shown that using the proportional odds model with covariates gave the 
greatest sample size reduction for all scenarios, treatment effects and covariates, it is 
of interest to see if this pattern is repeated when improvement, i.e. the treatment 
effect, is restricted to subjects with an intermediate prognosis.  Here for all 
comparisons the sliding dichotomy equal splits three bands plus covariates was used 
as the sliding dichotomy strategy. 
 
6.3.1 Comparing strategies - uniform treatment effect 
Here the simulated treatment effect followed a propo tional odds model. 
6.3.1.1 Three covariate model 
For both the 5% and 8% treatment effects, the proportional odds plus covariates 
strategy gave the greatest reduction in sample size when compared to the 
conventional treatment only strategy.  However, all alternative strategies also showed 
a reduction in sample size compared with the conventional treatment only strategy. 
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For the 5% treatment effect, as shown in Table 6-13 below a consistent pattern of 
results was not observed across all studies.  TCDB and EBIC both showed very 
modest reductions in sample size for the proportional dds treatment only strategy 
compared with the conventional treatment only strategy.  No consistent benefit was 
observed with the proportional odds treatment only strategy over the conventional 
plus covariates strategy.  Some studies showed a benefit, others did not. 
 
For the 8% treatment effect, for all studies except TINT, the sliding dichotomy 
strategy gave a greater reduction in sample size for ight of the eleven studies than 
the conventional plus covariates strategy as shown in Table 6-14 below.  In general, 
the reductions in sample size observed with the 8% treatment effect were greater than 
with the 5% treatment effect.  Using the proportional odds plus covariates gave much 
greater sample size reductions, typically at least double, than using the proportional 
odds treatment only strategy. 
 
Table 6-13 Improvement restricted to patients with an intermediate prognosis. Median and by 
trial reductions in sample size. Uniform treatment scenario, 5% treatment effect, three 
covariate model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
18.8 13.7 11.0 12.5 22.8 13.7 31.1 19.5 17.6 23.6 25.4 18.8 
Proportional 
Odds: no cov 
20.3 18.3 21.6 15.4 15.6 19.0 17.6 7.2 15.7 5.7 18.2 17.6 
                                                
10 Table cells are the percentage reductions in sample size, which can be achieved while preserving 
the power relative to the conventional unadjusted analysis of the dichotomised outcome scale. ‘SD’ 
means sliding dichotomy. ‘Equal splits’ means prognostic bands chosen to contain equal numbers of 
patients. ‘no cov’ means that the final analysis wa not covariate adjusted. ‘+cov’ means that the final 
analysis was covariate adjusted. 
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Study Scenario 
TINT  TIUS SLIN SAP PEG HITI  UK4 TCDB SKB EBIC HITII  
Median 
Proportional 
Odds: + cov 
37.2 28.6 34.5 32.8 40.8 37.4 45.2 39.8 35.7 38.4 46.9 37.4 
SD 3 bands, 
equal splits 
+cov 
12.5 13.7 15.5 16.8 27.8 24.3 32.5 25.5 27.6 24.6 29.7 24.6 
 
Table 6-14 Improvement restricted to patients with an intermediate prognosis. Median and by 
trial reductions in sample size. Uniform treatment scenario, 8% treatment effect, three 
covariate model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
17.5 18.6 12.9 18.6 22.8 20.3 25.8 25.5 15.2 26.5 18.2 18.6 
Proportional 
Odds: no cov 
16.6 21.9 18.9 21.2 0.2 24.9 14.1 13.7 19.2 10.2 20.0 19.2 
Proportional 
Odds: + cov 
34.6 40.4 33.7 39.7 42.0 42.1 46.9 42.2 34.1 43.3 39.4 40.4 
SD 3 bands, 
equal splits 
+cov 
14.8 23.4 22.8 21.8 27.6 28.1 31.4 32.5 22.8 26.9 23.7 23.7 
 
6.3.1.2 Seven covariate model 
For all studies for both the 5% and 8% treatment effects the proportional odds model 
plus covariates strategy gave the greatest reduction in sample size compared with the 
conventional treatment only strategy. 
5% treatment effect 
Almost all alternative strategies showed an improvement over the conventional 
treatment only strategy for the 5% treatment effect as shown in Table 6-15 below.  
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For EBIC using the proportional odds treatment only strategy was no better than 
using the conventional treatment only strategy.  For nine of the eleven studies the 
conventional plus covariates strategy resulted in a gre ter reduction in sample size 
compared with the proportional odds treatment only strategy.  For seven of the 
studies the sliding dichotomy strategy gave a smaller reduction in sample size than 
the conventional plus covariates strategy. 
 
Table 6-15 Improvement restricted to patients with an intermediate prognosis. Median and by 
trial reductions in sample size. Uniform treatment scenario, 5% treatment effect, seven 
covariate model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
15.7 28.1 17.1 23.7 25.4 20.8 29.3 27.7 22.3 30.7 23.6 23.7 
Proportional 
Odds: no cov 
20.4 21.1 22.3 17.6 11.9 16.9 14.9 12.3 11.1 0.0 15.2 15.2 
Proportional 
Odds: + cov 
32.4 46.3 37.8 36.9 41.6 40.9 45.1 45.9 36.5 45.0 38.5 40.9 
SD 3 bands, 
equal splits 
+cov 
3.7 23.9 17.8 19.1 24.9 24.2 31.1 22.9 25.0 29.9 17.9 23.9 
 
8% treatment effect 
For all studies, with the 8% treatment effect all alternative strategies showed an 
improvement over the conventional treatment only strategy as shown in Table 6-16 
below.  The conventional plus covariates strategy gave a greater reduction in sample 
size than the sliding dichotomy strategy for eight of the eleven studies.  As with the 
5% treatment effect, the results were not consistent from study to study.  The 
proportional odds treatment only strategy gave a smller reduction in sample size 
than the conventional plus covariates strategy for all studies except SLIN.  A similar 
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magnitude of reductions in sample size was observed with the 8% treatment effect as 
with the 5% treatment effect. 
 
Table 6-16 Improvement restricted to patients with an intermediate prognosis. Median and by 
trial reductions in sample size. Uniform treatment scenario, 8% treatment effect, seven 
covariate model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
18.0 29.8 16.2 23.0 23.3 25.6 28.0 30.3 23.2 31.4 19.3 23.3 
Proportional 
Odds: no cov 
13.5 20.9 24.1 17.8 14.1 19.0 13.5 11.5 12.5 16.4 17.7 16.4 
Proportional 
Odds: + cov 
33.8 45.6 38.5 43.4 2.2 42.7 44.0 44.3 41.7 46.3 39.9 42.7 
SD 3 bands, 
equal splits 
+cov 
10.2 28.2 14.6 17.6 24.6 19.0 29.3 26.7 26.0 29.8 14.6 24.6 
 
6.3.1.3 Nine covariate model 
5% and 8% treatment effect 
As with the seven covariate model, all alternative strategies showed an improvement 
over the conventional treatment only strategy for all studies.  Using the proportional 
odds plus covariates gave the greatest reduction in sample size. 
 
5% treatment effect 
For all studies, except SKB, a greater reduction in sample size was observed using 
the conventional plus covariates strategy compared with the sliding dichotomy 
strategy as shown in Table 6-17 below.  Using the covariates with the proportional 
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odds model typically at least doubled the reduction in sample size compared with 
using the proportional odds model alone. 
 
Table 6-17 Improvement restricted to patients with an intermediate prognosis. Median and by 
trial reductions in sample size. Uniform treatment scenario, 5% treatment effect, nine covariate 
model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
22.3 29.7 15.3 18.2 6.5 23.1 27.5 29.2 16.5 30.4 24.0 24.0 
Proportional 
Odds: no cov 
18.1 17.7 23.9 15.8 6.0 15.0 19.9 5.1 18.9 10.7 14.5 15.8 
Proportional 
Odds: + cov 
39.5 42.2 38.6 31.5 41.4 39.9 46.5 39.1 37.3 44.4 41.1 39.9 
SD 3 bands, 
equal splits 
+cov 
17.2 18.0 14.6 9.4 21.0 12.8 21.4 2 .7 26.4 23.2 16.7 18.0 
 
8% treatment effect 
A similar magnitude of reductions in sample size was observed with the 8% 
treatment effect as with the 5% treatment effect as shown in Table 6-18 below.  The 
conventional plus covariates strategy gave a greater reduction in sample size than the 
sliding dichotomy strategy for all studies.  The proportional odds treatment only 
strategy gave a smaller reduction in sample size than e conventional plus covariates 
strategy for nine of the studies; only for TINT and SLIN did this strategy give a 
greater reduction in sample size. 
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Table 6-18 Improvement restricted to patients with an intermediate prognosis. Median and by 
trial reductions in sample size. Uniform treatment scenario, 8% treatment effect, nine covariate 
model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
19.3 27.9 19.6 25.8 23.5 22.6 26.5 31.9 23.9 31.3 22.3 23.9 
Proportional 
Odds: no cov 
19.7 17.0 23.6 19.3 11.3 16.1 9.6 10.2 11.3 9.0 14.1 14.1 
Proportional 
Odds: + cov 
37.6 44.6 40.9 42.6 38.3 39.9 40.6 45.1 38.0 43.7 39.7 40.6 
SD 3 bands, 
equal splits 
+cov 
8.2 20.7 12.0 18.1 19.5 15.9 17.7 30.8 17.6 23.2 15.9 17.7 
 
All covariate models 
For most studies the reduction in sample size using the proportional odds plus 
covariates strategy was similar for the three, seven and nine covariate models.  The 
exception to this being EBIC where the addition of m re covariates did increase the 
reduction in sample size.  The proportional odds treatment only strategy gave a 
modest reduction in sample size which was usually less than with the conventional 
plus covariates strategy. 
 
6.3.2 Comparing strategies – mortality treatment effect 
Here the simulated treatment effect was a reduction in mortality. 
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6.3.2.1 Three covariate model 
5% and 8% treatment effects 
The proportional odds plus covariates strategy gave the greatest reduction in sample 
size for all studies.  Greater reductions in sample siz  were observed with the three 
covariate mortality scenario than with the three covariate uniform scenario. 
 
5% treatment effect  
Here consistent results were not observed over all studies as shown in Table 6-19 
below.  The proportional odds treatment only strategy gave a greater reduction in 
sample size than either the conventional plus covariates or the sliding dichotomy 
strategy for most studies. 
 
Table 6-19 Improvement restricted to patients with an intermediate prognosis. Median and by 
trial reductions in sample size. Mortality treatment scenario, 5% treatment effect, three 
covariate model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
14.9 24.7 16.5 14.4 24.1 18.6 19.7 22.2 16.0 29.8 19.4 19.4 
Proportional 
Odds: no cov 
25.2 23.8 12.6 26.4 30.7 32.3 35.7 35.0 30.2 32.3 30.9 30.7 
Proportional 
Odds: + cov 
44.4 46.0 36.4 45.2 47.4 47.6 49.0 50.0 45.7 50.0 47.0 47 
SD 3 bands, 
equal splits 
+cov 
9.0 17.0 -39.1 33.5 25.0 29.3 23.2 28.3 28.0 25.0 29.0 25 
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8% treatment effect  
Both TINT and SLIN showed an increase in sample sizusing the sliding dichotomy 
strategy compared to the conventional treatment only strategy as shown in Table 
6-20 below.  Slightly greater reductions in sample size were observed with the 8% 
compared to the 5% treatment effect. 
 
Table 6-20 Improvement restricted to patients with an intermediate prognosis. Median and by 
trial reductions in sample size. Mortality treatment scenario, 8% treatment effect, three 
covariate model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
12.7 17.1 8.3 21.1 19.5 17.0 24.8 25.2 17.2 27.0 23.8 19.5 
Proportional 
Odds: no cov 
13.1 16.4 12.6 31.2 32.5 34.3 36.5 35.7 34.5 30.7 32.9 32.5 
Proportional 
Odds: + cov 
33.5 39.9 29.8 45.8 49.1 48.8 54.1 50.3 50.5 53.7 48.4 48.8 
SD 3 bands, 
equal splits 
+cov 
-25.5 4.6 -62.6 31.2 28.1 29.9 25.7 27.4 36.4 25.5 29.3 27.4 
 
6.3.2.2 Seven covariate model 
For both the 5% and 8% treatment effects the greatest reduction in sample size is 
observed using the proportional odds plus covariates strategy for all studies. 
 
5% treatment effect 
All alternative strategies showed an improvement over using the conventional 
treatment only strategy as shown in Table 6-21 below.  For six of the eleven studies 
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the sliding dichotomy strategy gave a greater reduction in sample size than the 
conventional plus covariates strategy.  The addition of the covariates to either the 
conventional or the proportional odds models had the greatest effect for the three 
observational studies UK4, TCDB and EBIC. 
 
Table 6-21 Improvement restricted to patients with an intermediate prognosis. Median and by 
trial reductions in sample size. Mortality treatment scenario, 5% treatment effect, seven 
covariate model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
25.2 28.5 19.5 16.6 24.5 27.7 30.2 34.3 14.5 31.2 27.2 27.2 
Proportional 
Odds: no cov 
25.4 26.0 30.0 29.2 32.4 27.9 35.1 36.0 37.3 27.1 26.6 29.2 
Proportional 
Odds: + cov 
47.4 49.1 44.2 46.4 51.2 49.7 52.5 54.5 50.1 53.3 50.6 50.1 
SD 3 bands, 
equal splits 
+cov 
31.4 16.9 20.6 31.1 29.9 35.8 19.8 16.0 16.1 20.4 33.1 20.6 
 
8% treatment effect 
As with the three covariate model, using the sliding dichotomy strategy with SLIN 
gave an increase in sample size compared with using the conventional treatment only 
strategy.  Almost all of the studies showed a decrease in reduction in sample size 
using the sliding dichotomy compared with the 5% trea ment effect.  For all studies, 
except TIUS, the proportional odds treatment only strategy showed the second 
greatest reduction in sample sizes compared with the proportional odds plus 
covariates strategy as shown in Table 6-22 below. 
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Table 6-22 Improvement restricted to patients with an intermediate prognosis. Median and by 
trial reductions in sample size. Mortality treatment scenario, 8% treatment effect, seven 
covariate model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
16.5 27.1 14.9 20.2 4.0 23.5 28.4 27.5 18.6 30.0 23.6 23.6 
Proportional 
Odds: no cov 
20.3 21.5 25.1 30.9 34.8 29.5 36.3 34.7 39.1 32.7 31.9 31.9 
Proportional 
Odds: + cov 
42.5 49.0 43.0 48.0 52.1 47.8 55.2 53.2 50.2 52.8 49.1 49.1 
SD 3 bands, 
equal splits 
+cov 
7.4 18.3 -6.6 30.3 33.5 26.8 18.4 13.4 18.4 23.6 29.0 18.4 
 
 
6.3.2.3 Nine covariate model 
For both the 5% and 8% treatment effects the proportional odds plus covariates 
strategy gave the greatest reduction in sample size compared with the conventional 
treatment only strategy for all studies. 
 
5% treatment effect 
In general, the proportional odds treatment only strategy gave the second greatest 
reduction in sample size as shown in Table 6-23 below.  For all studies, except TIUS, 
a greater reduction in sample size was observed using the proportional odds 
treatment only strategy than the conventional plus covariates strategy.  For TIUS the 
reductions in sample size with both the proportional dds treatment only and the 
conventional plus covariates strategies were very similar although the conventional 
plus covariates gave a slightly greater reduction.  For both SAPHIR and PEGSOD 
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the sliding dichotomy strategy gave a greater reduction in sample size than the 
proportional odds treatment only strategy. 
 
Table 6-23 Improvement restricted to patients with an intermediate prognosis. Median and by 
trial reductions in sample size. Mortality treatment scenario, 5% treatment effect, nine 
covariate model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
27.8 22.3 14.2 21.5 19.7 23.9 25.2 30.3 28.1 21.9 24.1 23.9 
Proportional 
Odds: no cov 
30.4 21.1 27.0 29.9 25.5 27.9 37.5 32.1 44.8 32.6 32.1 30.4 
Proportional 
Odds: + cov 
50.0 46.0 37.8 53.3 47.8 46.6 53.9 52.9 57.5 51.1 48.8 50.0 
SD 3 bands, 
equal splits 
+cov 
28.1 17.3 11.6 34.4 25.7 33.2 18.0 15.4 28.1 13.1 30.1 25.7 
 
8% treatment effect 
Similar reductions in sample size were observed using the proportional odds plus 
covariates strategy with the 8% treatment effect as with the 5% treatment effect, as 
shown in Table 6-24 below.  For SLIN, using the sliding dichotomy strategy 
increased the sample size compared with using the conventional treatment only 
strategy.  For most of the studies, the proportional dds treatment only strategy gave 
the second greatest reductions in sample size compared with the proportional odds 
plus covariates strategy. 
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Table 6-24 Improvement restricted to patients with an intermediate prognosis. Median and by 
trial reductions in sample size. Mortality treatment scenario, 8% treatment effect, nine 
covariate model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
20.4 26.8 18.0 22.2 7.0 28.1 25.7 33.2 22.1 26.3 24.3 25.7 
Proportional 
Odds: no cov 
22.0 21.4 24.5 30.1 32.8 31.5 34.8 34.7 42.5 29.3 33.8 31.5 
Proportional 
Odds: + cov 
46.1 48.7 42.6 50.9 53.2 52.2 53.8 56.1 54.3 50.6 51.1 51.1 
SD 3 bands, 
equal splits 
+cov 
3.8 15.5 -12.8 27.8 34.6 29.5 23.7 18.7 23.8 17.2 30.4 23.7 
 
Discussion 
In general, there was a greater reduction in sample size when using a greater number 
of covariates.  For SLIN, the sliding dichotomy was a poor strategy to use as detailed 
previously. 
 
General comments for both uniform and mortality scenarios 
The addition of the covariates has a much larger eff ct under the uniform scenario 
compared with the mortality scenario. 
The studies which are unselected series show the greatest reductions in sample size 
although very large reductions in sample size are observed for all studies. 
The studies which are small trials show the least benefit from the alternative 
strategies however the studies which are small unselected series, e.g. TCDB, do 
show a larger benefit from using the alternative modelling strategies. 
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6.3.3 Graphical comparison – improvement restricted to patients with an 
intermediate prognosis 
When the treatment effect followed a proportional odds model using both the sliding 
dichotomy and proportional odds strategies gave a reduction in sample size for all 
studies as shown in Figure 6-6 and Figure 6-7.  Similar effects were observed with 
the 5% and 8% treatment effects.  For both the 5% and the 8% treatment effects 
using the proportional odds strategies consistently gave greater reductions in sample 
size than the sliding dichotomy strategies for all studies.  No consistent pattern was 
observed with increasing numbers of covariates.  For example, using a model with 
nine covariates rarely gives a greater sample size reduction than using a model with 
seven covariates. 
 
For all studies the proportional odds strategies gave a reduction in sample size even 
when the treatment effect modelled was a reduction in mortality as shown in Figure 
6-8 and Figure 6-9 below.  Using the sliding dichotomy strategies gave reductions 
for all studies except SLIN and TINT (although here only for three covariates with 
the 8% treatment effect).  For both the 5% and 8% treatment effects using the 
proportional odds strategies gave greater reductions han the sliding dichotomy 
strategies.  Slightly greater reductions were observed with the 8% treatment effect 
compared to the 5% treatment effect, although, for both, reductions were still around 
50% compared with using the conventional dichotomy. 
 
These results are summarised in Figure 6-10.  This shows the median reduction in 
sample size when the treatment effect followed both a proportional odds model and 
was a reduction in mortality.  A consistent pattern is observed over all treatment 
effects with the three covariate model giving reductions of around 25% and the seven 
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and nine covariate models giving reductions of 40 to 50% when improvement is 
restricted to those with an intermediate prognosis. 
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Figure 6-6 Uniform 5%: Restricting improvement to those with an intermediate prognosis.  


















Figure 6-7 Uniform 8%: Restricting improvement to those with an intermediate prognosis.  




















Key: Sliding Dichotomy 3 covariates (red) Sliding Dichotomy 7 covariates (dark blue), Sliding 
Dichotomy 9 covariates (green), Proportional odds 3 covariates (yellow), Proportional odds 7 
covariates (purple), Proportional odds 9 covariates (pink) 
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Figure 6-8 Mortality 5%: Restricting improvement to those with an intermediate prognosis.  




















Figure 6-9 Mortality 8%: Restricting improvement to those with an intermediate prognosis.  




















Key: Sliding Dichotomy 3 covariates (red) Sliding Dichotomy 7 covariates (dark blue), Sliding 
Dichotomy 9 covariates (green), Proportional odds 3 covariates (yellow), Proportional odds 7 
covariates (purple), Proportional odds 9 covariates (pink) 
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Figure 6-10 Median reductions in sample size. Restricting improvement to those with an 




























Key: Sliding Dichotomy 3 covariates (red) Sliding Dichotomy 7 covariates (dark blue), Sliding 
Dichotomy 9 covariates (green), Proportional odds 3 covariates (yellow), Proportional odds 7 
covariates (purple), Proportional odds 9 covariates (pink) 
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6.4 Improvement restricted to patients with a mass lesion 
With the scenario of restricting improvement to those with a mass lesion, only the 
three covariate model was used as both the seven and ine covariate models contain 
CT. 
 
6.4.1 Comparing strategies - uniform treatment effect 
Here strategies were compared assuming that the treatment effect followed a 
proportional odds model. 
5% and 8% treatment effects 
For all studies, all alternative strategies show a reduction in sample size compared 
with the conventional treatment only strategy.  The gr atest reduction in sample size 
was observed using the proportional odds plus covariates strategy.  The reductions 
seen with the sliding dichotomy were greatest under this scenario, when 
improvement was restricted to patients with a mass le ion, compared with both 
analyses restricted to those with a favourable outcome and analysis on all subjects. 
 
5% treatment effect, shown in Table 6-25 below. 
The sliding dichotomy strategy gave the second largest reduction in sample size, 
compared with the proportional odds plus covariates s rategy for eight studies, TIUS, 
SLIN, PEG, HIT I, UK4, TCDB, SKB and EBIC.  The unselected series showed the 
greatest benefit from using the sliding dichotomy strategy. 
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Table 6-25 Improvement restricted to patients with a mass lesion. Median and by trial 
reductions in sample size. Uniform treatment scenario, 5% treatment effect, three covariate 
model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0 
Conventional 
+ cov 
9.5 20.2 18.3 8.3 21.1 13.8 25.0 20.1 23.0 13.9 9.5 18.3 
Proportional 
Odds: no cov 
22.0 26.4 30.0 23.1 27.0 23.0 23.4 24.0 18.4 15.8 22.0 23.1 
Proportional 
Odds: + cov 
37.3 48.0 43.0 33.6 44.1 40.2 46.9 49.4 46.9 36.3 37.3 43.0 
SD 3 bands, 
equal splits 
+cov 
18.5 35.2 35.7 15.8 39.0 35.1 41.8 46.1 37.9 23.7 18.5 35.2 
 
8% treatment effect 
For some studies the sliding dichotomy strategy with the 5% treatment effect gave a 
greater reduction in sample size than the sliding dchotomy with the 8% treatment 
effect as shown in Table 6-26 below.  In general, the sliding dichotomy strategy gave 
similar or greater reductions in sample size to the proportional odds treatment only 
strategy. 
 
Table 6-26 Improvement restricted to patients with a mass lesion. Median and by trial 
reductions in sample size. Uniform treatment scenario, 8% treatment effect, three covariate 
model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
15.7 20.6 14.7 15.0 17.8 14.5 19.9 19.4 17.1 13.9 15.7 15.7 
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Study Scenario 
TINT  TIUS SLIN SAP PEG HITI  UK4 TCDB SKB EBIC HITII  
Median 
Proportional 
Odds: no cov 
27.0 33.4 35.2 23.6 23.0 17.7 21.8 21.6 20.9 22.6 27.0 23.0 
Proportional 
Odds: + cov 
38.5 48.8 46.0 40.5 42.2 38.1 42.6 45.3 48.4 37.7 38.5 42.2 
SD 3 bands, 
equal splits 
+cov 
24.5 34.6 37.6 21.4 26.2 27.8 34.2 36.7 37.3 23.2 24.5 27.8 
 
6.4.2 Comparing strategies – mortality treatment effect 
Here the treatment effect was a reduction in mortality. 
5% treatment effect 
In general, the sliding dichotomy strategy gave a greater reduction in sample size 
than the proportional odds treatment only strategy as shown in Table 6-27 below.  As 
with the uniform three covariate model, using the sliding dichotomy with SLIN 
resulted in an increase in sample size compared with the conventional treatment only 
strategy. 
 
Table 6-27 Improvement restricted to patients with a mass lesion. Median and by trial 
reductions in sample size. Mortality treatment scenario, 5% treatment effect, three covariate 
model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
11.8 24.0 13.7 17.5 14.7 12.9 18.8 26.6 17.1 19.8 11.8 17.1 
Proportional 
Odds: no cov 
27.4 24.0 15.5 30.8 46.7 41.4 41.9 44.4 39.7 33.8 27.4 33.8 
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Study Scenario 
TINT  TIUS SLIN SAP PEG HITI  UK4 TCDB SKB EBIC HITII  
Median 
Proportional 
Odds: + cov 
44.2 51.1 35.2 50.9 60.0 59.1 57.1 63.7 56.0 55.8 44.2 55.8 
SD 3 bands, 
equal splits 
+cov 
25.2 39.6 -41.0 48.6 57.7 57.7 51.9 57.8 48.7 51.1 25.2 48.7 
 
8% treatment effect 
Using the sliding dichotomy strategy with TINT, SLIN or HITII resulted in an 
increase in sample size compared with the conventional treatment only strategy as 
shown in Table 6-28 below.  Both HIT I and TCDB show a slightly greater reduction 
in sample size using the sliding dichotomy strategy compared with the proportional 
odds plus covariates strategy.  All other studies show the greatest reduction in sample 
size using the proportional odds plus covariates strategy.  The reduction in sample 
size increased from the 5% to 8% treatment effect using the sliding dichotomy 
strategy.  The reductions in sample size have also very slightly increased for the 
proportional odds strategy.  For both the 5% and 8% treatment effects the addition of 
the covariates to the proportional odds model gave a large effect. 
 
Table 6-28 Improvement restricted to patients with a mass lesion. Median and by trial 
reductions in sample size. Mortality treatment scenario, 8% treatment effect, three covariate 
model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
13.2 16.8 8.9 10.7 21.0 12.1 14.8 14.3 17.4 15.3 13.2 14.3 
Proportional 
Odds: no cov 
21.4 23.5 15.0 35.2 43.2 43.7 41.8 44.3 36.2 35.2 21.4 35.2 
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Study Scenario 
TINT  TIUS SLIN SAP PEG HITI  UK4 TCDB SKB EBIC HITII  
Median 
Proportional 
Odds: + cov 
45.6 51.2 36.6 52.9 61.1 59.4 59.6 59.9 54.6 52.4 45.6 52.9 
SD 3 bands, 
equal splits 
+cov 
-20.0 26.5 -53.5 48.1 60.1 60.2 57.1 62.1 . 48.6 -20.0 48.4 
 
6.5 Targeting only patients with an intermediate pr ognosis 
Here only subjects who had an intermediate prognosis of a favourable outcome were 
analysed. 
6.5.1 Comparing strategies - uniform treatment effect 
Here the treatment effect follows a proportional odds model. 
6.5.1.1 Three covariate model 
Both 5% and 8% treatment effects 
For all studies, all alternative strategies gave a greater reduction in sample size than 
the conventional treatment only strategy.  These reults are shown in Table 6-29 and 
Table 6-30 below.  Using the proportional odds plus covariates strategy gave the 
greatest reduction in sample size and the conventional plus covariates the least 
reduction in sample size when compared with the conventional treatment only 
strategy.  A very similar pattern was observed with both the 5% and 8% treatment 
effects.  The reductions in sample size observed when targeting only patients with an 
intermediate prognosis were smaller than when improvement was restricted to those 
with an intermediate prognosis above – possibly because of the smaller sample pool 
from which to sample subjects. 
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Table 6-29 Targeting only patients with an intermediate prognosis. Median and by trial 
reductions in sample size. Uniform treatment scenario, 5% treatment effect, three covariate 
model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
15.3 18.5 7.9 11.1 10.9 12.2 11.9 13.0 8.7 10.4 7.0 11.1 
Proportional 
Odds: no cov 
24.7 24.3 25.1 17.6 20.4 27.6 21.5 18.8 19.8 17.7 19.3 20.4 
Proportional 
Odds: + cov 
36.3 38.3 34.2 32.9 39.3 35.0 38.8 36.3 29.8 32.7 29.7 35.0 
SD 3 bands, 
equal splits 
+cov 
18.5 19.7 18.0 12.1 28.1 23.2 30.1 23.4 22.1 21.6 10.7 21.6 
 
Table 6-30 Targeting only patients with an intermediate prognosis. Median and by trial 
reductions in sample size. Uniform treatment scenario, 8% treatment effect, three covariate 
model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
10.9 10.4 5.9 11.3 10.8 10.1 11.3 15.1 6.0 10.9 9.8 10.8 
Proportional 
Odds: no cov 
21.3 25.1 25.0 22.3 20.4 21.8 23.6 20.9 17.3 27.3 24.8 22.3 
Proportional 
Odds: + cov 
34.9 35.9 32.9 36.8 34.5 29.3 36.7 40.7 27.9 38.2 34.6 34.9 
SD 3 bands, 
equal splits 
+cov 
19.6 22.2 16.5 19.1 22.6 18.5 27.1 29.7 18.7 25.5 18.1 19.6 
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6.5.1.2 Seven covariate model 
Both 5% and 8% treatment effects 
All alternative strategies showed an improvement over the conventional treatment 
only strategy.  For all studies, as with the three covariate model, the proportional 
odds plus covariates strategy gives the greatest reduction in sample size compared 
with the conventional treatment only strategy.  Using the conventional plus covariate 
strategy gave the smallest reductions in sample size.  For nine of the studies, using 
the proportional odds treatment only strategy gave a greater reduction in sample size 
than using the sliding dichotomy strategy.  Similar reductions in sample size were 
observed with both the 5% and the 8% treatment effects as shown in Table 6-31 and 
Table 6-32 respectively below. 
 
Table 6-31 Targeting only patients with an intermediate prognosis. Median and by trial 
reductions in sample size. Uniform treatment scenario, 5% treatment effect, seven covariate 
model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
10.9 17.0 11.2 9.5 8.1 13.4 14.3 15.4 7.8 10.2 10.6 10.9 
Proportional 
Odds: no cov 
28.1 24.2 27.7 22.0 19.1 16.9 20.3 18.5 18.6 17.7 21.6 20.3 
Proportional 
Odds: + cov 
38.2 37.4 37.1 31.6 30.0 34.8 36.4 36.3 32.0 32.2 36.2 36.2 
SD 3 bands, 
equal splits 
+cov 
21.9 17.2 19.6 20.8 18.0 8.4 22.4 26.9 22.2 17.2 16.9 19.6 
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Table 6-32 Targeting only patients with an intermediate prognosis. Median and by trial 
reductions in sample size. Uniform treatment scenario, 8% treatment effect, seven covariate 
model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
10.3 11.7 5.2 13.9 14.2 14.4 8.6 12.2 11.2 11.7 7.7 11.7 
Proportional 
Odds: no cov 
27.7 25.2 21.7 25.9 21.6 21.0 19.6 23.8 19.6 22.7 21.3 21.7 
Proportional 
Odds: + cov 
37.3 35.8 32.0 37.7 34.6 32.9 34.8 33.7 32.1 34.6 33.0 34.6 
SD 3 bands, 
equal splits 
+cov 
14.5 15.6 14.2 21.7 16.6 14.2 22.6 21.5 24.2 16.8 15.7 16.6 
 
6.5.1.3 Nine covariate model 
Both 5% and 8% treatment effects 
For all trials, all alternative strategies showed an improvement over the conventional 
treatment only strategy and using the proportional dds plus covariates strategy gave 
the greatest reduction in sample size.  As with the thr e and seven covariate models, 
the smallest reductions in sample size were obtained when the conventional plus 
covariates strategy was used.  For SKB only, using a 5% treatment effect, the sliding 
dichotomy strategy gave a greater reduction in sample size than the proportional 
odds treatment only strategy as shown in Table 6-33below.  For all other studies, 
and SKB using an 8% treatment effect, the proportional dds plus treatment strategy 
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Table 6-33 Targeting only patients with an intermediate prognosis. Median and by trial 
reductions in sample size. Uniform treatment scenario, 5% treatment effect, nine covariate 
model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
14.4 15.4 11.7 7.4 6.3 12.8 8.1 11.3 7.7 11.7 8.3 11.3 
Proportional 
Odds: no cov 
22.8 27.8 26.2 22.0 17.2 20.5 20.4 18.8 18.8 19.6 21.7 20.5 
Proportional 
Odds: + cov 
33.8 38.4 36.6 31.7 33.6 32.6 37.1 32.3 32.3 32.9 33.9 33.6 
SD 3 bands, 
equal splits 
+cov 
18.0 20.8 20.2 16.8 14.0 12.3 16.8 18.4 21.5 17.5 17.2 17.5 
 
Table 6-34 Targeting only patients with an intermediate prognosis. Median and by trial 
reductions in sample size. Uniform treatment scenario, 8% treatment effect, nine covariate 
model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
10.7 12.3 5.9 10.3 12.9 11.6 11.6 12.3 11.8 13.1 8.6 11.6 
Proportional 
Odds: no cov 
29.3 25.3 25.3 21.7 25.0 25.9 19.8 24.9 22.0 27.7 21.4 25.0 
Proportional 
Odds: + cov 
35.0 37.2 34.6 34.5 34.5 35.0 34.8 38.2 32.0 37.7 30.8 34.8 
SD 3 bands, 
equal splits 
+cov 
16.7 17.4 19.1 13.7 16.0 12.3 15.3 20.7 18.1 19.8 14.2 16.7 
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General remarks 
Using the seven covariate model gave a greater reduction in sample size than the 
three covariate model.  However, there was little difference in reduction in sample 
size between the nine and seven covariate models. 
 
6.5.2 Comparing strategies – mortality treatment effect 
Here the simulated treatment effect is a reduction in mortality. 
 
6.5.2.1 Three covariate model 
For both the 5% and 8% treatment effects the proportional odds plus covariates 
strategy gives the greatest reduction in sample size compared with the conventional 
treatment only strategy for all studies. 
 
5% treatment effect 
Using the sliding dichotomy strategy gave an increase in sample size compared with 
the conventional treatment only strategy for TINT and SLIN as shown in Table 6-35 
below.  For all studies the smallest reduction in sample size was observed when the 
conventional plus covariates strategy is used. 
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Table 6-35 Targeting only patients with an intermediate prognosis. Median and by trial 
reductions in sample size. Mortality treatment scenario, 5% treatment effect, three covariate 
model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
12.4 15.1 12.1 2.8 12.1 10.0 7.6 16.7 10.4 4 3 6.9 10.4 
Proportional 
Odds: no cov 
25.8 28.3 24.1 28.8 37.0 34.3 34.4 34.8 36.8 33.6 30.3 33.6 
Proportional 
Odds: + cov 
33.8 41.9 34.4 38.0 47.0 42.4 45.3 49.5 49.0 41.2 40.2 41.9 
SD 3 bands, 
equal splits 
+cov 
-9.6 17.1 -28.2 22.4 30.5 32.7 29.9 35.6 37.1 27.2 18.6 27.2 
 
8% treatment effect 
For TINT, TIUS and SLIN, using the sliding dichotomy strategy resulted in an 
increase in sample size compared with using the conventional treatment only strategy 
as shown in Table 6-36 below.  For SLIN this increase is greater than 50% of the 
sample size with the conventional treatment only strategy.  Using the conventional 
plus covariates strategy gave a modest reduction in sample size compared with using 
the conventional treatment only strategy.  Using the proportional odds treatment only 
strategy gave the second greatest reduction in sample size. 
 
 
Chapter 6 Comparing different modelling strategies 185 
Table 6-36 Targeting only patients with an intermediate prognosis. Median and by trial 
reductions in sample size. Mortality treatment scenario, 8% treatment effect, three covariate 
model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
8.8 16.1 6.0 9.9 9.1 11.4 11.4 13.1 9.2 9.9 11.1 9.9 
Proportional 
Odds: no cov 
28.6 27.7 21.5 28.0 33.8 34.5 37.5 41.1 36.4 32.3 29.4 32.3 
Proportional 
Odds: + cov 
40.3 42.1 32.3 41.8 42.0 43.6 45.0 51.6 44.5 42.9 39.6 42.1 
SD 3 bands, 
equal splits 
+cov 
-25.8 -25.3 -52.2 16.3 30.9 24.4 31.7 37.8 24.5 23.8 3.0 23.8 
 
6.5.2.2 Seven covariate model 
For both the 5% and the 8% treatment effects using the proportional odds plus 
covariates strategy gave the greatest reduction in sample size compared with using 
the conventional treatment only strategy. 
 
5% treatment effect 
Using the sliding dichotomy strategy gave a very small increase in sample size 
compared to the conventional treatment only strategy for SLIN as shown in Table 
6-37 below.  The smallest reductions in sample size were observed when the 
conventional plus covariates strategy was used.  Using the proportional odds 
treatment only strategy gave the second largest reductions in sample size, greater in 
all cases than using the sliding dichotomy. 
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Table 6-37 Targeting only patients with an intermediate prognosis. Median and by trial 
reductions in sample size. Mortality treatment scenario, 5% treatment effect, seven covariate 
model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
7.2 11.3 8.8 13.6 9.5 5.6 7.6 7.1 8.2 11.3 8.8 8.8 
Proportional 
Odds: no cov 
35.5 30.2 35.5 37.7 34.7 32.8 34.4 32.9 39.5 38.0 31.3 34.7 
Proportional 
Odds: + cov 
43.7 41.8 43.5 47.9 43.8 40.7 41.0 43.2 49.6 45.7 39.0 43.5 
SD 3 bands, 
equal splits 
+cov 
18.5 15.4 -1.0 31.3 28.7 20.8 25.9 31.6 37.2 33.4 16.3 25.9 
 
8% treatment effect 
A similar pattern was observed with the 8% treatment effect as with the 5% 
treatment effect in that the proportional odds treatment only strategy gave greater 
reductions in sample size than the sliding dichotomy strategy as shown in Table 6-38 
below.  Using the sliding dichotomy resulted in an increase in sample size for TINT, 
TIUS, SLIN and HIT II compared with using the convetional treatment only 
strategy.  No consistent increase in reduction in sample size was observed when 
using the 8% treatment effect compared with the 5% treatment effect. 
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Table 6-38 Targeting only patients with an intermediate prognosis. Median and by trial 
reductions in sample size. Mortality treatment scenario, 8% treatment effect, seven covariate 
model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
11.6 8.2 9.7 9.4 8.0 9.6 8.1 11.1 7.2 7.8 8.5 8.5 
Proportional 
Odds: no cov 
30.8 32.4 31.9 33.6 40.1 31.7 36.6 38.8 37.4 35.1 32.3 33.6 
Proportional 
Odds: + cov 
40.4 42.2 39.9 46.6 47.3 41.6 45.5 49.8 45.4 43.4 40.6 43.4 
SD 3 bands, 
equal splits 
+cov 
-13.9 -13.9 -20.3 8.8 27.0 4.5 30.8 27.5 25.5 20.1 -5.8 8.8 
 
6.5.2.3 Nine covariate model 
A similar pattern was observed with the nine covariate model as with the seven 
covariate model.  Using the sliding dichotomy strategy resulted in an increase in 
sample size for SLIN with the 5% treatment effect and TINT, TIUS, SLIN and HIT 
II with the 8% treatment effect compared with using the conventional treatment only 
strategy.  Very similar reductions in sample size were observed both with the 5% and 
8% treatment effects as shown in Table 6-39 and Table 6-40 below.  The 
conventional plus covariates strategy gave the smallest reductions in sample size of 
any of the alternative strategies. 
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Table 6-39 Targeting only patients with an intermediate prognosis. Median and by trial 
reductions in sample size. Mortality treatment scenario, 5% treatment effect, nine covariate 
model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
13.9 7.7 14.3 4.9 11.7 6.6 11.0 10.3 9.2 7.5 9.7 9.7 
Proportional 
Odds: no cov 
36.6 32.8 33.0 35.2 34.5 32.5 41.2 40.6 44.8 33.8 35.7 35.2 
Proportional 
Odds: + cov 
44.7 41.8 40.7 43.9 45.6 40.4 47.9 49.6 50.9 39.4 43.1 43.9 
SD 3 bands, 
equal splits 
+cov 
13.6 10.7 -8.2 21.7 23.5 6.6 35.1 37.0 36.7 17.9 8.4 17.9 
 
Table 6-40 Targeting only patients with an intermediate prognosis. Median and by trial 
reductions in sample size. Mortality treatment scenario, 8% treatment effect, nine covariate 
model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
10.7 14.2 9.6 12.4 12.8 9.5 6.9 12.1 8.0 8.4 9.5 9.6 
Proportional 
Odds: no cov 
32.2 33.5 33.1 34.0 37.0 33.1 40.8 38.0 42.2 33.3 33.6 33.6 
Proportional 
Odds: + cov 
42.1 43.5 43.9 46.7 47.3 44.1 48.4 50.7 48.5 43.0 44.2 44.2 
SD 3 bands, 
equal splits 
+cov 
-20.1 -15.4 -25.7 3.9 19.0 -19.3 26.2 23.9 31.5 5.6 -14.6 3.9 
 
In general, similar reductions in sample size were observed when using the three, 
seven and nine covariate models. 
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6.5.3 Graphical comparison – targeting only patients with an intermediate 
prognosis 
Figure 6-11 and Figure 6-12 show that, for all studies, using either the sliding 
dichotomy or proportional odds strategies gives a reduction in sample size when the 
treatment effect follows a proportional odds model.  Greater reductions were 
observed using the proportional odds strategies than t e sliding dichotomy strategies.  
Using models with greater numbers of covariates did not give corresponding greater 
reductions in sample size for either the sliding dichotomy or proportional odds 
strategies. 
 
The proportional odds strategies gave greater reductions in sample size compared 
with the conventional dichotomy for all studies when simulating a treatment effect 
that gave a reduction in mortality, as shown in Figure 6-13 and Figure 6-14 below.  
These reductions were typically around 40% for all three covariate models and both 
the 5% and 8% treatment effects.  Using the sliding ichotomy strategies with the 5% 
treatment effect showed a reduction in sample size for all studies except SLIN and 
TINT.  However, the sliding dichotomy strategies performed more poorly with the 
8% treatment effect with four of the trials showing an increased sample size 
compared with the conventional dichotomy. 
 
This pattern is confirmed when the median reduction in sample size over all trials is 
shown, Figure 6-15.  All scenarios over all treatment effects showed a reduction in 
sample size compared with the conventional dichotomy.  Using the seven covariate 
model with covariates or the nine covariate models gave the greatest reductions in 
sample size of 35 to 45%. 
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Figure 6-11 Uniform 5%: Targeting only those with an intermediate prognosis.  Comparison of 

















Figure 6-12 Uniform 8%: Targeting only those with an intermediate prognosis.  Comparison of 


















Key: Sliding Dichotomy 3 covariates (red) Sliding Dichotomy 7 covariates (dark blue), Sliding 
Dichotomy 9 covariates (green), Proportional odds 3 covariates (yellow), Proportional odds 7 
covariates (purple), Proportional odds 9 covariates (pink) 
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Figure 6-13 Mortality 5%: Targeting only those with an intermediate prognosis.  Comparison of 



















Figure 6-14 Mortality 8%: Targeting only those with an intermediate prognosis.  Comparison of 




















Key: Sliding Dichotomy 3 covariates (red) Sliding Dichotomy 7 covariates (dark blue), Sliding 
Dichotomy 9 covariates (green), Proportional odds 3 covariates (yellow), Proportional odds 7 
covariates (purple), Proportional odds 9 covariates (pink) 
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Figure 6-15 Median reductions in sample size. Targeting only those with an intermediate 


























Key: Sliding Dichotomy 3 covariates (red) Sliding Dichotomy 7 covariates (dark blue), Sliding 
Dichotomy 9 covariates (green), Proportional odds 3 covariates (yellow), Proportional odds 7 
covariates (purple), Proportional odds 9 covariates (pink) 
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6.6 Targeting only patients with a mass lesion 
Only the results from the three covariate model are shown for both the uniform and 
mortality scenarios as both the seven and nine covariate models contain CT. 
 
6.6.1 Comparing strategies – uniform treatment effect 
For both the 5% and 8% treatment effects all alternative strategies showed an 
improvement over the conventional treatment only strategy for all studies when the 
treatment effect followed a proportional odds model as shown in Table 6-41 and 
Table 6-42 below.  Using the proportional odds plus covariates strategy gives the 
greatest reduction in sample size, again for all studies.  Similar reductions are 
observed with the conventional plus covariates and the proportional odds treatment 
only strategies.  The sliding dichotomy strategy gave  greater reduction in sample 
size than the conventional plus covariates and the proportional odds treatment only 
strategies. 
 
Table 6-41 Targeting only patients with a mass lesion. Median and by trial reductions in sample 
size. Uniform treatment scenario, 5% treatment effect, three covariate model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
22.3 21.0 16.2 15.0 25.4 26.3 26.5 28.0 34.2 14.8 22.3 22.3 
Proportional 
Odds: no cov 
22.5 18.2 24.2 16.9 25.4 23.4 20.7 20.4 27.1 17.3 22.5 22.5 
Proportional 
Odds: + cov 
44.1 44.7 39.0 38.1 48.2 48.4 45.5 48.4 53.5 39.5 44.1 44.7 
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Study Scenario 
TINT  TIUS SLIN SAP PEG HITI  UK4 TCDB SKB EBIC HITII  
Median 
SD 3 bands, 
equal splits 
+cov 
36.0 32.2 27.4 26.2 38.5 42.7 33.4 39.1 47.6 33.0 36.0 36.0 
 
Table 6-42 Targeting only patients with a mass lesion. Median and by trial reductions in sample 
size. Uniform treatment scenario, 8% treatment effect, three covariate model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
22.6 25.0 11.8 20.5 21.1 25.1 23.9 31.1 26.2 19.1 22.6 22.6 
Proportional 
Odds: no cov 
25.6 22.3 23.8 21.8 19.4 20.3 22.5 25.1 19.6 19.7 25.6 22.3 
Proportional 
Odds: + cov 
46.4 46.7 40.0 42.3 43.9 45.9 46.6 52.7 50.2 40.8 46.4 46.4 
SD 3 bands, 
equal splits 
+cov 
33.1 36.7 29.8 31.9 31.1 37.0 34.3 42.4 39.7 28.4 33.1 33.1 
 
6.6.2 Comparing strategies – mortality treatment effect 
For both the 5% and 8% treatment effects, for all studies, except SLIN, all alternative 
strategies show an improvement over the conventional treatment only strategy when 
the treatment effect was modelled as a reduction in mortality as shown in Table 6-43 
and Table 6-44 below.  For SLIN, using the sliding dichotomy strategy gave an 
increase in sample size compared to the conventional treatment only strategy.  For all 
studies the greatest reduction in sample size was observed using the proportional 
odds plus covariates strategy.  The conventional plus covariates strategy gave the 
smallest reductions in sample size.  The sliding dichotomy and the proportional odds 
treatment only strategies gave similar reductions in sample size.  Overall, the greatest 
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reductions in sample size were observed in the studies which were unselected series.  
The trials with the smallest numbers of participants had the smallest reductions in 
sample size. 
 
Table 6-43 Targeting only patients with a mass lesion. Median and by trial reductions in sample 
size. Mortality treatment scenario, 5% treatment efect, three covariate model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
24.6 21.6 12.3 17.6 16.0 21.5 22.1 23.9 29.0 14.8 24.6 21.6 
Proportional 
Odds: no cov 
32.3 30.9 16.0 42.0 43.9 44.2 45.9 48.1 46.7 39.6 32.3 42.0 
Proportional 
Odds: + cov 
49.3 47.6 32.1 51.4 54.1 61.5 55.7 62.1 62.0 53.5 49.3 53.5 
SD 3 bands, 
equal splits 
+cov 
39.0 41.1 -8.9 36.7 44.1 48.8 47.2 60.4 45.5 37.8 39.0 41.1 
 
Table 6-44 Targeting only patients with a mass lesion. Median and by trial reductions in sample 
size. Mortality treatment scenario, 8% treatment efect, three covariate model10 
Study Scenario 




0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Conventional 
+ cov 
17.6 21.2 12.1 19.4 21.8 22.0 19.6 23.5 24.7 17.7 17.6 19.6 
Proportional 
Odds: no cov 
30.3 35.0 18.0 38.3 45.6 41.3 45.9 47.5 43.3 37.8 30.3 38.3 
Proportional 
Odds: + cov 
46.0 50.2 35.6 52.1 57.7 57.0 58.8 60.7 60.0 53.2 46.0 53.2 
SD 3 bands, 
equal splits 
+cov 
32.0 37.3 -30.3 41.7 41.7 42.2 45.2 58.2 39.4 38.6 32.0 39.4 
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6.7 Discussion 
The first part of this chapter has shown the comparison of the optimised sliding 
dichotomy with a number of different modelling strategies.  The second part has 
examined whether the results observed for all subjects, as shown in the first part, are 
replicated when either improvement is restricted to a group of patients or a group of 
patients were targeted for improvement.  When restricting improvement to those with 
an intermediate prognosis the same pattern was observed for both the Uniform and 
Mortality treatment effects as with using data from all subjects.  For improvement 
restricted to patients with a mass lesion, for some studies under certain scenarios 
using the sliding dichotomy actually increased the sample size compared with the 
conventional analysis.  This was possibly because of the smaller subset of patients in 
this analysis.  Targeting only patients with an intermediate prognosis, showed a 
similar pattern to that observed when improvement was restricted to patients with an 
intermediate prognosis.  However, as expected, the reductions in sample size seen 
were smaller.  When targeting only patients with a mass lesion almost all scenarios 
for all studies showed a reduction in sample size compared with the conventional 
dichotomous analysis. 
 
All of the modelling results have shown consistently that adding covariates to the 
models results in greater sample size reductions for all scenarios.  Using covariates 
with the proportional odds model consistently gave the greatest sample size 
reductions both when the data followed a proportional dds treatment effect (the 
Uniform treatment scenario) and when the data did not (the Mortality treatment 
scenario).  Using the sliding dichotomy with covariates typically gave the next 
greatest reductions in sample size although for some scenarios using the proportional 
odds model without covariates or the conventional alysis with covariates gave a 
similar magnitude of reduction.  Almost without excption all alternative strategies 
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performed much better than the conventional analysis eading to reductions in sample 
size of typically around 40%. 
 
 
Chapter 7 Discussion and Recommendations 198 
7 Chapter 7 Discussion and Recommendations 
7.1 Findings 
Some of the text below, in particular the section on the sliding dichotomy has been 
published (McHugh et al. 2010). 
This thesis has shown that by using the ordinal nature of the Glasgow Outcome Scale 
it is possible to achieve substantial sample size reductions whilst still preserving 
power.  These sample size gains are in addition to those achieved by covariate 
adjustment alone (Hernandez et al. 2006).  Indeed, ad ing covariates to those 
strategies which exploited the ordinal nature of the GOS gave an additional benefit, 
with sample size reductions of over 50% in some cass. 
 
The proportional odds model was the most statistically efficient, consistently giving 
the greatest sample size reductions.  It is perhaps not urprising that it performed well 
when the simulated treatment effect was structured to follow a proportional odds 
model - the Uniform model.  What is more surprising is that using the proportional 
odds model still gave the greatest sample size reductions when the treatment effect 
clearly did not follow the proportional odds assumption – the Mortality model.  The 
proportional odds model was also statistically efficient when the treatment effect was 
restricted to those with an intermediate prognosis and when it was restricted to those 
with a mass lesion.  Even when targeting groups of patients, those with an 
intermediate prognosis and those with a mass lesion, it still gave the largest sample 
size reductions.  The sliding dichotomy also performed well.  Although it did not 
give quite the magnitude of sample size reductions observed with using the 
proportional odds model, it still gave a vastly superior result compared with using the 
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7.2 Related work 
Others have found comparable study results in different populations.  The 
Optimising Analysis of Stroke Trials (OAST) collaboration have performed two 
studies which have shown that statistical approaches which exploited the ordered 
nature of the outcomes were statistically more efficient than those which collapsed 
the data into two categories (Bath 2007;The Optimising Analysis of Stroke Trials 
(OAST) collaboration 2008).  Using a combination of individual patient data and 
summarised data from 55 stroke studies they found that the findings were consistent 
both over different measures of functional outcome and different studies.  In the first 
study, (Bath et al. 2007), three outcome scales were examined: the modified Rankin 
Scale; the Barthel Index; and the “3-questions” (taken from the modified Rankin 
Scale) (Lindley et al. 1994).  Within each trial, tests which exploited the ordinal 
nature of the data, such as ordinal logistic regression and tests which dichotomised 
the data, such as the Chi-squared test, were compared.  Statistical tests which 
dichotomised the data were assessed multiple times at ach of the possible 
dichotomies.  The results of all of these tests were then ranked within each trial.  The 
test which produced the most significant result, i.e. the largest z score was given the 
lowest rank.  Two way analysis of variance was then used to examine which test on 
average over all of the trials produced the lowest rank.  This then enabled ordering of 
the tests in terms of efficiency of identifying treatment effects.  Ordinal logistic 
regression was consistently given the lowest rank showing it to be the most efficient 
at identifying treatment effects with the Chi-squared test and the Kolmogorov-
Smirnov test consistently showing the least efficien y in identifying treatment 
effects.  In the second study (The Optimising Analysis of Stroke Trials (OAST) 
collaboration 2008), sample sizes were calculated using comparisons of proportions, 
means, medians and ordinal data.  Ordinal methods, with sample size calculated 
according to Whitehead’s formula (Whitehead 1993) on average reduced sample size 
by 28%. 
The results shown in this thesis, on head injury trials, expand these findings.  The 
OAST collaborators used a mixture of individual patient data where available and 
summarised data.  Only individual patient data made into a common database format 
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were used in this thesis.  It is interesting that our overall results were similar with 
both groups finding that ordinal methods consistently gave substantial sample size 
reductions.  Interestingly, in the second study, the OAST group found that no method 
of analysis, except one dichotomy, worked well with the thrombolysis trials.  They 
comment that “ordinal methods may not be optimal for interventions which both 
improve functional outcome and cause a hazard in a subset of patients, e.g. 
thrombolysis.”  This thesis has also shown some situations where an ordinal analysis 
may not be optimal, for example, when modelling a reduction in mortality for some 
studies.  The OAST work has been expanded here as cov riates have been used to 
develop prognostic models which have been used to discriminate patients on the 
basis of baseline risk.  Here too, many more modelling strategies which are used with 
ordinal data have been compared, firstly the refinement of the sliding dichotomy then 
the comparison with the other methods. 
 
Lees et al (Lees et al. 2006a) also examined outcome after stroke, as measured by the 
NIHSS scale.  A number of simulations were performed comparing the power 
achieved for a fixed sample size when the outcome was analysed, using the Cochran 
Mantel Haenszel test, both using the full NIHSS scale and when the scale was 
dichotomised.  All simulations showed a decrease in power when using the 
dichotomous analysis.  For example, even with a sample size as large as 4700 
subjects, analysing the total NIHSS score gave 75% power and dichotomising the 
score gave a power of only 55%. 
 
A similar method of analysis has been applied to the Glycine Antagonist In 
Neuroprotection (GAIN) stroke trial (Lees et al. 2000).  Young and colleagues 
(Young, Lees, & Weir 2003) performed imputation on the stroke data to predict 
outcome on the Barthel and Rankin (Bonita & Beaglehol  1988) scales. They 
simulated 24 000 trials exploring various patterns of outcome, although not 
prognosis based outcomes, and found that using the Rankin Scale instead of the 
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dichotomised Barthel scale could reduce sample size by up to 84%.  In a second 
examination of the data, Young and colleagues (Young, Lees, & Weir 2005) reported 
that the use of a prognosis based endpoint could also reduce sample size by up to 
49%. 
 
Others have also examined the effects of adjusting for covariates on sample size and 
power.  The OAST collaboration (Gray, Bath, & Collier 2009) performed simulation 
studies examining this.  Using data from over 25 000 patients in 23 stroke trials they 
compared adjusted (treatment model adjusted for age, sex and baseline severity) and 
unadjusted (treatment only) ordinal regression models over three levels of treatment 
effect.  They observed similar results to the ones reported in this thesis with 
reductions of sample size of at least 20% to 30% when covariates were taken into 
account. 
 
One published trial, SCAST (Sandset et al. 2011), has compared both ordinal logistic 
regression and the sliding dichotomy on real trial data.  Using ordinal regression 
analysis gave a statistically significant result whereas using the sliding dichotomy did 
not.  This may have been because of the reduced power with this method of analysis 
compared with ordinal regression. 
 
Two other stroke trials have also used the sliding ichotomy to analyse outcome.  
The STICH trial (Mendelow et al. 2005) and the PAIS trial (den Hertog et al. 2009) 
used the sliding dichotomy methodology as their prima y analysis.  It is interesting 
that the PAIS trial was originally going to use a dichotomisation of the modified 
Rankin Scale as its primary outcome.  However, as the s udy recruited patients it was 
realised that the planned number of patients could not be recruited.  The protocol was 
then modified before the treatment codes were broken (d n Hertog et al. 2008) to 
specify use of the sliding dichotomy as a way of increasing the power of the study to 
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detect a statistically significant difference.  The authors commented that if analysis 
had been as originally planned the study would have had only 60% power to find the 
difference specified (den Hertog et al. 2009). 
 
A recent reanalysis of the CRASH (Edwards et al. 2005) trial has compared both the 
sliding dichotomy and proportional odds approach (Roozenbeek et al. 2011).  The 
published dichotomous analysis showed a non-significant treatment effect 1.09 (0.98 
to 1.21) p=0.096.  Using both proportional odds modelling and the sliding 
dichotomy, highly statistically significant treatment effects were observed, showing a 
deleterious effect of the active treatment.  The odds of an unfavourable outcome was 
1.15 95%CI (1.06 to 1.25) p=0.0007 using proportional odds modelling and an odds 
ratio of 1.19, 95%CI (1.08 to 1.30) p=0.0002 for the sliding dichotomy. 
 
7.3 Limitations 
All of the simulation studies were based on a sample size of 800 subjects.  It would 
be of interest to see if the findings in the thesis would be repeated with smaller and 
larger studies.  A few limited simulations were runon a larger sample size and these 
showed a similar pattern to the simulations with 800 subjects.  This thesis also only 
considered two treatment effects, 5% and 8%.  Althoug  the results were consistent 
over both treatment effects, a natural extension would be to model different treatment 
effects.  Only three covariate models were compared.  From these findings there was 
not a direct relationship between number of covariates nd increase in sample size.  It 
would however be interesting to explore whether the addition of many more 
covariates would lead to greater gains. 
 
A potential criticism is that the IMPACT data may not be representative of current 
head injury trials as the last study was completed in 1995.  The same pattern of 
results were shown when both restricting improvement to certain groups and when 
 
Chapter 7 Discussion and Recommendations 203 
targeting certain groups of patients.  As this is currently done in trial recruitment this 
would seem to show the robustness of these methods. 
 
The analysis of the IMPACT data could be criticised b cause it was only performed 
on one large dataset, albeit one which contained elven composite studies.  To have 
external validity the models would need to be fitted on another dataset different from 
the ones on which the models were derived (Justice, Covinsky, & Berlin 1999). Two 
of the prognostic models used in the IMPACT database have been validated in other 
datasets.  Steyerberg at al (Steyerberg et al. 2008) used data from the CRASH trial 
(Edwards et al. 2005) to validate the models used with the IMPACT data.  Subjects 
with a GCS <=12 and a 6 month GOS were selected from the CRASH data to allow 
validation on a similar population.  As CRASH did not record lab values, two models 
were validated.  The first was the three covariate set (age, motor and pupil).  This 
gave an AUC of 0.776 when modelling survival and an AUC of 0.780 when 
modelling unfavourable outcome.  A five variable model was also fitted to the 
CRASH data.  This added CT and tSAH to the three covariate model, giving AUC of 
0.801 and 0.796 for the mortality and unfavourable outcome models respectively.  
All models had adequate discrimination.  Of course, no statistical model is ‘correct’ 
so future work could be done on the refinement of these models and their clinical 
impact (Lingsma et al. 2010).  This is, of course, a criticism of prognostic models in 
general rather than a limitation of the simulation studies described. 
 
Criticisms could be levelled because the assumption of proportional odds did not 
hold for all analyses.  Senn and Julious make the argument that two different 
statisticians could cut the same continuous scale at two different cut points.  If we 
can accept the results from either dichotomy, then accepting the compromise answer 
from the proportional odds model seems reasonable (Senn & Julious 2009).  
Wardlaw et al (Wardlaw et al. 2000) have shown this empirically with stroke data.  
They performed a meta-analysis of twelve thrombolysis trials which measured 
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outcome after stroke using the dichotomised modifie Rankin Scale.  Wardlaw used 
two different definitions of good and poor outcome.  They compared two cut points 
of the modified Rankin Scale: 0 to 2 (good outcome) versus 3 to 6 (poor outcome) 
and 0 to 1(good outcome) versus 2 to 6 (poor outcome).  Both analyses gave very 
similar results: poor outcome 3 to 6 OR=0.83; poor outcome 2 to 6 OR=0.79, 
showing that the treatment effect was robust to using d fferent definitions of good or 
poor outcome.  Changing the definitions did however change the outcomes in several 
trials from “success” to “failure” and vice versa.  This emphasises how changing just 
one point on a scale can change the outcome from “succe s” to “failure” when in fact 
there is no difference in the magnitude of the result. 
 
When combining estimates from the different studies th re was statistically 
significant heterogeneity in some cases.  Bailey (Bailey 1987) made the important 
point that it is not surprising that studies with different designs have heterogeneous 
outcomes.  He proposed three important questions.  “(1) which question one is trying 
to answer; (2) the degree of similarity or dissimilarity of design, and (3) the degree to 
which heterogeneity of outcomes can be explained.”  In this thesis the question has 
always been focussed on what methods are best to analyse ordinal outcome data.  
The studies that were compared had two distinct designs of being unselected cohorts 
and trials however all were in patients with moderat  to severe head injury and the 
heterogeneity of the outcomes could usually be explained by the different study 
designs. 
 
Meta analysis and the pooling of studies can also be criticised.  Studies included 
should have enough in common that the evidence fromthe  can be interpreted for 
current patients (Thompson & Pocock 1991).  The studies pooled for these meta 
analyses were similar in that they were all in moderately to severely head injured 
patients.  However, three of the studies were observational series and the rest were 
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trials.  However, by using covariates such as gender as a ‘treatment effect’ this 
probably offers enough commonalties between studies. 
 
The findings in this thesis that the proportional odds model gives a robust and 
sensitive analysis even when the formal assumption of proportional odds in not held 
has been found by others.  Tsodikov et al (Tsodikov, Hasenclever, & Loeffler 1998) 
modelled a U shaped treatment effect  and found that the proportional odds model 
gave the most stable estimates when repeated bootstrap sampling was done, albeit on 
a much smaller sample than was studied in this thesis.  Whitehead et al (Whitehead 
et al. 2001) also fitted the proportional odds model to a variety of scenarios and 
found that it performed well. 
 
Other trial designs have been proposed to deal with the problem of recruitment in 
trials.  Relton et al (Relton et al. 2010) proposed a “cohort multiple randomised 
controlled trial” design.  This involves obtaining a large epidemiological cohort who 
agree to observational measurements being taken.  Trial subjects are then randomised 
from within this cohort.  The authors argue that this design will help with patient 
recruitment issues however no mention is made of the difficulties of recruiting the 
large epidemiological cohort and why this would be easier that recruiting for a 
pragmatic trial per se.  Using more efficient statitical analysis, giving greater power 
and hence a reduction in sample size would seem to be a much simpler and more 
robust strategy for dealing with this problem. 
 
7.4 Future work 
More sophisticated approaches to implementing the sliding dichotomy could be used.  
For example, the thresholds could be constrained to be monotonic, so that moving 
from a poorer prognosis band to a better prognosis band, the threshold for 
‘favourable’ would need to be at the same point as the previous band or else higher 
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up the GOS scale.  Indeed, an interesting approach would be to use an extremely 
large number of bands but to enforce monotonicity, giving a very flexible way of 
assigning an appropriate definition of ‘favourable’ outcome for each individual 
patient.  Ultimately, it is not necessary to think of bands at all.  In this context of 
analysing a 4-point ordinal scale, the sliding dichotomy will always end up with 
three groups of patients.  Those with poor prognosis, where the threshold will be 
between D/V and SD; those with intermediate prognosis, where the threshold will be 
between SD and MD; and those with good prognosis, where the threshold will be 
between MD and GR.  In some situations with extreme outcome distributions, one or 
even two of these groups might not contain any patients.  What is required in general 
is an efficient way of splitting the ordered list of patients (ordered by baseline 
prognosis) into these three groups.  Another possible approach, for example, might 
be to work from the worst prognosis patient upwards until a group is obtained with 
an approximate 50:50 split between D/V and better, and make this the poor prognosis 
group.  Then work from the best prognosis patient downwards until a group is 
obtained with an approximate 50:50 split between GR versus worse, and make this 
the good prognosis group.  The remaining patients would be the intermediate 
prognosis group.  However, in practice, these groups might overlap or it might not be 
possible to find a group with the required 50:50 outc me split.  Considerable 
ingenuity would need to be applied to make the approach robust over all possible 
extreme outcome distributions.  Since the sliding dichotomy approach collapses the 
ordinal scale to a binary one for final analysis, it must still be discarding some 
relevant information.  Thus, from first principles, and as supported by the simulation 
results, one would expect that, in most situations, the potential efficiency gains from 
a fully optimised sliding dichotomy analysis would be bounded above by the gains 
that can be achieved using the proportional odds model. 
 
This thesis could have examined a composite endpoint rather than just GOS.  Two 
studies used this approach on summarised data from trials (Bath et al. 
2008;Geeganage et al. 2010).  Bath examined vascular prevention trials and 
Geeganage examined blood pressure reduction and cardiov scular prevention trials.  
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Instead of categorising outcome as stroke/no stroke and comparing event rates 
between treatment groups, both Bath and Geeganage expanded this firstly to a three 
category ordinal outcome i.e. fatal event/non fatal event/no event.  This was then 
expanded to a four category ordinal outcome: fatal stroke/severe non fatal 
stroke/mild stroke/no stroke and then a five category ordinal outcome: fatal stroke/ 
severe non fatal stroke/ mild stroke/ transient ischaemic event/no event.  Instead of 
considering outcome as a range of different points o  a scale, as with the Glasgow 
Outcome Scale, different outcomes were thought of as being on the same continuum.  
In addition to studying stroke Bath and Geeganage similarly categorised MI, vascular 
events and bleeding (Bath only).  Bath compared 10 ifferent statistical tests on each 
of the 85 trials (four of the tests assumed ordinal data, the rest assumed binary or 
continuous data).  The results within each trial were then ordered and Friedman’s test 
used to assess which test gave the lowest ranks i.e. the most statistically significant 
values.  For all outcomes, using ordinal analysis methods consistently outperformed 
using binary analysis methods.  Geeganage used summarised data from 38 trials and 
found similar odds ratios were obtained from binary nd ordinal outcomes.  She 
showed, with one trial, that using a five level ordinal endpoint could reduce sample 
size by 56% compared with using a binary endpoint. 
 
The GOS could have been treated as a linear scale.  Th  modified Rankin Scale is 
conventionally dichotomised between scores 2 and 3 however Hong (Hong & Saver 
2009) found that there was little difference between scores 2 and 3 when they are 
compared using disability weights.  This further supports the hypothesis that it is the 
change in scale that matters rather than the jumping over a, possibly arbitrary, 
boundary. 
This thesis has only looked at the five point GOS.  A natural extension to this would 
be to look at the GOSE to see if the results observed would be observed in this scale.  
Subsequent work since this thesis has found that the proportional odds model and the 
sliding dichotomy both still perform excellently when compared to the traditional 
binary dichotomisation of the GOSE (Weir et al. 201).  The efficiency gains found 
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are slightly more than was found using the GOS, indicating that more information 
can be obtained by using the extended scale.  Levin et al (Levin et al. 2001) also 
found that the GOSE was more sensitive to change than the GOS, again indicating 
that this may be a better outcome scale to use than the GOS. 
In conclusion, this thesis has shown that when analysing an ordinal outcome scale 
using any analysis which exploits this ordering is typically far superior to the binary 
analysis which is usually performed.  When appropriate, using an ordinal approach 
will either allow far fewer subjects to be recruited for the same power or will allow 
the same number of subjects to be recruited but a much smaller treatment effect to be 
detected.  Of course, there are some models of treatment effect where using either 
proportional odds modelling or the sliding dichotomy would be inappropriate, for 
example a “kill or cure” model.  However, with this kind of treatment effect the 
conventional dichotomous analysis will also be inappro riate. 
The concept of the sliding dichotomy has, arguably, more clinical appeal.  Bagiella et 
al (Bagiella et al. 2010) claims that a dichotomised measure is more easily translated 
to a general population.  This may be so but using a fixed dichotomy of the GOSE 
for all trials, both exploratory and confirmatory does not make clinical sense.  An 
exploratory trial is a mechanistic trial looking for a sensitive outcome whereas a 
confirmatory trial is looking for something relevant to patients measured using, say, 
the GOSE. 
The choice of whether to use the sliding dichotomy or the proportional odds analysis 
can depend on the balance between simplicity and cli ica  appeal (the sliding 
dichotomy) and statistical efficiency with perhaps a more complex argument (the 
proportional odds model).  This is typically the threshold between, say, a late Phase 
II trial/early Phase III trial where one wishes to have maximum statistical efficiency, 
and hence use the proportional odds model, compared with a late Phase III trial 
where one may sacrifice statistical efficiency for clinical relevance, and hence use 
the sliding dichotomy.  However, no matter which one is used, large gains can 
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9.1 Appendix A Scales 
Table 9-1 Glasgow Outcome Scale 
Item Description 
Good recovery Resumption of normal life despite minor deficits 
Moderately disabled Disabled but independent 
Severely disabled Conscious but disabled.  Dependent for daily support 
Vegetative state Minimal responsiveness 
Death Dead 
 
Table 9-2 Glasgow Coma Scale Components 
Item Description 
Eye opening  
1 None: no eye opening at all 
2 To painful stimulus, should not be applied to the face 
3 To speech – not necessarily a request for eye opening 




1 None: no vocalisation at all 
2 Incomprehensible sounds – grunts and groans but no words 
3 Inappropriate words – recognisable words are produce  but does not 
converse or answer 
4 Confused – converses and answers questions but is confused 





1 None: no movement elicited at all 
2 Extensor response – extensor response posture in response to 
stimulus 
3 Abnormal flexion – flexor posture in response to stimulus 
4 Withdraws – pulls away from painful stimulus but does not localise 
5 Localises - consistent purposeful motion towards  painful stimulus 
applied at different locations 
6 Obeys – moves limb to command and pain is not requi d 
 
Table 9-3 Marshall CT classification11 
Classification Description 
Diffuse Injury I  
(no visible pathology) 
No visible intracranial pathology seen on CT scan 
Diffuse Injury II Cisterns present with midline shift 0-5mm and/or no 
lesion densities present, no-high or mixed density 
lesion>25cc 
Diffuse Injury III 
(swelling) 
Cisterns compressed or absent with midline shift 0-
5mm.  No high or mixed density lesion >25cc 
Diffuse Injury IV 
(shift) 
Midline shift >5mm.  No high or mixed density 
lesion >25cc 
Evacuated mass lesion Any lesion surgically evacuated. 
Non-evacuated mass lesion High or mixed density lesion >25cc not surgically 
evacuated 
                                                
11 Taken from (Marshall et al. 1991) 
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9.2 Appendix B Publications 
The following publications are included both with publishers’ and co-authors’ 
permission. 
1) A simulation study evaluating approaches to the analysis of ordinal outcome 
data in randomized controlled trials in traumatic brain injury: results from the 
IMPACT Project 
McHugh GS, Butcher I, Steyerberg EW, Marmarou A, Lu J, Lingsma HF, Weir J, 
Maas AIR, Murray GD 
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12 My surname was previously Taylor 
